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General introduction 
 
The normal right ventricle and pulmonary circulation 
In his ‘Exercitatio Anatomica de Motu Cordis et Sanquinis in Animalibus’, 
the English physician William Harvey described in 1628 for the first time the 
importance of the right ventricle (RV) and its interaction with the pulmonary 
circulation. However, for four centuries the RV remained largely 
understudied and it is only during the last decades that the RV is finally 
receiving increased attention.  
The RV receives deoxygenated blood from the right atrium and conducts it 
into the pulmonary artery and the lungs where the blood becomes 
oxygenated. Subsequently the oxygenated blood flows from the lungs into 
the left atrium and left ventricle (LV). The LV pumps the blood into the aorta 
and systemic circulation that provides the tissues of the body with 
oxygenated blood. Finally, the deoxygenated blood from the body flows via 
the vena cava into the right atrium and the cycle will start over again 
(Figure 1A).  
 
Figure 1. Pulmonary circulation in health and pulmonary hypertension.  
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(A) Schematic presentation of the pulmonary circulation. The right atrium receives 
deoxygenated blood from the body. The right ventricle pumps the blood into the main 
pulmonary artery and the lungs. Subsequently, the left atrium and left ventricle receive 
oxygenated blood from the lungs and pump it into the aorta towards the body. (B) Normal 
pulmonary arteries. (C) In patients with pulmonary arterial hypertension (PAH) the 
pulmonary arteries are remodeled and narrowed. 
 
The normal RV has a complex crescent shape, a thin wall with prominent 
trabeculae (i.e. muscle bundles that support the RV wall) and is separated 
from the LV by the interventricular septum (IVS). The RV is primarily build 
to conduct blood volume and to function in a low-resistance, low-pressure 
system in relation with the pulmonary circulation. The normal blood 
pressure in the lungs of an healthy adult is on average 14 mmHg. When the 
pulmonary vascular resistance (PVR) and the pulmonary artery pressure 
(PAP) are elevated, the RV has to adapt in order to maintain adequate 
blood flow. Unfortunately, the RV is built as a volume pump and is poorly 
able to cope with rising pulmonary pressures1.  
 
Pulmonary arterial hypertension 
Pulmonary hypertension (PH) is defined by an elevated mean PAP ≥25 
mmHg at rest, invasively measured during a right heart catheterization. PH 
can be classified into five groups (Table 1).  
 
Table 1. Clinical classification of pulmonary hypertension. 
Group 1 Pulmonary arterial hypertension (PAH) 
   Idiopathic 
   Heritable 
   Drugs and toxins induced 
   Associated pulmonary arterial hypertension (APAH) 
     Connective tissue diseases 
     HIV infection 
     Portal hypertension 
     Congenital heart disease 
     Schistosomiasis 
     Chronic haemolytic anemia 
   Persistent pulmonary hypertension of the new born 
   (Group 1’) Pulmonary veno-occlusive disease and/or pulmonary 
capillary hemangiomatosis  
Group 2 Pulmonary hypertension due to left heart disease 
Group 3 Pulmonary hypertension due to lung diseases and/or hypoxia 
Group 4 Chronic thromboembolic pulmonary hypertension (CTEPH) 
Group 5 Pulmonary hypertension with unclear or multifactorial mechanism 
 
PH related to left heart disease (Group 2) and PH related to lung diseases 
(Group 3) are the most common forms of PH. Group 1, pulmonary arterial 
hypertension (PAH) is a progressive disease of the small pulmonary 
arteries that results in increased PVR and PAP2. The pulmonary vessels 
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show vasoconstriction, obstruction and remodeling (Figure 1B,C). 
Histopathologic examinations revealed intima hyperplasia, media 
thickening, fibrosis of the adventitia, thrombotic lesions and the presence of 
plexiform lesions in the small pulmonary arteries which are thought to be 
major contributors to the elevated PVR3.  
PAH is a rare disease with an estimated prevalence of 15 cases per million 
in the general adult population. The incidence was estimated at 2.4 cases / 
million adult people / year. Most PAH patients are female (ratio 
female:male: 1.9:1) with a peak prevalence at the age of 50 years4. Most 
frequently, the cause is idiopathic (unknown) but PAH can also be heritable 
or associated with other conditions including congenital heart disease, 
collagen vascular disease, portal hypertension, HIV infection and exposure 
to drugs or toxins such as appetite suppressants.  
 
The RV determines the symptoms and survival in patients with PAH 
PAH patients present with symptoms of a limited exercise capacity and 
dyspnea on exertion. Due to the non-specific nature of its symptoms and its 
insidious development, PAH is often ignored by the patient and mistreated 
by the medical doctor, contributing to a delay in the establishment of the 
diagnosis. The symptoms are related to the presence of RV dysfunction. 
Chronic elevated pressure overload initially results in a temporarily adapted 
RV and preserved RV function, ultimately followed by RV maladaptation 
and dysfunction (Figure 2). RV failure is the primary cause of death5,6. 
Without treatment, the natural median survival of PAH is 2.8 years7.  
 
 
Figure 2. Magnetic resonance imaging (MRI) of the RV in a healthy 
individual and in a patient with PAH.  
(A) The normal RV has a thin wall, crescent shape and numerous trabeculae. (B) The RV of 
a PAH patient has developed a spherical shape, hypertrophy, pronounced trabecularisation, 
severe dilatation, apical ballooning, bulging of the (IVS) into the LV, LV underfilling, an 
enlarged right atrium (RA), tricuspid insufficiency and pericardial effusion. LA = left atrium. 
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Pathophysiology of RV remodeling and dysfunction 
The heart functions as an ‘on-demand’ pump in order to fulfill the needs of 
sufficient oxygen delivery to the body8. During chronic pressure overload, 
the RV has to increase its work in order to sustain cardiac output (CO). 
According to the Law of Laplace (i.e. wall stress = intraluminal pressure 
times chamber internal radius, divided by wall thickness), wall stress in 
PAH is elevated and the RV has to compensate by increasing its wall 
mass. Hypertrophy is initially considered a favorable adaptation mechanism 
by reducing wall stress and improving pumping effectiveness to maintain 
adequate blood flow. An additional adaptive mechanism is RV dilatation 
which aids in sustaining CO via the Frank-Starling mechanism, but at the 
same time contributes to increased RV wall stress. The elevated RV mass 
and wall stress are associated with an increased myocardial oxygen 
demand and simultaneous impairment of myocardial blood flow9,10. The 
balance between oxygen demand and supply is further disturbed by a 
decreased myocardial mechanical efficiency which increases the amount of 
oxygen needed for a given amount of work9. Whether or not associated 
with an impaired oxygen balance, metabolite use in the hypertrophic RV of 
PAH patients switches from predominantly fatty acid towards glucose in 
order maintain the supply of adenosine triphosphate (ATP) for force 
generation11-14. 
A disturbed balance between RV pressure overload, hypertrophy and 
progressive dilatation result in a persistent increase of wall stress. In 
addition to concurrent ischemia, changes in metabolism and potential other 
factors such as altered RV contractility and activation of the neurohormonal 
system15-17, are all detrimental for the RV in the long run and contribute to 
progressive RV dysfunction and failure18,19.  
Most studies have focused on remodeling of the RV free wall. The 
pressure-overloaded RV is heavily trabecularised but it is unknown whether 
hypertrophic responses are similar in the RV free wall and in trabeculae. In 
addition, the IVS significantly contributes to normal RV function20,21. In 
patients with PAH, the IVS cannot function properly and bows into the LV, 
which is associated with LV underfilling, decreased stroke volume and poor 
survival22-25. Leftward IVS bowing is considered a consequence of 
interventricular dyssynchrony23,25-27. It is unknown whether underlying 
remodeling processes occur in the IVS as well and if so, whether these 
processes are comparable to the changes in the RV free wall. If the IVS 
reflects the changes of the RV free wall, than taking biopsies from the IVS 
could allow clinical assessment of RV failure mechanism and treatment 
response monitoring, because taking biopsies directly from the RV free wall 
is considered unsafe28.  
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Advanced assessment of the RV by cardiac MRI and- PET imaging 
Cardiac magnetic resonance imaging (MRI) provides high-resolution 
imaging, does not require geometric assumptions, lacks ionizing radiation 
and is considered the gold-standard to assess RV mass, volumes and 
function29. Global RV function is usually quantified by RV ejection fraction 
(RVEF)1, which is determined as the amount of blood ejected per heart 
beat relative to the amount of RV filling (i.e. RV end-diastolic volume 
(RVEDV)). Although the diagnostic role of MRI in PAH is limited, it is 
valuable in the monitoring of RV therapeutic effects30,31. Furthermore, it has 
been demonstrated that increased RVEDV, low RVEF and stroke volume 
on MRI are strong predictors of a poor survival32. Disadvantages of MRI are 
that the technique is relative expensive, requires operator expertise and 
relative long scan times. Positron emission tomography (PET), despite its 
high costs and labor intensity, is a rapidly evolving technique that allows 
assessment of RV molecular and pathophysiological tissue processes.  
 
Therapeutic approach to improve RV function 
The current therapeutic strategy in PAH is aimed at improving RV function 
by reducing RV load. This approach is based on the results obtained after 
lung transplantation and pulmonary endarterectomy in chronic 
thromboembolic PH patients in which normalization or a strong decrease in 
PVR guarantees restoration of the function of the RV33,34. 
During the last decade, multiple medical therapies (i.e. prostacyclins, 
endothelin receptor antagonists, phosphodiesterase five inhibitors) have 
been developed that have mainly pulmonary vasodilator effects resulting in 
reduced PVR and improved CO35,36. These therapies have contributed to a 
more stable clinical condition and better survival of PAH patients35,37,38. 
However, PAH cannot be cured with these therapies and long-term survival 
remains unsatisfactory38,39. The contrast between hemodynamic success 
and a poor prognosis after medical treatment, raises the question whether 
a reduced, but non-normalized PVR is automatically followed by an 
improved RV function. The relationship between changes in PVR and the 
effects on RV function after medical therapies have been scarcely 
assessed however. Little is known about the influence of additional factors 
contributing to a successful response to medical therapies. Of interest, 
females have a better survival than male patients despite optimal medical 
treatment39,40 but the cause for this gender difference is currently unknown.  
An increasing clinical problem is that even after years of a stable clinical 
condition under medical treatment, patients may experience an 
unexpected, rapid clinical deterioration which is associated with progressive 
RV dysfunction and is related to poor survival41-43. In order to prevent this 
worsening, it is of great importance to identify the transition from adaptive 
RV remodeling to refractory RV dysfunction and failure as early as 
possible.  
General introduction and thesis outline 
15 
 
Rationale and outline of this thesis 
 
In 1997, the VU University Medical Center was the first hospital in the 
Netherlands to introduce a program for diagnosis, assessment and 
treatment of patients with PAH. During more than 15 years, the RV has 
been studied extensively using MRI as part of a standard clinical protocol. 
More recently, PET imaging has also been applied. The data gathered into 
a large, growing PAH database and formed the basis of the research 
performed in this thesis.  
 
The aims of the studies described in this thesis were twofold. The first aim 
was to improve knowledge of RV structural adaptation to chronic pressure 
overload. In Chapter 2, the structural remodeling of the RV free wall and 
trabeculae are studied. Using MRI to assess RV structural remodeling and 
right heart catheterization (RHC) to measure hemodynamics, we assessed 
whether trabeculare and papillary muscles showed a similar remodeling 
process as the RV free wall in relationship to pressure overload. In Chapter 
3, we focused on the role of the IVS and did not only study the 
morphological changes by MRI but also assessed the changes in glucose 
metabolism using PET imaging. In addition, alterations on a cellular level of 
the IVS were studied in a rat model with PH. The aim of this study was to 
assess whether the changes in the IVS resembled the changes in the RV 
free wall.  
The second aim of this thesis was to assess the changes in RV adaptation 
and function over time in relationship to the changes in RV afterload after 
medical therapies. In Chapter 4 of this thesis, the relationship between the 
changes in PVR and RV function and survival was investigated. We 
assessed whether a decrease in PVR after medical treatment was 
automatically followed by improved RV function and better survival. In 
Chapter 5 we compared the PVR-RV function relationship between female 
and male PAH patients under medical treatment. We investigated whether 
worse survival of male patients is caused by more severe pulmonary 
vascular disease, more impaired RV function or a different therapeutic 
response. In Chapter 6 of this thesis, the hypothesis is tested that 
accomplishment of a large decrease in PVR after medical treatment is 
associated with a guaranteed improvement in RV function and survival. In 
Chapter 7, we studied PAH patients with a longstanding stable response to 
medical treatment. Some of these patients can show an ultimate 
unexpected clinical deterioration and it was hypothesized that clinical 
deterioration in these patients, was preceded by progressive adverse RV 
remodeling during the initial seemingly stable disease period. Assessment 
of this adverse RV remodeling would enable early detection of an ultimate 
clinical worsening.  
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In Chapter 8 we provide a general overview of current and future 
applications of MRI and PET imaging in the assessment of chronic RV 
failure. We review the current clinical relevance of MRI and PET 
applications and explain how advanced imaging techniques could improve 
our knowledge in the mechanisms of RV failure under chronic pressure 
overload. Finally, in Chapter 9, we provide conclusions of this thesis and 
present future perspectives.  
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Abstract 
 
Introduction. To assess the contribution of right ventricular (RV) 
trabeculae and papillary muscles (TPM) to RV mass and volumes in 
controls and patients with pulmonary arterial hypertension (PAH). 
Furthermore, to evaluate whether TPM shows a similar response as the RV 
free wall (RVFW) to changes in pulmonary artery pressure (PAP) during 
follow-up.  
Methods. 50 patients underwent cardiac magnetic resonance imaging 
(CMR) and right heart catheterization at baseline and after one-year follow-
up. Furthermore 20 controls underwent CMR. RV masses were assessed 
with and without TPM.  
Results. TPM constituted a larger proportion of total RV mass and RV end-
diastolic volume (RVEDV) in PAH than in controls (Mass: 35 ± 7% vs. 25 ± 
5%, p<0.001, RVEDV: 17 ± 6% vs. 12 ± 6%, p = 0.003). TPM mass was 
related to the RVFW mass in patients (baseline: R = 0.65, p <0.001, follow-
up: R = 0.80, p <0.001) and controls (R = 0.76, p <0.001). In PAH and 
controls, exclusion of TPM from the assessment resulted in altered RV 
mass, volumes and function than when included (all p <0.01). Changes in 
RV TPM mass (β = 0.44, p = 0.004) but not the changes in RVFW mass (p 
= 0.095) were independently related to changes in PAP during follow-up.  
Conclusions. RV TPM showed a larger contribution to total RV mass in 
PAH (~35%) compared to controls (~25%). Inclusion of TPM in the 
analyses significantly influenced the magnitude of the RV volumes and 
mass. Furthermore, TPM mass was stronger related to changes in PAP 
than RVFW mass. Our results implicate that TPM are important 
contributors to RV adaptation during pressure overload and cannot be 
neglected from the RV assessment.  
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Introduction 
 
An increased right ventricular (RV) load in patients with pulmonary arterial 
hypertension (PAH) results in marked RV hypertrophy1,2. Generally studies 
have focused on hypertrophy of the compact layer of the RV free wall. 
However the RV is highly trabecularised in PAH and even in the normal 
RV, trabeculae and papillary muscles (TPM) are prominent components. It 
is unknown whether in PAH during the process of hypertrophy, all RV mass 
components increase in size to the same extent. 
Cardiac magnetic resonance imaging (CMR) provides high resolution 
imaging that enables visual contrast between the cardiac free wall, 
trabeculae and blood pool3. CMR RV parameters are of strong diagnostic4-
6, therapeutic7-11 and prognostic12 importance in PAH. Yet the issue of 
trabeculations has not received much attention, while previous studies have 
variably included5,7,10,13-15 or excluded16-19 TPM from the cardiac 
assessment of control subjects and PAH patients. However it is unknown 
whether TPM contributions to RV measures are constant over time in 
individual subjects and across patient populations. It therefore remains 
unascertained if it is possible to neglect TPM during RV assessment. 
Studies on the left ventricle (LV) of normal subjects and patients with LV 
cardiomyopathies have shown that LV assessments are greatly affected by 
the in- or exclusion of TPM20-26.  
The aim of the present study was to assess the contribution of RV TPM to 
RV mass and volumes using CMR in patients with PAH and in normal RV 
subjects. Furthermore to evaluate in PAH patients whether TPM shows a 
similar response as the RV compact free wall mass to changes in RV load 
during follow-up.  
 
 
Methods 
 
Study population 
The present study is a retrospective data-analysis partly obtained from an 
ongoing prospective research program to assess the value of CMR in 
patients with pulmonary hypertension. Since several years CMR has 
become part of our clinical protocol and the other part of the CMR data 
included in this study were initially obtained for clinical purposes. The study 
was approved by The Medical Ethics Review Committee of the VU 
University Medical Center. Due to the fact that the study does not fall within 
the scope of the Medical Research Involving Human Subjects Act (WMO), 
the study was approved without requirement of a consent statement. 
PAH was diagnosed according to World Health Organization guidelines, 
including a right heart catheterization (RHC)27. From an imaging database 
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consisting of 103 PAH patients who underwent CMR at baseline and after 
one-year of follow-up at our institution between 2003 and 2012, 50 patients 
were randomly selected. All included patients underwent CMR and RHC at 
baseline and after a median time period of 13 months (interquartile range: 
12 - 17 months). CMR and RHC were obtained within a median time period 
of one day. Patients received optimal PAH targeted therapies. Patients with 
a positive response to the acute vasodilator challenge27 were treated with 
calcium channel antagonists. NYHA II and III patients received oral medical 
therapy consisting of endothelin receptor antagonsists (ERA) and/or 
phophodiesterase 5 inhibitors (PDE-5I) and NYHA IV patients received 
intravenous prostacyclins with or without additional oral medical treatment. 
During follow-up, many patients went through one or multiple treatment 
regimens. All patients received oral anticoagulation.  
In addition, 20 control subjects with no known risk factors for or history of 
pulmonary and cardiovascular diseases were selected from a database 
consisting of 30 subjects and included in the present study. Control 
subjects and patients were matched for age and gender.  
 
Right heart catheterization 
Hemodynamic assessment was performed with a 7F balloon tipped, flow 
directed Swan-Ganz catheter (131HF7, Baxter, Healthcare Corp Irvine, 
California). During continuous electrocardiographic monitoring, the 
following variables were recorded: mean pulmonary artery pressure 
(mPAP), mean right atrial pressure (RAP), cardiac output (CO), pulmonary 
arterial wedge pressure (PAWP). Pulmonary vascular resistance (PVR) is 
calculated as: 80*(mPAP – PAWP)/CO.  
 
CMR image acquisition 
Image acquisition was performed on a Siemens 1.5T Sonata scanner 
(Siemens Medical Solutions, Erlangen, Germany), equipped with a 6-
element phased-array receiver coil. Electrocardiographic-gated cine 
imaging was performed using a balanced steady-state precession pulse 
sequence during repeated breath-holds. Short-axis images from base to 
apex of the ventricles were obtained with a typical slice thickness of 5 mm 
and an interslice gap of 5 mm. MR parameters were: temporal resolution 
between 35 and 45 ms, typical voxel size 1.8 x 1.3 x 5.0 mm3, flip angle 
60°, receiver bandwith 930 Hz/pixel, field of view 280 x 340 mm2, repetition 
time/echo time 3.2/1.6 ms, and matrix 156 x 256. 
 
CMR image analysis 
During post-processing, two independent observers analyzed the CMR-
images by the MASS software package (MEDIS Medical Imaging Systems, 
Leiden, the Netherlands). On end-diastolic (ED) images (first cine after the 
R-wave trigger) and end-systolic (ES) short-axis cine images (cine with 
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visually the smallest cavity), endocardial and epicardial contours of the RV 
were obtained by manual tracing. Short-axis images of the ventricles were 
cross-referenced with the four-chamber cine to determine whether basal 
slices should be included in the analysis. For each patient and image 
section, the contrast and brightness settings were optimized to achieve the 
best possible contrast between myocardium, TPM and blood pool.  
RV volumes and masses were calculated using Simpson’s rule. Stroke 
volume (SV) was calculated as (RVEDV - RVESV) and RV ejection fraction 
was calculated as SV/RVEDV multiplied by 100%, where RVEDV is RV 
end-diastolic volume and RVESV is RV end-systolic volume. For mass 
calculation, the myocardial volume was multiplied by the specific density of 
the heart (1.05 g/cm3)28. RV mass was reported as the average of RV ED 
and ES mass. Masses and volumes were corrected for body surface area 
(BSA).  
Analysis time and observer variability were recorded in a subset of patients. 
To assess intraobserver variability, observer 1 analyzed a random subset 
of 20 baseline and 20 follow-up CMR-scans of the PAH patients and 10 
control scans twice with a three month interval between repeat 
measurements. Observer 2 assessed the same scans to analyze 
interobserver variability. The observers did not know whether a scan was a 
baseline or follow-up measurement. Contours from each dataset were 
saved in separate databases and both observers were blinded to the initial 
results.  
 
Determination of RV mass components 
The compact myocardium of the RV free wall was defined as a myocardial 
layer of homogeneous medium signal intensity on the image without 
inclusion of blood of brighter signal intensity. TPM was defined as a 
meshwork of medium signal intensities interspersed with blood of bright 
signal intensity.  
All contours were traced twice, using two different methods. First, RV TPM 
were included in the compact myocardium of the RV free wall (Figure 1A, 
C, RV total wall mass = RV compact free wall mass + TPM). Second, TPM 
were excluded from the RV total wall mass and included in the blood 
volume (Figure 1B, D, RV compact free wall mass). The difference between 
the RV total mass and RV compact free wall mass represents the RV TPM 
mass. The difference between the RVEDV with and without TPM 
represents the RV TPM volume. 
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Figure 1. Determination of RV masses 
The volume between the grey continuous line and black continuous line illustrates the right 
ventricular (RV) total mass: RV compact free wall mass with inclusion of trabeculae and 
papillary muscles (TPM) in controls (A) and PAH patients (C). The volume between the 
black dotted line and the grey continuous line represents the RV compact free wall mass 
without TPM in controls (B) and PAH patients (D).  
 
Statistical analysis 
Continuous data are presented as mean ± SD for continuous variables and 
absolute for categorical variables. Differences between the PAH patient-
group and control-group were calculated using the unpaired Student t test. 
The absolute difference between RV volumes and mass with and without 
TPM and between ED and ES were tested using the paired Student t test. 
Pearson correlation analysis was applied to test the relationship between 
RV total mass, RV compact free wall mass, TPM mass and RV load (i.e. 
mPAP and PVR). Multivariate linear regression analysis was applied to 
determine the independent relationships between RV load, RV compact 
free wall mass and RV TPM mass after correction for potential confounding 
by age, gender and type of PAH diagnosis. Regression analysis was 
repeated for the second set of analyses from observer 1 and the analyses 
from observer 2. The intra and- interobserver variability were tested using 
Bland-Altman analysis. In addition, the intra and- interobserver coefficient 
of variability (i.e. the SD of the difference between the two measurements 
divided by the mean of the two measurements, expresses as a percentage) 
was calculated. All statistical analyses were performed using SPSS 
(version 19.0, SPSS, inc, Chicago, Illinois). P-values <0.05 were 
considered statistically significant.  
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Results 
 
Study population 
Table 1 summarizes the demographic and hemodynamic data of the study 
population. After baseline measurements, 28 patients were initiated on 
ERA, 5 patients received PDE5I, 8 patients were treated with prostacyclins, 
2 patients received calcium channel antagonists and 7 patients received 
upfront medical combination therapies.  
PAH patients showed greater RV mass, higher RV volumes and diminished 
RV function compared to controls (Table 2) (p-value between groups for all 
RV parameters: p-inter <0.001).  
 
Table 1. Demographics and hemodynamics of the study population. 
 
 
Variable 
 
PAH patients 
(n = 50) 
Control 
subjects 
(n = 20) 
 
 
P-value 
Age, years 46  13 48  18 0.465 
Female, n (%) 43 (86) 16 (80) 0.717 
BSA, m
2
 1.8 ± 0.2 1.8 ± 0.2 0.862 
Diagnosis, n (%) 
   Idiopathic PAH 
   Familial PAH 
   Associated PAH 
     Connective tissue 
disease 
     Portal hypertension 
     Pulmonary veno 
occlusive disease 
 
37 (74) 
4 (8) 
 
5 (10) 
2 (4) 
2 (4) 
  
Hemodynamics 
   mPAP, mmHg 
   PVR, dyne.s.cm
-5
 
   CO, L/min 
   RAP, mmHg 
   PAWP, mmHg 
 
51 ± 15 
833 ± 416 
4.7 ± 1.4 
8 ± 5 
8 ± 4 
  
BSA = body surface area, CO = cardiac output, mPAP = mean pulmonary artery pressure, 
PAWP = pulmonary arterial wedge pressure, PVR = pulmonary vascular resistance, RAP = 
right atrial pressure. 
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Table 2. RV mass and volumes at baseline in PAH patients and control 
subjects. 
 PAH patients 
(n = 50) 
Control subjects* 
(n = 20) 
 
 
Variable 
TPM in 
RV 
mass 
TPM ex 
RV 
mass 
 
 
P-intra 
TPM in 
RV 
mass 
TPM ex 
RV 
mass 
 
 
P-intra 
RV mass, g/m
2
 50 ± 15 32 ± 9 <0.001 19 ± 4 14 ± 3 <0.001 
RVEDV, ml/m
2
 79 ± 23 95 ± 28 <0.001 66 ± 14 70 ± 15 0.002 
RVESV, ml/m
2
 52 ± 22 68 ± 27 <0.001 26 ± 9 31 ± 10 <0.001 
RVEF, % 36 ± 13 29 ± 12 <0.001 61 ± 8 57 ± 8 <0.001 
SV, ml/m
2
 27 ± 11 27 ± 11 0.215 40 ± 9 40 ± 9 0.268 
RV = right ventricular, RVEDV = right ventricular end-diastolic volume, RVESV = right 
ventricular end-systolic volume, RVEF = right ventricular ejection fraction, SV = stroke 
volume, TPM = trabeculae and papillary muscles. 
TPM in RV mass = TPM included in the RV mass assessment. TPM ex RV mass = TPM 
excluded from the RV mass assessment and included in the blood pool.  
*Difference in TPM in RV mass and TPM ex RV mass between PAH patients and control 
subjects, P-inter <0.001 for all parameters.  
 
Contributions of the RV compact free wall mass and TPM mass in a 
normal and hypertrophic RV 
TPM constituted a larger proportion of RV mass in PAH patients than in 
control subjects (PAH: 35 ± 7% vs. controls: 25 ± 5%, p <0.001) (Figure 
2A). In addition, the TPM mass was linear but non-proportionally related to 
the RV compact free wall mass (Figure 2B) (PAH: total RV mass = 1.93 * 
RV TPM mass + 16.6). RV TPM volume constituted 17 ± 6% of RV EDV in 
PAH and 12 ± 6% in controls (p for difference: 0.003).  
 
 
Figure 2 Relationship between TPM mass and RV compact free wall mass. 
(A) Relative contributions of RV compact free wall mass (filled bars) and TPM mass (open 
bars) in controls (light grey), PAH patients at baseline (B) (black) and at follow-up (FU) (dark 
grey). (B) RV TPM mass was related to the RV compact free wall mass in PAH patients at 
baseline (R = 0.65, p <0.001); at follow-up (R = 0.80, p <0.001) and in controls (R = 0.76, p 
<0.001). 
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At baseline RV compact free wall mass and TPM mass were both related to 
mPAP and PVR (Table 3). Linear multivariate regression analysis 
consisting of RV TPM mass, RV free wall mass and mPAP revealed that 
RV TPM mass was an independent predictor of baseline mPAP (β = 0.040, 
p = 0.043) whereas RV compact free wall mass was not (p = 0.630). 
Multivariate analysis for PVR did not reveal an independent RV mass 
predictor.  
After one year of medical treatment, PAH patients as a group showed no 
change in RV compact free wall mass (-0.1 ± 7.1 g/m2, p = 0.924) or TPM 
mass (-0.7 ± 4.9 g/m2, p = 0.305) whereas mPAP and PVR showed small 
average improvements (-6 ± 9 mmHg and -177 ± 273 dyne.s.cm-5 resp., 
both: p <0.001). The changes in TPM mass were moderately related to the 
changes in RV compact free wall mass (r = 0.530, p = 0.001). The changes 
in TPM mass showed a stronger correlation to the changes in mPAP and 
PVR than he changes in RV compact free wall mass (Table 3). The 
changes in mPAP during follow-up were independently predicted by the 
changes in RV TPM mass (β = 0.444, p = 0.004) and not by the changes in 
RV compact free wall mass (β = 0.246, p = 0.095). Similar results were 
found for the other analyses of observers 1 and 2. In addition comparable 
results were obtained for the relationship with the changes in PVR. After 
correction for possible confounding by age, gender and type of PAH 
diagnosis, the results remained unchanged. 
 
Table 3. Correlations between RV masses and hemodynamics in PAH 
patients. 
 mPAP PVR 
Baseline 
   RV total mass, g/m
2
 
   RV compact free wall mass, g/m
2
 
   RV TPM mass, g/m
2
 
   Percentage RV TPM mass, % 
r 
0.447 
0.478 
0.586 
0.396 
P-value 
0.014 
0.007 
<0.001 
0.039 
r 
0.254 
0.215 
0.433 
0.378 
P-value 
0.075 
0.138 
0.019 
0.049 
 ΔmPAP ΔPVR 
Changes during follow-up 
   ΔRV total mass, g/m
2
 
   ΔRV compact free wall mass, g/m
2
 
   ΔRV TPM mass, g/m
2
 
   ΔPercentage RV TPM mass, % 
r 
0.427 
0.472 
0.580 
0.288 
P-value 
0.003 
0.001 
<0.001 
0.043 
r 
0.223 
0.183 
0.502 
0.394 
P-value 
0.136 
0.228 
0.001 
0.007 
 
Influence of RV TPM assessment on the magnitude and 
reproducibility of RV volumes and mass 
Measurements of RV mass in PAH did not differ between ED and ES (RV 
compact free wall mass + TPM: PAH: ED: 49 ± 15 g/m2, ES: 50 ± 15 g/m2, 
p = 0.330, RV compact free wall mass: ED: 32 ± 9 g/m2, ES: 33 ± 10 g/m2, 
p = 0.396). Both in controls and in PAH, measurements of RVEDV and 
RVESV were significantly larger when TPM were excluded from the RV 
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mass (Table 2) (p values within groups for all RV parameters: p-intra: 
<0.01). In the overall study population no differences in SV were observed 
between both methods. Consequently, a similar SV and larger RVEDV 
resulted in lower values of RVEF. 
Bland-Altman analysis of the intra and- inter observer differences between 
RV compact free wall mass with and without inclusion of TPM for PAH 
patients and control subjects are presented in Figure 3. The intra-observer 
coefficient of variation was better when RV TPM were included in the RV 
mass assessment than when excluded (8.5% vs. 12.9%). Similarly, 
inclusion of TPM in the RV mass assessment showed a smaller inter-
observer coefficient of variation than exclusion of TPM (12.5% vs. 17.7%).  
Analysis time was significantly shorter when TPM were not included in the 
analysis in comparison with the inclusion of TPM (mean of 14 vs. 21 
minutes). 
 
 
Figure 3. Bland Altman analysis for the RV mass determination. 
(A) Intra-observer agreement of RV total mass assessment with inclusion of TPM (TPM in 
RV mass) and (C) without TPM (TPM ex RV mass). (B) Inter-observer agreement of RV 
mass assessment with inclusion of TPM and (D) without TPM of PAH patients at baseline 
(black), at follow-up (dark-grey) and in controls (triangle, light-grey). On each plot, the dotted 
lines represent the bias and limits of agreement of the PAH patients.  
 
 
Discussion 
 
In the present study, we showed that TPM mass comprised a larger 
proportion of total RV wall mass in PAH patients (~35%) than in controls 
(~25%). Furthermore in PAH, changes in RV TPM were independently 
related to changes in loading conditions whereas such a relationship does 
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not exist for changes in the RV compact free wall mass. Because the RV 
TPM constitutes a large part of total RV mass and volume in both PAH 
patients and controls, exclusion of TPM measurements significantly 
affected the magnitude of CMR RV measures.  
 
RV hypertrophy is more prominent in TPM than in the RV compact 
free wall 
We found a significant linear but non-proportional relationship between 
TPM and RV compact free wall mass in PAH and controls. In addition we 
showed that TPM constituted a larger proportion of total RV mass in PAH 
patients (~35%) compared to controls (~25%). In line with our findings, in 
the autopsy study of Fulton et al. it was observed that RV trabeculae were 
hypertrophied in a hypertrophic RV but the relative contribution of 
trabeculae to total RV weight was not studied29. In addition, Vogel-
Claussen et al. observed a moderate relationship between septomarginal 
trabeculae and RV free wall mass in controls and PAH patients. Although 
not statistically tested it appeared that septomarginal trabeculae constituted 
a larger proportion of total RV free wall mass in PAH than in controls30. An 
echocardiographic study on the LV showed that LV papillary muscles form 
a larger fraction of LV volumes in the hypertrophied human heart than in 
the normal LV31. In addition, Janik et al. found by CMR assessment a 
twofold larger impact of TPM to total LV mass in the hypertrophic LV 
compared to controls32.  
The significant correlation between TPM and the RV compact free wall 
mass might be explained by a similar embryological origin implicating that 
RV trabeculae are an integral part of RV structural remodeling33. However 
we found that RV TPM have a relative larger contribution in the 
hypertrophic RV and showed a stronger relation to changes in pulmonary 
pressures than the RV compact free wall which might suggest that TPM are 
more responsive to changes in loading conditions. A possible physiological 
explanation is a greater sensitivity of RV TPM to changes in wall stress. 
Damon et al. found greater strain and more stretch in trabeculae than in the 
compact layer of the embryonic animal heart34. Similarly, a CMR study 
demonstrated that high myocardial strain was related to TPM in the human 
LV35. Another explanation could be that TPM respond differently to changes 
in oxygen delivery. RV papillary muscles are more susceptible to ischemia 
since blood is required to course uphill to perfuse the papillary muscle by 
coronary blood flow36. RV trabeculae receive blood from both the coronary 
circulation and surrounding ventricular blood but it has been found that the 
capillary density of trabeculae in the normal animal RV is about the half of 
that of the ventricular walls37. In autopsy tissues from the RV compact free 
wall of PAH patients, a reduced capillary density has been found38 but it is 
unknown what happens to the oxygenation of RV TPM in PAH.  
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Influence of TPM assessment on the magnitude and reproducibility of 
CMR RV measures 
In- or exclusion of TPM in CMR measures of RV mass, volumes and 
function significantly affected the magnitude of the measure. Our results 
correspond to the 1.5 times higher measured RV mass in PAH studies that 
included TPM7-12 compared to studies that excluded TPM14,16. When TPM 
were excluded from the RV mass and included into the blood pool, it 
resulted in significantly higher measured RVEDV, RVESV and lower RVEF 
in PAH patients. In theory the amount of TPM is similar in diastole and 
systole and therefore does not influence SV measurements. Previously 
Winter et al. observed similar variations in RV volume measurements with 
or without inclusion of TPM in patients with a systemic RV39. In line with our 
findings, Sievers et al. observed systemic differences between the method 
with or without inclusion of TPM in control subjects40.  
Our reproducibility results are consistent with previous studies in PAH28,41 
and control subjects15,18. Although analysis time was reduced by ~35% 
when TPM were excluded from the RV mass analyses, observer variability 
was larger than when TPM were included in the RV mass of PAH patients. 
These findings correspond to the study of Bradlow et al.41. For complete 
assessment of RV mass, volumes and function, the RV has to be assessed 
both in ED and ES. If only RV mass assessment is required than it simply 
needs to be assessed during ED saving 50% of time due to the fact that RV 
mass measures were similar in ED and ES. 
 
Clinical implications 
In the present study, we found that the relative contributions of TPM and 
compact free wall to total RV mass alter during the RV hypertrophic 
process which implicates that RV TPM and the compact free wall should 
not be considered as strictly homogeneous. TPM are important contributors 
to RV adaptation and might be sensitive components to detect changes in 
RV afterload. Although future studies are required to assess the 
physiological importance of TPM, it might be that hypertrophy of TPM 
significantly contributes to a favorable RV adaptation pattern in order to 
lower the wall stress in the direction orthogonal to the RV wall.  
In addition, TPM constitute a large proportion of RV mass and volumes in 
controls and PAH patients and thus cannot be neglected from the RV 
assessment. Observer variability was better when TPM were included but 
was still relatively modest for RV mass measurements. Therefore 
measuring RV mass is reliable when measured in a group but might not be 
sensitive enough to accurately detect changes in the individual patient.  
 
Limitations 
TPM might be relatively small in controls and therefore more difficult to 
visualize by CMR leading to potential underestimation of the TPM mass. 
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Although we cannot completely exclude measurement errors, previous 
studies have demonstrated that CMR is highly accurate to determine RV 
mass in a healthy subject28,32,42,43. Therefore it is unlikely that the absolute 
difference in TPM mass between controls and PAH patients of 18 g/m2 can 
be explained by underestimation of RV TPM mass in controls.  
In the image analysis of ventricular masses window/level display settings 
influence ventricular measurements. Although, the settings were optimized 
during each analysis, in future studies standardized settings should be 
sought. In the present study, inter-study reproducibility was not addressed. 
However, in a previous study the repeatability of image acquisition in PAH 
patients has been assessed and a coefficient of variation of 8% was found 
for RV mass with inclusion of TPM and of 12% when TPM were excluded41.  
 
 
Conclusions 
 
RV TPM showed a larger contribution to total RV mass in the hypertrophic 
RV of PAH patients (~35%) compared to controls (~25%). Furthermore 
TPM mass was stronger related to changes in loading conditions than 
mass of the RV compact free wall. Inclusion of TPM in the RV analyses 
significantly altered the magnitude of the RV parameters and resulted in 
better observer variability. Our results implicate that TPM are important 
contributors to RV adaptation during pressure overload and cannot be 
neglected from RV volumetric and mass assessments. 
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To the Editor: 
 
Chronic pressure overload in patients with pulmonary hypertension (PH) 
results in hypertrophy, dilatation, metabolic alterations1-3 and disturbed 
oxygen and calcium handling of the right ventricular (RV) free wall, leading 
to RV failure4,5. Being structurally and functionally related to the left 
ventricle (LV), the interventricular septum (IVS) might adapt differently to 
high RV pressures compared with the RV free wall.  
The IVS plays a major role in the maintenance of RV function6-8. In PH, its 
function is impaired and associated with poor prognosis9,10. A comparison 
of remodeling processes of the IVS and the RV free wall may contribute to 
better understand the development of RV dysfunction in PH. Moreover if 
IVS remodeling does not reflect global processes of right heart remodeling, 
this would imply that IVS biopsies which have been advocated for the 
clinical management of PH patients because of a higher complication risk 
of RV wall biopsies11, might have limited potential. 
The aim of the current study was to assess whether the IVS shows similar 
changes in morphology and glucose metabolism as the RV free wall in PH 
patients in vivo. In addition, we studied whether cellular alterations of the 
IVS were comparable to the RV free wall in a monocrotaline PH rat model. 
 
Seventeen prevalent patients with a clinical stable condition of idiopathic 
pulmonary arterial hypertension (IPAH) were included. They underwent 
right heart catheterization and exercise testing12. The IVS, RV and LV free 
wall mass and myocardial glucose uptake rate (MRglu) were studied using 
magnetic resonance imaging (MRI) and [18F]-2-fluoro-2-deoxy-D-glucose 
(FDG) positron emission tomography (PET) respectively as described 
previously12-15. A priori, the study was approved by the local Medical Ethics 
Committee and each patient gave written informed consent (approval 
number: 2007/259). In addition, seventeen age and gender matched control 
subjects without history of cardiopulmonary diseases underwent MRI.  
A male Wistar rat PH model was used to assess cardiac cellular changes16. 
The study was approved by the local Animal Ethics Committee (approval 
number: FYS11-03). Severe PH was induced in eight rats with 
subcutaneous injection of 60 mg/kg monocrotaline. Eight animals were 
used as healthy controls. After three weeks follow-up, in vivo cardiac 
function was measured using echocardiography before the rats were 
sacrificed. Cardiomyocyte cross sectional area (CSA), capillary density, 
fibrosis and leukocyte infiltration were measured16-19. 
 
Cardiac segments were compared by two-way repeated measurements 
analysis of variance with Bonferroni post-hoc testing. Differences between 
groups were assessed using unpaired t-tests. SPSS 20.0 (SPSS Inc., 
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Chicago) was used for statistical analysis. Data are presented as mean ± 
SD, unless stated otherwise. A p-value <0.05 was considered significant.  
 
Table 1 shows the characteristics and MRI-parameters of IPAH patients 
and controls.  
 
Table 1. Clinical characteristics and MRI measurements of patients with 
idiopathic pulmonary arterial hypertension (IPAH) and control subjects. 
 
Variable 
IPAH patients 
(n = 17) 
Control subjects 
(n = 17) 
 
P-value 
Age, years 46 ± 13 46 ± 16 0.89 
Female / male, n 16 / 1 16 / 1 1.00 
BSA, g/m
2
 1.83 ± 0.19 1.79 ± 0.15 0.53 
NYHA class, II / III, n 9 / 8   
NT-proBNP, ng/L 1383 ± 1790   
6MWT, distance, m 453 ± 140   
Hemodynamics 
   mPAP, mmHg 
   RAP, mmHg 
   PVR, dyne·s·cm
-5
 
   PAWP, mmHg 
   CI, L/min/m
2
 
   SvO2, % 
 
52 ± 15 
8 ± 7 
693 ± 369 
10 ± 4 
3.1 ± 1.2 
65 ± 8 
  
MRI parameters 
   RV free wall mass, g/m
2
 
   RVEDV, ml/m
2
 
   RVEF, % 
   SV, ml/m
2
 
   LVEDV, ml/m
2
 
   LVEF, % 
   LV free wall mass, g/m
2 
   IVS mass, g/m
2
 
 
56 ± 12 
82 ± 15 
39 ± 15 
33 ± 11 
52 ± 16 
64 ± 9 
41 ± 10 
17 ± 4 
 
18 ± 3 
65 ± 14 
61 ± 8 
44 ± 10 
67 ± 15 
66 ± 6 
41 ± 9 
14 ± 2 
 
<0.001 
<0.01 
<0.001 
0.001 
<0.01 
0.41 
0.81 
0.05 
6MWT = six-minute walking test, BSA = body surface area, CI = cardiac index, IVS = 
interventricular septum, LV = left ventricular, LVEDV = left ventricular end-diastolic volume, 
LVEF = left ventricular ejection fraction, mPAP = mean pulmonary artery pressure, NT-
proBNP = N-terminal pro-brain natriuretic peptide, NYHA = New York Heart Association, 
PAWP = pulmonary arterial wedge pressure, PVR = pulmonary vascular resistance, RAP = 
right atrial pressure, RV = right ventricular, RVEDV = right ventricular end-diastolic volume, 
RVEF = right ventricular ejection fraction, SV = stroke volume, SvO2 = mixed venous oxygen 
saturation.  
 
Figure 1 demonstrates a higher RV free wall mass (p <0.001) but 
comparable IVS mass (p >0.05) in IPAH compared to controls. PET in 
IPAH patients showed that MRglu in the IVS was higher than in the RV 
(0.34 ± 0.09 vs. 0.25 ± 0.08 µmol/g/min, p <0.01) and comparable to the LV 
(0.33 ± 0.09 µmol/g/min, p = 0.38). 
 
The interventricular septum in pulmonary hypertension does not show features of right ventricular failure 
43 
 
 
Figure 1. Interventricular septum (IVS) and right ventricular (RV) free wall 
mass measured by cardiac magnetic resonance imaging (MRI).  
Control subjects (grey) and patients with idiopathic pulmonary arterial hypertension (IPAH) 
(black). RV free wall mass index was significantly increased in IPAH compared to controls. 
In contrast, IVS mass was similar in both groups. Data are presented as mean ± SEM. ***p 
<0.001. 
 
Table 2 shows echocardiography results of the PH rats. Although RV free 
wall thickness was increased in PH compared with controls (p <0.001), IVS 
wall thickness was not (p = 0.24) (p-interaction <0.001).  
 
Table 2. Rat echocardiographic parameters. 
 
Variable 
PH rats 
(n = 8) 
Control rats 
(n = 8) 
 
P-value 
eRVSP, mmHg 81.4 ± 5.5 24.4 ± 5.1  <0.001 
PVR, mmHg/ml/min/mg 13.46 ± 3.37
 
0.76 ± 0.20 <0.001 
SV, ml 0.07 ± 0.01 0.21 ± 0.04 <0.001 
Heart rate, bpm 264 ± 28 432 ± 22 <0.001 
CI, ml/min/g 0.08 ± 0.02 0.34 ± 0.07 <0.001 
TAPSE, mm 1.4 ± 0.4 3.1 ± 0.3 <0.001 
RVWT, mm 1.3 ± 0.1 1.1 ± 0.1 <0.001 
IVSWT, mm 1.5 ± 0.1 1.6 ± 0.1 0.24 
LVWT, mm 1.7 ± 0.1 1.7 ± 0.1 0.74 
RVEDD, mm 7.2 ± 0.4 3.5 ± 0.7 <0.001 
LVEDD, mm 5.2 ± 0.6 8.4 ± 0.7 <0.001 
RVWT / RVEDD 0.18 ± 0.01 0.32 ± 0.08 <0.001 
LVWT / LVEDD 0.34 ± 0.06 0.20 ± 0.02 <0.001 
eRVSP = estimated right ventricular systolic pressure, IVSWT = interventricular septum wall 
thickness, LVEDD = left ventricular end diastolic diameter, LVWT = left ventricular wall 
thickness, PH = pulmonary hypertension, PVR = pulmonary vascular resistance, RVEDD = 
right ventricular end diastolic diameter, RVWT = right ventricular wall thickness, TAPSE = 
tricuspid annular plane systolic excursion. 
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Figure 2. Cellular changes in the IVS in control (grey) and pulmonary 
hypertension (PH) rats (black).  
(A) Although the RV cross-sectional area (CSA) of the cardiomyocytes was significantly 
increased in PH compared to controls, the IVS CSA was comparable in controls and PH 
rats. (B) The number of capillaries remained unchanged in both the IVS and RV of PH rats 
compared to controls. (C) The capillary density was decreased in the RV but remained 
preserved in the IVS. (D) Leukocyte infiltration is highly present in the RV in PH, but is 
absent in the PH IVS. (E) In both the IVS and the RV, fibrosis was increased in PH 
compared to controls, but the magnitude of increase was significantly smaller in the IVS. 
Data are presented as mean ± SEM. ***p <0.001. 
 
Figure 2 demonstrates a higher cardiomyocyte CSA in the RV free wall of 
PH rats than of controls (p <0.001). In PH but not in controls, we found 
larger cardiomyocytes on the right side of the IVS similar to RV free wall 
and smaller cardiomyocytes on the left side of the IVS, comparable to the 
LV free wall (Figure 3).  
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Figure 3. Cross-sectional area (CSA) of cardiomyocytes in rats with 
pulmonary hypertension (PH) and controls (Con).  
Cardiomyocytes are significantly larger at the RV cavity side of the IVS (RV-IVS) and 
smaller at the LV cavity side of the IVS (LV-IVS) in PH rats compared to controls. Data are 
presented as mean ± SEM. *p <0.05, ***p <0.001. 
 
Although the number of capillaries was similar in both groups, the capillary 
density in PH was decreased in the RV free wall due to increased CSA but 
preserved in the IVS (p-interaction <0.001). The amount of fibrosis was 
increased in both the RV free wall and IVS of PH rats compared with 
controls but the magnitude of increase was smaller in the IVS (p-interaction 
<0.001). Leukocyte infiltration was present in the RV free wall but absent in 
the IVS of PH rats. We did not observe regional heterogeneity in the IVS 
with respect to capillary density, fibrosis and leukocyte infiltration (not 
shown).  
 
In the transition from RV adaptation towards failure in PH, several RV free 
wall changes have been reported: hypertrophy, metabolic changes, altered 
cardiomyocyte contractile properties, disturbed calcium and oxygen 
handling, fibrosis and inflammation4,5. The absence of such changes in the 
IVS in the present study indicates a different biological response to 
pressure overload than the RV free wall. Both IVS mass and MRglu were 
unrelated to the RV free wall in IPAH patients. In addition, we found in PH 
rats that the CSA of RV free wall cardiomyocytes was increased whereas 
the average CSA in the IVS remained unaltered. Although the RV free wall 
showed capillary rarefaction, IVS capillary density was preserved. A 
reduced capillary density seems to be a heart-failure specific symptom20 
and therefore our results may imply that the IVS is not clearly involved in 
the process of RV failure in PH. Although not observed in the IVS, in the 
failing RV free wall high inflammatory activity results in oxidative stress, cell 
damage and apoptosis5.  
The absence of failure signs in the IVS might suggest that IVS 
cardiomyocytes are capable to sustain higher pressures/wall stress than 
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RV free wall cardiomyocytes. Another possible explanation could be that, 
with the exception of leftward IVS bulging during the RV post-systolic 
contraction period10, the IVS is not stretched/dilated during most part of the 
cardiac contraction cycle due to counterbalancing LV pressures, which 
translates into a relatively lower wall stress. 
To conclude, we showed that despite similar pressure overload in IPAH 
patients, right heart remodeling is different in the IVS and RV free wall. The 
RV free wall shows hypertrophic and metabolic changes that do not occur 
in the IVS. In PH rats, in contrast to the RV free wall, the IVS demonstrates 
preserved cardiomyocyte size and capillary density, no fibrosis and 
leukocyte infiltration. Our results imply that the IVS is an inadequate 
substitute to study remodeling processes in the right heart. Therefore, the 
future role of IVS biopsies in PH might be limited. 
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Abstract 
 
Introduction. Despite the fact that medical therapies reduce pulmonary 
vascular resistance (PVR), the prognosis of patients with pulmonary arterial 
hypertension (PAH) is still poor. The primary cause of death is right 
ventricular (RV) failure. One possible explanation for this apparent paradox 
is the fact that a reduction in PVR is not automatically followed by an 
improvement in RV function. The purpose of this study was to examine the 
relationship between changes in PVR, RV ejection fraction (RVEF) and 
survival in PAH patients under PAH targeted therapies.  
Methods. A cohort of 110 incident PAH patients underwent baseline right 
heart catheterization, cardiac magnetic resonance imaging and six-minute 
walk testing. These measurements were repeated in 76 patients after 12 
months of therapy.  
Results. Two patients underwent lung transplantation, 13 patients died 
during the first year, and 17 patients died in the subsequent follow-up of 47 
months. Baseline RVEF (hazard ratio (HR): 0.938, p = 0.001) and PVR 
(HR: 1.001, p = 0.031) were predictors of mortality. During the first 12 
months, changes in PVR were moderately correlated to changes in RVEF 
(R = 0.330, p = 0.005). Changes in RVEF (HR: 0.929, p = 0.014) were 
associated with survival but changes in PVR (HR: 1.001, p = 0.920) were 
not. In 68% of patients, PVR decreased after medical therapy. Twenty-five 
percent of those patients with decreased PVR showed a deterioration of RV 
function and had a poor prognosis.  
Conclusions. After PAH-targeted therapy, RV function can deteriorate 
despite a reduction in PVR. Loss of RV function is associated with a poor 
outcome, irrespective of any changes in PVR. 
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Introduction 
 
Pulmonary arterial hypertension (PAH) is a progressive disease of the 
pulmonary vasculature, leading to increased pulmonary vascular resistance 
(PVR), an elevated pulmonary artery pressure (PAP), right ventricular (RV) 
dysfunction, and ultimately, RV failure and death1,2. Prognosis is strongly 
associated with RV parameters, such as cardiac index and right atrial 
pressure3-5. Guided by the premise that RV failure follows an increased 
load, the current strategy to preserve RV function is by attempting to 
reduce the PVR. This strategy is effective when loading conditions can be 
normalized, which is the case in PAH patients after lung transplantation and 
in patients with chronic thrombo-embolic pulmonary hypertension after 
pulmonary endarterectomy6-8. Although PVR can be reduced by means of 
PAH-specific medication, PVR remains elevated in the vast majority of 
patients and the prognosis remains unsatisfactory3,9. This apparent contrast 
between hemodynamic success and poor prognosis raises the question 
whether RV dysfunction can progress even when the PVR is lowered but 
not normalized by current medical therapies.  
Therefore, the aim of the present study is to investigate the relationship 
between changes in PVR, right ventricular ejection fraction (RVEF) and 
survival as assessed by means of right heart catheterization (RHC) and 
cardiac magnetic resonance imaging (CMR) in a cohort of PAH patients 
receiving PAH-targeted medical therapy.  
 
 
Methods 
 
Patients 
This study is part of a prospective on-going research program to assess the 
value of CMR in patients with pulmonary hypertension. Between March 
2002 and March 2007, 657 patients were referred to the VU University 
Medical Center because of a suspected diagnosis of pulmonary 
hypertension. Based on world health organisation (WHO) guidelines10, 179 
patients were diagnosed as having PAH.  
Inclusion criteria were: (1) patients diagnosed with PAH; (2) RHC, CMR 
and six-minute walking test (6MWT) completed within 2 weeks of diagnosis 
and before the initiation of therapy. Exclusion criteria were: (1) congenital 
systemic-to-pulmonary shunts (n = 32), (2) contraindications for CMR (e.g., 
implanted devices, claustrophobia) (n = 28).  
In total, 119 PAH patients met the criteria and were enrolled. Nine patients 
were excluded because of incomplete data. Baseline measurements were 
completed in 110 patients. Thirteen patients died during the first year of 
follow-up. Seven patients did not undergo a second RHC and were 
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excluded from the follow-up analysis. Ninety out of the 110 patients 
underwent follow-up measurements consisting of a second RHC, CMR and 
6MWT, after 12 months of PAH-targeted medical treatment. Six patients 
were excluded from the final analysis because the time between the 
second RHC and CMR was >1 month. Five patients were excluded due to 
incomplete CMR data and three patients were excluded due to insufficient 
CMR quality. Seventy-six patients completed follow-up measurements 
(Figure 1). All 110 patients were followed clinically on a regular basis by 
outpatient visits and telephone contacts during a period up to May 1, 2010. 
Medical treatment comprised of prostacyclins, endothelin receptor 
antagonists and phosphodiesterase 5 inhibitors, either alone or in various 
combinations. Patients with a positive response to an acute vasodilator 
challenge were treated with calcium antagonists10. All patients received oral 
anticoagulants. During follow-up, many patients went through one or more 
treatment regimens.  
This study was approved by the institutional “Review Board on Research 
Involving Human Projects” of the VU University Medical Centre. All 
participants gave written informed consent. 
 
 
Figure 1. Study profile.  
*Excluded due to: a missing second right heart catheterization (RHC) (n = 7), interval 
between the second RHC and cardiac magnetic resonance imaging (CMR) >1 month (n = 
6), incomplete CMR cines (n = 5), and insufficient CMR image quality (n = 3). 
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Right heart catheterization 
Hemodynamic assessment was performed with a 7F balloon tipped, flow 
directed Swan-Ganz catheter (131HF7; Baxter Healthcare Corp; Irvine, CA) 
during continuous electrocardiography monitoring. PVR was calculated as: 
80*(mPAP - PCWP)/CO (mPAP is mean pulmonary artery pressure, PCWP 
is pulmonary capillary wedge pressure and CO is cardiac output).  
 
Six-minute walking test 
The 6MWT was performed according to American Thoracic Society 
guidelines11. 
 
Cardiac magnetic resonance imaging 
CMR was performed on a Siemens 1.5-T Sonato scanner (Siemens 
Medical Solutions, Siemens, Erlangen, Germany), equipped with a 6-
element phased-array receiver coil. Electrocardiographic gated cine 
imaging was performed using a balanced steady-state precession pulse 
sequence, during repeated breath-holds. Short-axis images from base to 
apex of the ventricles were obtained with a typical slice thickness of 5 mm 
and an interslice gap of 5 mm. MR parameters were: temporal resolution 
between 35 and 45 ms, typical voxel size 1.5 x 1.8 x 5.0 mm³, flip angle 
60o, receiver bandwidth 930 Hz/pixel, field of view 280 x 340 mm²; TR/TE 
3.2/1.6 ms, matrix 256 x 156. 
During post-processing, a blinded observer analysed the short-axis images 
with the MASS software package (MEDIS Medical Imaging Systems, 
Leiden, the Netherlands). On end-diastolic images (first cine after the R-
wave trigger) and end-systolic images (cine with visually the smallest cavity 
area), endocardial contours of the left ventricle (LV) and RV were obtained 
by manually tracing. Papillary muscles and trabeculae were excluded from 
the cavity. Ventricular volumes were estimated using the Simpsons rule. 
Ejection fraction was calculated as: (EDV – ESV)/EDV (EDV is end-
diastolic volume and ESV is end-systolic volume). Ventricular volumes 
were indexed by correcting for body surface area. 
 
Statistical analysis 
Data were expressed as mean ± SD for continuous variables and absolute 
for categorical variables. P <0.05 was considered significant. Comparisons 
between and within groups were calculated using unpaired and paired 
Student t-tests. Correlation coefficients were calculated by the Pearson 
method. Univariate Cox proportional hazards analyses were applied to test 
the relationship between survival and selected demographic, New York 
Heart Association functional class (NYHA), distance at 6MWT, 
hemodynamic and CMR variables measured at baseline. Kaplan-Meier 
survival estimates were stratified by the optimal cut-off values of PVR and 
RVEF and compared by log-rank tests. The optimal cut-off values were 
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identified from receiver operating characteristic (ROC) curve analyses by 
taking the sum of the highest specificity and sensitivity. Bivariate Cox 
regression analysis was used to test the relationship between baseline 
RVEF, PVR and mortality. Survival was estimated from time of enrolment 
with cardiopulmonary death and lung transplantation as the endpoints 
(median period 59 months (interquartile range: (IQR): 30 to 74 months)). 
Other causes of death were censored. We performed a sensitivity analysis 
to test whether missing values influenced the results.  
The follow-up analysis was performed in 76 patients after 12 months of 
follow-up. Univariate Cox-proportional hazard analyses were performed to 
analyse the relationship between survival and the changes in 6MWT, 
selected hemodynamic and CMR variables during 1 year of follow-up. 
Multivariable Cox survival analyses were used to examine the independent 
effect of RVEF and PVR on survival after correction for potential 
confounders. These analyses take into account the number of events and 
the number of non-events to achieve sufficient power of the test. Based on 
baseline RVEF and PVR and the changes in RVEF and PVR during follow-
up, a backward multivariable survival analysis was applied to compare the 
prognostic values of baseline parameters with those of follow-up 
parameters. 
Patients were considered to have a decreased PVR after a decrease in 
PVR of at least 15 dyne·s·cm-5. In addition, according to the results of 
Bradlow et al.12, a change of +3% defined an increased RVEF and a value 
of -3% defined a decreased RVEF. Patients with a decreased PVR were 
dichotomised: decreased PVR + stable/increased RVEF and decreased 
PVR + decreased RVEF. A landmark analysis (landmark at month 12) was 
applied to compare survival rates of both subgroups. 
All statistical analyses were carried out with SPSS (Version 15.0, SPSS, 
Inc, Chicago, Illanois). 
 
 
Results 
 
Patient characteristics 
Table 1 summarizes the demographics of the study population and Table 2 
shows the hemodynamics and volume measurements. All baseline 
measures were obtained in treatment naïve patients with PAH. The mean 
age of the study population was 53 ± 15 years, 76% were female, and most 
patients (66%) were diagnosed as having idiopathic PAH. The time 
between baseline measurements and the end of the study represents a 
long-term median follow-up period of 59 months (IQR: 30 to 74 months. 
During that period, 30 patients died from cardiopulmonary causes and two 
patients underwent lung transplantation. Thirteen patients died during the 
first year, and 17 patients died during the median subsequent follow-up of 
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47 months. One patient who died during follow-up was treated as a 
censored case: the cause of death was given as lung cancer.  
 
Table 1. Patient demographics.  
 
 
 
Variable 
Total study 
population  
 
(n = 110) 
Population 
without 
follow-up 
(n = 34) 
Follow-up 
population 
 
(n = 76) 
 
 
 
P-value 
Age, years 53 ± 15 57 ± 17 50 ± 14 0.023 
Female, n (%) 84 (76) 21 (62) 63 (83) 0.139 
Diagnosis, n (%) 
   Idiopathic PAH 
   Familial PAH 
   Associated PAH 
     CTD 
     PHT 
     HIV infection 
     Drugs/toxins 
 
73 (66) 
7 (6) 
 
20 (18) 
5 (5) 
2 (2) 
3 (3) 
 
19 (56) 
2 (6) 
 
9 (26) 
3 (9) 
1 (3) 
0 
 
54 (71) 
5 (7) 
 
11 (14) 
2 (3) 
1 (1) 
3 (4) 
 
0.445 
0.834 
 
0.419 
0.326 
0.542 
0.550 
Body surface area, m
2
 1.8 ± 0.2 1.8 ± 0.2 1.9 ± 0.2 0.170 
NYHA, n (%) 
   I/II 
   III 
   IV 
 
53 (48) 
51 (46) 
6 (6) 
 
16 (47) 
17 (50) 
1 (3) 
 
37 (49) 
34 (45) 
5 (7) 
 
0.222 
0.217 
0.628 
6MWT 
   Distance, m 
 
414 ± 135 
 
405 ± 170 
 
421 ± 117 
 
0.675 
Therapy, n (%)* 
   None 
   Ca
2+
 antagonists 
   ERA 
   PDE5I 
   Prostacyclins 
   Combination 
 
2 (2) 
3 (3) 
39 (35) 
17 (15) 
15 (14) 
34 (31) 
 
2 (6) 
2 (6) 
13 (38) 
7 (21) 
7 (21) 
3 (9) 
 
0  
1 (1) 
26 (34) 
10 (13) 
8 (11) 
31 (41) 
 
0.011 
0.966 
0.387 
0.291 
0.251 
<0.001 
*Refers to the period after baseline measurements. 6MWT = six-minute walk test, CA
2+
 = 
calcium, CTD connective tissue disease, ERA = endothelin receptor antagonists, n = 
number, NYHA = New York Heart Association functional class, PAH = pulmonary arterial 
hypertension, PDE5I = phosphodiesterase 5 inhibitors, PHT = portal hypertension. 
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Table 2. Baseline hemodynamics and volume measurements. 
 
 
 
Variable 
Baseline 
population  
 
(n = 110) 
Population 
without 
follow-up 
(n = 34) 
Follow-up 
population  
 
(n = 76) 
 
 
 
P-value 
RHC 
   mPAP, mmHg 
   mRAP, mmHg 
   PCWP, mmHg 
   PVR, dyne·s·cm
-5 
   CO, L/min 
   CI, L/min/m
2 
   Heart rate, bpm 
   SvO2, % 
 
49 ± 16 
7 ± 5 
7 ± 4 
745 ± 432 
5.1 ± 1.9 
2.8 ± 1.0 
82 ± 14 
66 ± 9 
 
47 ± 17 
6 ± 5 
8 ± 4 
720 ± 513 
5.2 ± 2.4 
2.8 ± 1.3 
80 ± 16 
65 ± 10 
 
50 ± 16 
7 ± 4 
7 ± 4 
772 ± 384 
4.9 ± 1.3 
2.7 ± 0.7 
85 ± 16 
66 ± 8 
 
0.474 
0.623 
0.220 
0.463 
0.444 
0.325 
0.313 
0.727 
CMR 
   RVEDVI, ml/m
2
 
   RVESV, ml/m
2
 
   RVEF, % 
   LVEDVI, ml/m
2
 
   LVESVI, ml/m
2
 
   LVEF, % 
   SVI, ml/m
2
 
 
71 ± 23 
47 ± 21 
36 ± 11 
42 ± 14 
15 ± 9 
67 ± 10 
28 ± 9 
 
69 ± 22 
45 ± 18 
38 ± 12 
45 ± 18 
16 ± 12 
68 ± 10 
30 ± 11 
 
72 ± 24 
48 ± 22 
35 ± 10 
41 ± 13 
14 ± 7 
66 ± 10 
27 ± 8 
 
0.611 
0.709 
0.160 
0.268 
0.364 
0.323 
0.133 
CI = cardiac index, CMR = cardiac magnetic resonance imaging, CO = cardiac output, 
LVEDVI = left ventricular end-diastolic volume index, LVEF = left ventricular ejection 
fraction, LVESV = left ventricular end-systolic volume index, mPAP = mean pulmonary 
artery pressure, mRAP = mean right atrial pressure, PCWP = pulmonary capillary wedge 
pressure, PVR = pulmonary vascular resistance, RHC = right heart catheterization, RVEDVI 
= right ventricular end-diastolic volume index, RVEF = right ventricular ejection fraction 
RVESVI = right ventricular end-systolic volume index, SVI = stroke volume index, SvO2 = 
mixed venous oxygen saturation. 
 
Baseline survival analyses 
Table 3 shows univariate Cox regression analyses. It was found that both 
RVEF (Hazard ratio (HR): 0.938, 95% confidence interval (CI): 0.902 to 
0.975, p = 0.001) and PVR (HR: 1.001, 95% CI: 1.001 to 1.002, p = 0.031) 
were associated with survival. In addition, age and connective-tissue-
disease PAH were associated with outcome. Multivariable analyses 
showed that RVEF and PVR remained significantly associated with survival 
after correction for age and type of underlying diagnosis (RVEF: HR: 0.921, 
95% CI: 0.884 to 0.959, p <0.001; PVR: HR: 1.001, 95% CI: 1.001 to 1.002, 
p = 0.002).  
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Table 3. Univariate Cox-regression analyses of baseline variables. 
 Baseline population 
(n = 110) 
 
Variable Hazard ratio 95% CI P-value 
Age, years 1.027 1.001 – 1.052 0.040 
Gender 
   Male 
   Female 
 
1 
0.789 
 
 
0.323 - 1.926 
 
 
0.603 
Diagnosis 
   Idiopathic PAH 
   Familial PAH 
   Associated PAH 
     CTD 
     PHT 
     HIV infection 
     Drugs/toxins 
 
2.064 
0.982 
 
0.306 
0.364 
0.876 
0.726 
 
0.866 - 4.238 
0.862 - 1.119 
 
0.143 - 0.654 
0.086 - 1.544 
0.545 - 1.408 
0.099 - 5.342 
 
0.163 
0.784 
 
0.002 
0.170 
0.585 
0.753 
6MWT 
   Distance, m 
 
0.993 
 
0.990 - 0.997 
 
<0.001 
RHC 
   mPAP, mmHg 
   mRAP, mmHg 
   PCWP, mmHg 
   PVR, dyne·s·cm
-5 
   CO, L/min 
   CI, L/min/m
2
 
   Heart rate, bpm 
   SvO2, % 
 
0.998 
1.048 
0.986 
1.001 
0.669 
0.560 
1.014 
0.936 
 
0.976 - 1.020 
0.981 - 1.120 
0.898 - 1.082 
1.001 - 1.002 
0.483 - 0.928 
0.323 - 0.970 
0.989 - 1.039 
0.900 - 0.972 
 
0.850 
0.167 
0.761 
0.031 
0.016 
0.039 
0.274 
0.001 
CMR 
   RVEDVI, ml/m
2
 
   RVESVI, ml/m
2
 
   RVEF, % 
   LVEDVI, ml/m
2
 
   LVESVI, ml/m
2
 
   LVEF, % 
   SVI, ml/m
2
 
 
1.011 
1.014 
0.938 
0.962 
0.942 
0.998 
0.945 
 
0.996 - 1.024 
1.001 - 1.027 
0.902 - 0.975 
0.931 - 0.994 
0.888 - 0.998 
0.960 - 1.036 
0.899 - 0.993 
 
0.121 
0.048 
0.001 
0.019 
0.045 
0.900 
0.025 
95% CI = 95% confidence interval. 
 
ROC-curve analysis revealed that RVEF and PVR at a cut-off of 35% and 
650 dyne·s·cm-5 respectively were indicators of survival (RVEF: area under 
the ROC curve (AUC): 0.749, p = 0.007, PVR: AUC: 0.628, p = 0.035). 
Univariate Cox-regression analyses based on cut-off values showed that a 
low RVEF (HR: 0.237, 95% CI: 0.102 to 0.551, p = 0.001) and a high PVR 
(HR: 2.296, 95% CI: 1.016 to 5.184, p = 0.046) were associated with 
mortality. Bivariate analysis showed that a low RVEF was independently 
associated with a poor survival (HR: 0.260, 95% CI: 0.101 to 0.670, p = 
0.005). Figure 2 shows Kaplan-Meier survival analyses based on the cut-off 
values of PVR and RVEF. Patients with low RVEF (groups 3 and 4) had a 
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significantly poorer prognosis compared with patients with high RVEF 
(groups 1 and 2), regardless of their PVR (Figure 2C). Bivariate Cox 
regression analysis applied to the combination of the binary values of 
RVEF and PVR showed that the patients with high RVEF/high PVR (group 
2) did not have a different prognosis compared to the patients with high 
RVEF/low PVR (group 1) (p = 0.579). Patients with low RVEF/low PVR 
(group 3) had a similar prognosis compared to patients with low RVEF/high 
PVR (group 4) (p = 0.830). In addition, patients of group 3 and patients of 
group 4 had 5.2 times greater HRs compared to high RVEF/low PVR 
patients (group 1) (p <0.01).  
 
 
Figure 2. Survival rates of PAH patients stratified according to PVR and 
RVEF at baseline.  
(A) Patients with pulmonary vascular resistance (PVR) <650 dyne·s·cm
-5
 showed better 
survival rates than patients with PVR >650 dyne·s·cm
-5
 (p = 0.04). (B) Patients with right 
ventricular ejection fraction (RVEF) >35% showed better survival rates compared to patients 
with RVEF <35% (p <0.001). (C) Survival rates based on the coupling of PVR and RVEF. 
PAH = pulmonary arterial hypertension. 
 
Changes with follow-up 
After a median period of 12 months (IQR: 10 to 16 months) of PAH-specific 
medical treatment, pulmonary pressures remained almost unaltered while 
PVR was significantly decreased. In addition, CI was improved and the 
6MWT was stable. No other changes in cardiac functional parameters were 
observed (Table 4). Furthermore, with respect to the effects of the different 
classes of drugs, we found no significant differences between groups 
(Table 5). 
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Table 4. Differences between characteristics at baseline and at 12 months 
follow-up. 
 (n = 76)  
Variable Baseline Follow-up P-value 
6MWT 
   Distance, m 
 
421 ± 117 
 
425 ± 139 
 
0.727 
RHC 
   mPAP, mmHg 
   mRAP, mmHg 
   PCWP, mmHg 
   PVR, dyne·s·cm
-5 
   CO, L/min 
   CI, L/min/m
2
 
   Heart rate, bpm 
   SvO2, % 
 
50 ± 16 
7 ± 4 
7 ± 4 
772 ± 384 
4.9 ± 1.3 
2.7 ± 0.7 
85 ± 16 
66 ± 8 
 
47 ± 16 
7 ± 5 
7 ± 4 
660 ± 378 
5.4 ± 2.4 
3.0 ± 1.2 
83 ± 12 
65 ± 10 
 
0.176 
0.557 
0.966 
0.003 
0.032 
0.026 
0.182 
0.641 
CMR 
   RVEDVI, ml/m
2 
   RVESVI, ml/m
2
 
   RVEF, % 
   LVEDVI, ml/m
2
 
   LVESVI, ml/m
2
 
   LVEF, % 
   SVI, ml/m
2
 
 
72 ± 24 
48 ± 22 
35 ± 10 
41 ± 13 
14 ± 7 
66 ± 10 
27 ± 8 
 
76 ± 32 
51 ± 30 
36 ± 13 
43 ± 14 
14 ± 8 
67 ± 10 
29 ± 8 
 
0.099 
0.167 
0.413 
0.374 
0.965 
0.267 
0.224 
 
Table 5. Differences between different classes of medical therapies (n = 
76). 
 
Variable* 
ERA 
(n = 26) 
PDE5I 
(n = 10) 
Prosta 
(n = 8) 
Combi 
(n = 31) 
 
P-value 
Changes in PVR, 
dyne·s·cm
-5
 
 
-133 ± 315 
 
-33 ± 271 
 
95 ± 201 
 
-180 ± 271 
 
0.311 
Changes in RVEF, 
% 
 
1 ± 8 
 
-1 ± 6 
 
-3 ± 10 
 
2 ± 9 
 
0.360 
*One patients was treated with calciumantagonists and not included in the analysis. Combi = 
combination therapy, prosta = prostacyclins. 
 
Follow-up survival analyses 
Changes in PVR correlated moderately to changes in RVEF (R = 0.330; p = 
0.005) (Figure 3). PVR decreased in both survivors (-121 ± 297 dyne·s·cm-
5) and non-survivors (-132 ± 432 dyne·s·cm-5) (p = 0.927). Changes in 
RVEF differed significantly between survivors (+3 ± 9%) and non-survivors 
(-5 ± 6%) (p = 0.001) (Figure 4). Similar results were found for the relative 
changes in PVR (survivors: -13%, non-survivors: –11%, p = 0.765) and 
relative changes in RVEF (survivors: +10%, non-survivors: -20%, p 
<0.001). Changes in PVR were not associated with outcome (HR: 1.000, 
95% CI: 0.998 to 1.001, p = 0.820), whereas changes in RVEF were 
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independently related to mortality (HR: 0.929, 95% CI: 0.875 to 0.985, p = 
0.014).  
 
Figure 3. Relation between changes in PVR and changes in RVEF. 
Changes in PVR were moderately correlated to changes in RVEF (R = 0.330, p = 0.005). 
 
 
Figure 4. Changes in PVR and RVEF after 12 months follow-up according 
to survival. 
(A) Changes in PVR did not differ between survivors (black) and non-survivors (grey). (B) 
Survivors showed an increased RVEF whereas non-survivors showed a decreased RVEF 
during follow-up. Data are presented as mean ± SEM. 
 
Table 6 shows univariate analyses of changes in hemodynamic and 
imgaging variables during follow-up. After correction for age and connective 
tissue disease PAH, changes in RVEF remained significantly associated 
with survival (HR: 0.928, 95% CI: 0.870 to 0.991, p = 0.026). A backward 
multivariable survival analyses based on baseline RVEF and PVR and the 
changes in RVEF and PVR showed that baseline RVEF and the changes in 
RVEF during follow-up had similar prognostic value (baseline RVEF: HR: 
0.926, 95% CI: 0.876 to 0.978, p = 0.006; changes in RVEF: HR: 0.909, 
95% CI: 0.846 to 0.976, p = 0.009).  
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Table 6. Univariate survival analyses of changes in follow-up variables. 
 (n = 76)  
Variable Hazard ratio 95% CI P-value 
Changes in 6MWT 
   Distance, m 
 
0.996 
 
0.989 - 1.003 
 
0.239 
Changes in RHC 
   mPAP, mmHg 
   mRAP, mmHg 
   PCWP, mmHg 
   PVR, dyne·s·cm
-5 
   CO, L/min 
   CI, L/min/m
2
 
   Heart rate, bpm 
   SvO2, % 
 
1.013 
1.050 
1.027 
1.000 
0.811 
0.705 
0.986 
0.965 
 
0.975 - 1.053 
0.945 -1.167 
0.944 - 1.118 
0.998 - 1.001 
0.619 - 1.062 
0.443 - 1.123 
0.950 - 1.024 
0.911 - 1.096 
 
0.504 
0.360 
0.530 
0.820 
0.128 
0.141 
0.475 
0.314 
Changes in CMR 
   RVEDVI, ml/m
2
 
   RVESVI, ml/m
2
 
   RVEF, % 
   LVEDVI, ml/m
2
 
   LVESVI, ml/m
2
 
   LVEF, % 
   SVI, ml/m
2
 
 
1.029 
1.036 
0.929 
0.928 
0.971 
0.988 
0.928 
 
1.013 - 1.045 
1.018 - 1.053 
0.875 - 0.985 
0.937 - 1.014 
0.909 - 1.037 
0.947 - 1.031 
0.843 - 1.015 
 
<0.001 
<0.001 
0.014 
0.179 
0.377 
0.576 
0.110 
 
In total, 52 patients (68%) showed a significant decrease of PVR after 
therapy and were included in the landmark analysis. In this group, patients 
with a decreased RVEF had a significantly poorer survival than patients 
with stable/increased RVEF (p <0.001) (Figure 5). Both groups had a 
similar decrease in PVR (mean: -284 ± 248 dyne·s·cm-5, difference in PVR: 
p = 0.437). We observed no differences in the baseline characteristics that 
could account for a different RV response to a similar decrease in PVR 
(Supplement, Table A1). Supplement, Table A2 shows the characteristics 
of both groups after follow-up.  
Thirteen patients did not survive the first year and therefore did not undergo 
follow-up measurements. The non-survivors without follow-up 
measurements showed similar characteristics as the seventeen non-
survivors with follow-up measurements (Supplement, Table A3). 
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Figure 5. Landmark analysis. 
Landmark at month 12 of 52 patients with decreased PVR after therapy. Patients with 
stable/increased RVEF (n = 39) had better survival rates than patients with decreased RVEF 
(n = 13) (p <0.001).  
 
 
Discussion 
 
Our study shows that in a large group of World Health Organisation group 1 
patients with PAH on PAH-targeted therapies, RVEF measured at baseline 
is a better predictor of mortality than PVR. Changes in RVEF after 12 
months predict long-term outcome, whereas changes in PVR do not. In 
addition, we found that changes in PVR were moderately related to 
changes in RVEF and that after medical therapy, RV dysfunction can 
progress despite a decrease in PVR. 
 
Significance of baseline parameters 
In accordance with previous studies, we showed that RVEF as assessed by 
CMR had a strong prognostic value13,14. Kawut et al. showed that RVEF is 
an independent predictor of long-term outcome15. In correspondence with 
earlier studies, we found that baseline PVR was a prognostic predictor3,4. 
However, we showed that although a high PVR at baseline was associated 
with outcome, the prognosis was primarily determined by RVEF. 
Previously, Ghio et al. found similar results in patients with pulmonary 
hypertension secondary to left heart disease16.  
 
Effects of medical therapies 
Thus far, only few studies have studied the therapeutic effects on changes 
in PVR and RV function. It was previously shown by Roeleveld et al. that 
epoprostenol therapy lowered PVR but did not affect RV dilation and 
hypertrophy17. Chin et al. reported that while bosentan reduced PVR, it did 
not affect either RVEF or RVEDV18. Wilkins et al. showed that RV mass 
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decreased after sildenafil treatment and remained stable after bosentan 
therapy19. A randomised clinical trial by Galie et al. showed that bosentan 
treatment was associated with improvement of RV systolic function as 
assessed by the RV Doppler index20. The last two studies cited did not 
include hemodynamic measures in the analyses. Although the former 
studies analysed treatment effects in PAH-patients, the relationship 
between changes in load and RV function was not been quantified.  
 
The majority of patients in our cohort (68%) had a reduced PVR after 
medical treatment. However, the reduction in PVR was modest (-12%) and 
mPAP remained almost unaltered (-5%). Despite the small patient groups, 
we found non-heterogeneity in the effects between different classes of 
medical treatment. These results are in correspondence with meta-
analyses of randomised controlled trials showing moderate reductions in 
PVR and only small reductions in mPAP over an average study duration of 
14 weeks9. Furthermore, our results agree with the findings of previous 
studies reporting a lowered PVR (ranging from –11% to –39%) after a long-
term treatment period21-26. 
 
Significance of follow-up parameters 
Our results on PVR show that although this parameter, when measured at 
baseline was of prognostic significance, a change over time of this 
parameter was not. However, we cannot conclude from this result that a 
change in PVR is not important. It has been found in an earlier study that 
PVR reduction only will lead to an improvement in survival only if reduced 
to more than 30%25. Because this was the case in a minority of our 
patients, no conclusions can be made whether a larger reduction in PVR 
will lead to an improved survival in our study.  
In the present study, we showed that the changes in RVEF during follow-up 
had similar prognostic value in comparison with baseline RVEF. In addition, 
a previous study of our group found that the changes in stroke volume 
index, RV and LV volumes were associated with mortality13. The results of 
both studies suggest that follow-up parameters may provide important 
prognostic insights.  
 
The paradox of progressive RV dysfunction despite decreased PVR 
We found that the changes in RVEF were moderately correlated to the 
changes in PVR. The most important finding of this study is that in 25% of 
the patients with a reduced PVR, RV function deteriorated further after 
follow-up. We showed that the group with a deteriorating RV function had a 
poor outcome. This deterioration was not explained by the PVR since the 
reduction in PVR occurred to a similar extent in patients with improving and 
deteriorating RVEF.  
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RV load consists of PVR, compliance and impedance of the proximal 
pulmonary artery. In previous studies of our group27,28, it was shown that 
PVR and compliance are inversely related (PVR = Constant * 
1/compliance). As a consequence, compliance is strongly correlated to 
PVR (= peripheral resistance + characteristic impedance), and therefore we 
do not think that compliance can explain additional variance in relation with 
RVEF. Recently, we showed that RV total power (associated with total 
load, i.e. compliance and PVR) and mean power (associated with non-
pulsatile load, i.e. PVR) are proportional29. These findings emphasize that 
PVR is a valid reflection of the load on the RV. 
The moderate correlation between PVR and RVEF indicated that RV 
function does not fully adapt to changes in vascular properties, as is 
expected in healthy subjects due to “coupling” of the heart and arterial 
functions. Therefore, we expected that others factors play an important role 
in the changes in RVEF over time. Kawut et al. showed that older age, 
male gender and higher von Willebrand factor were associated with lower 
RVEF30. We speculate that genetic differences in RV adaptation to 
pressure overload2 and possible direct effects of current PAH treatments on 
the heart are responsible for different RV responses. In addition, we 
hypothesize that the deterioration in RV function might possibly be 
explained by an important physiological principle: ventricular wall tension. 
The current results show that despite a reduction in PVR, pulmonary 
pressures were unaltered after medical treatment and consequently, 
ventricular wall tension will remain unchanged31. In case that wall tension is 
the driving force for the RV to fail, therapies will not prevent the RV from 
failure if failing conditions were already present at baseline.  
 
Implications 
Here we showed that changes in PVR as accomplished by currently 
available therapies do not prevent RV deterioration in 25% of the patients. 
Therefore, as RV function is the primary determinant of prognosis, it is 
important to analyse the factors that predict RV dysfunction.  
It has been shown that larger reductions in PVR and mPAP (e.g. after lung 
transplantation or endarterectomy) can result in improved RV function. We 
therefore consider that a medical treatment strategy that is more effective 
at onset could have a more pronounced effect on patient outcome. 
Furthermore, understanding the pathways that underlie RV failure could 
lead to the development of strategies that are directly targeted at improving 
RV function.  
 
Limitations 
A limitation of this study is that RHC and CMR measurements could not be 
obtained simultaneously which may have potentially resulted in 
measurements in different hemodynamic states. However, the median time 
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between CMR imaging and RHC was one day; therefore, it was unlikely 
that the delay affected our conclusions.  
In addition, since our study required follow-up measurements, patients who 
died between baseline and follow-up measurements could not be included 
in the follow-up analyses (immortal time bias)32. However, we observed no 
differences in baseline characteristics between the non-survivors without 
follow-up measurements and the non-survivors with follow-up 
measurements.  
 
 
Conclusions 
 
In PAH, baseline RVEF was a stronger prognostic predictor than baseline 
PVR. Changes in PVR after follow-up were moderately correlated with 
changes in RVEF. Moreover, this study showed that in the presence of 
PAH, right heart dysfunction may progress despite a reduced PVR by PAH-
targeted medical therapies. A deterioration of RV function was associated 
with a poor outcome, irrespective of any changes in PVR.  
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Data supplement 
 
Table A1. Subanalysis of 52 patients with decreased PVR after medical 
treatment.  
Baseline characteristics of patients with stable/increased RVEF (PVR , 
RVEF = / ) were compared to patients with decreased RVEF (PVR , 
RVEF ). 
 
 
Variable 
PVR ,  
RVEF = /   
(n = 39) 
PVR ,  
RVEF  
(n = 13) 
 
 
P-value 
Age, years 52 ± 14 47 ± 13 0.265 
Diagnosis, n (%) 
   Idiopathic PAH 
   Associated PAH 
     CTD 
 
33 (89) 
 
4 (11) 
 
10 (77) 
 
3 (23) 
 
0.780 
 
0.357 
Female, n (%) 32 (82) 9 (69) 0.420 
Survivors, n (%) 36 (92) 5 (38) <0.001 
RHC 
   mPAP, mmHg 
   mRAP, mmHg 
   PCWP, mmHg 
   PVR, dyne·s·cm
-5 
   CI, L/min/m
2
 
   Heart rate, bpm 
   SvO2, % 
CMR 
   RVEDVI, ml/m
2
 
   RVESVI, ml/m
2
 
   RVEF, % 
   LVEDVI, ml/m
2
 
   LVESVI, ml/m
2
 
   LVEF, % 
   SVI, ml/m
2
 
 
53 ± 14 
6 ± 4 
8 ± 4 
789 ± 326 
2.7 ± 0.8 
84 ± 14 
67 ± 6 
 
70 ± 27 
46 ± 25 
35 ± 10 
41 ± 12 
14 ± 5 
67 ± 9 
28 ± 8 
 
51 ± 17 
9 ± 6 
6 ± 4 
969 ± 622 
2.5 ± 0.7 
85 ± 16 
67 ± 11 
 
77 ± 24 
52 ± 23 
36 ± 10 
44 ± 17 
16 ± 10 
67 ± 13 
28 ± 9 
 
0.712 
0.158 
0.108 
0.335 
0.347 
0.820 
0.270 
 
0.430 
0.492 
0.973 
0.632 
0.541 
0.897 
0.793 
CI = cardiac index, CMR = cardiac magnetic resonance imaging, CO = cardiac output, CTD 
= connective tissue disease, LVEDVI = left ventricular end-diastolic volume index, LVEF = 
left ventricular ejection fraction, LVESVI = left ventricular end-systolic volume index, mPAP = 
mean pulmonary artery pressure, mRAP = mean right atrial pressure, PCWP = pulmonary 
capillary wedge pressure, PVR = pulmonary vascular resistance, RHC = right heart 
catheterization, RVEDVI = right ventricular end-diastolic volume index, RVEF = right 
ventricular ejection fraction, RVESVI = right ventricular end-systolic volume index, SVI = 
stroke volume index, SvO2 = mixed venous oxygen saturation. 
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Table A2. Subanalysis of 52 patients with decreased PVR after therapy.  
Changes in characteristics during follow-up of patients with 
stable/increased RVEF (PVR , RVEF = / ) were compared to patients 
with decreased RVEF (PVR , RVEF ).  
 
 
Variable 
PVR ,  
RVEF = /   
(n = 39) 
PVR ,  
RVEF  
(n = 13) 
 
 
P-value 
Changes in 6MWT 
   Distance, m 
 
24 ± 68 
 
58 ± 115 
 
0.349 
Changes in RHC 
   mPAP, mmHg 
   mRAP, mmHg 
   PCWP, mmHg 
   PVR, dyne·s·cm
-5 
   CI, L/min/m
2
 
   Heart rate, bpm 
 
-10 ± 10 
-1 ± 5 
7 ± 4 
-268 ± 212 
0.7 ± 1.3 
-2 ± 13 
 
-4 ± 16 
-2 ± 4 
5 ± 4 
-331 ± 308 
0.5 ± 0.6 
-7 ± 23 
 
0.112 
0.433 
0.247 
0.437 
0.650 
0.392 
Changes in CMR  
   RVEDVI, ml/m
2
 
   RVESVI, ml/m
2
 
   RVEF, % 
   LVEDVI, ml/m
2
 
   LVESVI, ml/m
2
 
   LVEF, % 
   SVI, ml/m
2
 
 
2 ± 21 
-2 ± 18 
7 ± 8 
6 ± 10 
1 ± 7 
3 ± 9 
5 ± 6 
 
1 ± 32 
5 ± 26 
-6 ± 3 
-1 ± 13 
-1 ± 10 
-3 ± 12 
-2 ± 5 
 
0.909 
0.377 
<0.001 
0.092 
0.619 
0.077 
0.001 
6MWT = six-minute walking test, n = number, PAH = pulmonary arterial hypertension.  
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Table A3. Differences in baseline characteristics between survivors, non-
survivors without follow-up measurements and non-survivors with follow-up 
measurements. 
 
 
 
 
Variable 
Survivors 
 
 
 
(n = 78) 
Non-survivors  
without follow-
up 
measurements 
(n = 14) 
Non-survivors  
with follow-up 
measurements 
 
(n = 18) 
Age, years 52 ± 15 57 ± 18 56 ± 15 
Female, n (%) 60 (77) 11 (79) 13 (72) 
Diagnosis, n (%) 
   Idiopathic PAH 
   CTD 
   Other 
 
57 (73) 
10 (13) 
11 (14) 
 
7 (50) 
5 (36) 
2 (14) 
 
9 (50) 
5 (28) 
6 (33) 
6MWT 
   Distance at 6WT, m 
 
443 ± 128 
 
247 ± 132 
 
388 ± 102
†,║
 
RHC 
   mPAP, mmHg 
   mRAP, mmHg 
   PCWP, mmHg 
   PVR, dyne·s·cm
-5 
   CO, L/min 
   CI, L/min/m
2 
   Heart rate, bpm 
   SvO2, % 
 
50 ± 16 
6 ± 4 
7 ± 4 
731 ± 372 
5.2 ± 1.8 
2.9 ± 1.1 
82 ± 14 
66 ± 9 
 
49 ± 15 
7 ± 8 
8 ± 4 
871 ± 631 
4.2 ± 2.0 
2.5 ± 1.2 
80 ± 16 
62 ± 11
*
 
 
49 ± 16 
8 ± 5 
6 ± 4 
915 ± 508
 
4.4 ± 1.0 
2.5 ± 0.6 
86 ± 17 
61 ± 10
§
 
CMR 
   RVEDVI, ml/m
2
 
   RVESVI, ml/m
2
 
   LVEDVI, ml/m
2
 
   LVESVI, ml/m
2
 
   RVEF, % 
   LVEF, % 
   SVI, ml/m
2
 
 
69 ± 23 
45 ± 16 
44 ± 15 
16 ± 9 
38 ± 11 
67 ± 10 
30 ± 9 
 
70 ± 20 
48 ± 21 
35 ± 8
*
 
10 ± 5
*
 
33 ± 10 
70 ± 8 
25 ± 6 
 
79 ± 37 
56 ± 33 
38 ± 11 
14 ± 7 
30 ± 8
§
 
65 ± 11 
25 ± 5
‡
 
*
p <0.05 survivors vs. non-survivors <12months, 
†
p <0.001 survivors vs. non-survivors <12 
months, 
‡
p <0.05 survivors vs. non-survivors >12 months, 
§
p <0.01 survivors vs. non-
survivors >12 months, 
║
p <0.05 non-survivors <12 months vs. non-survivors >12 months.  
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Abstract 
 
Introduction. Male sex is an independent predictor of worse survival in 
pulmonary arterial hypertension (PAH). This finding might be explained by 
more severe pulmonary vascular disease, worse right ventricular (RV) 
function or different response to therapy. The aim of this study was to 
investigate the underlying cause of sex differences in survival in treated 
PAH patients. 
Methods. This was a retrospective cohort study of 101 patients with PAH 
(82 idiopathic, 15 heritable, 4 anorexigen associated) who were diagnosed 
at our institute between February 1999 and January 2011 and underwent 
right heart catheterization and cardiac magnetic resonance imaging to 
assess RV function. Change in pulmonary vascular resistance (PVR) was 
taken as a measure of treatment response on the pulmonary vasculature, 
whereas change in right ventricular ejection fraction (RVEF) was used to 
assess right ventricular (RV) response to therapy.  
Results. PVR and RVEF were comparable between men and women at 
baseline, however male patients had a worse transplant-free survival 
compared to female patients (p = 0.002). While male and female patients 
showed a similar reduction in PVR after one year, RVEF improved in 
female patients whereas it deteriorated in male patients. In a mediator 
analysis, after correcting for confounders, 39.0% of the difference in 
transplant-free survival between men and women was mediated through 
changes in RVEF after initiating PAH medical therapies. 
Conclusions. This study suggests that differences in RVEF response with 
initiation of medical therapy in PAH explain a significant portion of the 
worse survival seen in males. 
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Introduction 
 
Pulmonary arterial hypertension (PAH) is a rare disease characterized by 
obstructive lesions of the small pulmonary vessels, leading to increased 
pulmonary artery pressure (PAP), right-sided heart failure and death within 
several years1-2. Despite the advent of improved therapies outcome 
remains poor3,4. Prognosis correlates with severity of right ventricular (RV) 
structure and function2,5. More recently, male sex was identified as an 
independent predictor of mortality6-10. Men treated with endothelin receptor 
antagonists had less six minute walk improvement11. The cause of these 
sex differences is unknown, however a distinct vascular and/or RV 
response to medical therapies is one possibility. Considering the need for 
improved treatments and “personalized therapy”, a better understanding of 
these sex differences would be important. The aim of our study was to 
investigate the role of the pulmonary vasculature and the right ventricle in 
explaining sex differences in survival of treated IPAH.  
 
 
Methods 
 
Patients 
All idiopathic (IPAH), anorexigen associated (APAH) and heritable PAH 
(HPAH) treated at the VU University Medical Center (VUMC) between 
February1999 and January 2011 were eligible. Diagnosis was according to 
the guidelines and included right heart catheterization (RHC). Medical 
treatment comprised prostacyclin analogues, endothelin receptor 
antagonists (ERA) and phosphodiesterase type-5 inhibitors (PDE5-I) either 
alone or in various combinations. Patients with a positive vasodilator 
challenge were treated with calcium antagonists1. This was a retrospective 
cohort study of patients enrolled in an ongoing prospective study to assess 
the clinical value of cardiac magnetic resonance imaging (CMR) in PAH. All 
patients who had RHC and CMR performed prior to initiation of medical 
therapy (n = 101 out of n = 186 patients evaluated during this period) were 
included.  
 
Right heart catheterization 
Hemodynamic assessment was performed with a 7-F balloon tipped flow 
directed Swan-Ganz catheter (131HF7, Baxter Healthcare Corp., Irvine, 
California). Baseline and follow-up RHC measurements of pulmonary artery 
pressure (PAP), right atrial pressure (RAP), pulmonary capillary wedge 
pressure (PCWP), cardiac output (CO) were obtained. Pulmonary vascular 
resistance (PVR) was calculated as 80*(meanPAP-PCWP)/CO. 
Vasoreactivity testing was with inhaled nitric oxide (20 ppm). Acute 
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vasoreactivity defined as a mean PAP reduction ≥10 mmHg to reach an 
absolute value ≤40 mmHg with increased or unchanged CO. 
Venous blood sampling was performed to measure glomerular filtration rate 
(GFR) (Cockgroft), creatinine and N-terminal pro-brain natriuretic peptide 
(NT-proBNP). 
 
Six-minute walking test 
The six-minute walking test (6MWT) was performed according to ATS-
guidelines. 
 
Cardiac magnetic resonance imaging 
CMR was performed on a Siemens Avanto 1.5 T and 1.5 T Sonata scanner 
(Siemens Medical Solutions, Erlangen, Germany), equipped with a 6-
element phased-array coil. ECG-gated cine imaging was performed using a 
balanced steady, free precession pulse sequence, during repeated breath-
holds. Short-axis slices were obtained with, slice thickness 5 mm and 
interslice gap 5 mm, fully covering both ventricles from base to apex. 
Temporal slice resolution between 35 and 45 ms, voxel size 1.8 x 1.3 x 5.0 
mm3, flip angle 60o, receiver bandwidth 930 Hz/pixel, TR/TE 3.2/1.6 ms, 
matrix 256 x 156. 
End-diastolic and end-systolic endocardial and epicardial contours were 
delineated manually by an observer blinded to other clinical information and 
processed using MASS software (MEDIS Medical Imaging Systems, 
Leiden, the Netherlands) to obtain RV end-diastolic and end-systolic 
volumes (RVEDV and RVESV respectively) and RV mass. Papillary 
muscles and trabeculae were excluded from the cavity, and included in RV 
mass. RV stroke volume (RVSV) and ejection fraction (RVEF) were 
calculated: RVSV = RVEDV – RVESV and RVEF = RVSV/RVEDV12. RV 
mass / RVEDV was used as a measure of relative RV wall thickness13,14. 
 
Statistical analysis 
Measurements are reported as mean ± standard deviation and median 
(interquartile range) where appropriate. Continuous variables were 
compared using student t-tests or Mann-Whitney U, where not normally 
distributed. Categorical variables compared using Pearson Chi-square tests 
and Fisher’s exact tests, as needed.  
Follow-up was until September 2011. Transplant-free sex survival 
differences were confirmed using Kaplan Meier curves and log-rank test. 
Confounders accounted for by Cox regression. Variables leading to a 10% 
change in the coefficient for sex were included in the final survival 
prediction model. Variables screened for confounding included: age, height, 
weight, World Health Organization functional class (WHO FC), number of 
comorbidities (1, 2 and 3), RVEF, RV wall thickness, GFR, PVR and type 
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of medical therapy used (prostacyclins yes/no, endothelin receptor 
antagonist yes/no and phosphodiesterase type 5 inhibitor yes/no). 
Sex differences in secondary treatment outcomes, NT-proBNP, 6-minute 
walking distance, renal function, RHC hemodynamics and CMR were 
confirmed using linear regression with the follow-up measurement as the 
dependent variable and the baseline measurement and sex as independent 
variables. WHO FC change differences were confirmed by ordinal 
regression. Multiple imputation was used for missing follow-up CMR 
variables. We multiply imputed 100 datasets. Linear regression models 
were estimated in each dataset and regression coefficients and standard 
errors pooled and the p-value of each coefficient in the model determined. 
To correct for confounders a similar approach was used as discussed 
above for the survival analysis. 
An exploratory mediator analysis was done to confirm that transplant-free 
sex survival differences were mediated through differences in RVEF 
change. Analysis was done according to Baron and Kenny15 and consists 
of 3 steps. In step 1, sex was confirmed as an independent predictor of 
transplant-free survival by Cox regression. Step 2 was to confirm that sex 
was an independent predictor of the proposed mediator by linear 
regression. Step 3 employs a Cox regression model for transplant-free 
survival including sex and the potential mediator as independent variables 
and its purpose is to confirm the proposed mediator is a significant 
predictor of survival, while controlling for sex. RVEF and PVR changes 
were both examined as potential mediators. This was done by adding 
follow-up measurements of respectively RVEF and PVR to a Cox 
regression equation containing gender and the baseline value. A greater 
than 10% change in the coefficient of sex after adding the follow-up value 
of the proposed mediator was accepted as evidence of significant 
mediation. The magnitude of the indirect (mediated) effect was calculated 
according to the following formula: 
 
Indirect effect = 1 – ( c’ / c ) 
 
In the formula, c is the coefficient for sex in the Cox regression formula 
predicting survival, corrected for baseline RVEF; c’ is the coefficient for sex 
in the Cox regression formula predicting survival corrected for RVEF 
baseline value and RVEF change by adding the follow-up RVEF value to 
the equation. In addition a mediator analysis corrected for all potential 
confounders mentioned earlier was performed16. 
Analysis were performed using IBM SPSS statistics 19.0 software. This 
study was approved by the VUMC Research and Ethics Review boards 
(METC) (approval number 2012288). 
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Results 
 
Patient characteristics and treatments 
One-hundred-eighty-six patients (155 IPAH, 25 HPAH and 6 APAH) were 
treated at the VUMC between February 1999 and January 2011. Eight-five 
patients were excluded. Reasons for exclusion were: no CMR due to 
logistical reasons (n = 44), first-line treatment elsewhere (n = 25), 
contraindications for CMR (n = 11) and no PAH medication initiated (n = 5). 
Apart from age, Table A1 (Supplement) indicates similar characteristics 
compared to those included for further analysis (n = 101). The six-minute 
walking distance tended to be greater in those included, however the % 
predicted distance was similar.  
The remaining 101 patients had CMR and RHC at baseline before starting 
PAH specific medical therapies (Table 1). In these patients men had larger 
RVEDV and RVESV, but had similar invasively measured hemodynamics 
and similar RVSV and RVEF compared to women. Median (IQR) time 
between baseline CMR and RHC was 0.2 months (0.0 - 1.95 months). 
Table A2 (Supplement) depicts prescribed medications between baseline 
and follow-up assessment. Follow-up CMR and RHC were performed after 
respectively 1.1 years (0.9 - 1.7 years) and 1.1 years (0.9 - 2.2 years). Time 
on PAH specific medication was 5.4 years (2.1 - 7.7 years). Time to 
addition of other PAH specific therapy was 5.0 months (2.3 - 6.0 months) 
for those patients who had PAH specific drugs added before follow-up 
measurements. 
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Table 1. Baseline patient characteristics, RHC and CMR measurements in 
male and female pulmonary arterial hypertension (PAH). 
 
Variable 
Male 
(n = 26) 
Female 
(n = 75) 
 
P-value 
Age, years 50 ± 19 47 ± 15 0.31 
Idiopathic, n (%) 23 (88) 59 (79) 0.55 
Heritable, n (%) 3 (12) 12 (16) 0.75 
Anorexigen, n (%) 0 (0) 4 (5) 0.57 
BMI, kg/m
2
 27 ± 3 26 ± 6 0.34 
WHO FC, n (%)   0.09 
   Class I 1 (4) 0  (0)  
   Class II 7 (27) 12 (16)  
   Class III 13 (50) 40 (53)  
   Class IV 5 (19) 23 (31)  
Comorbidities, n (%)   0.82 
   0 9 (35) 25 (33)  
   1 6 (23) 26 (35)  
   2 8 (31) 12 (16)  
   ≥ 3 3 (12) 12 (16)  
6MWD, m 388 ± 189 353 ± 150 0.40 
6MWD, % predicted 62 ± 27 61 ± 23 0.82 
Creatinine, mmol/L 110 ± 27 94 ± 17 0.001 
GFR, ml/min 88 ± 31 75 ± 19 0.01 
NT-proBNP, ng/L
* 
1414 ± 1668 1887 ± 1913 0.34 
RHC    
   RAP, mmHg 10 ± 6 9 ± 5 0.11 
   mPAP, mmHg 53 ± 15 57 ± 13 0.29 
   PCWP, mmHg 8 ± 4 8 ± 5 0.65 
   CO, L/min 4.73 ± 1.63 4.55 ± 1.63 0.61 
   PVR, dyn·s·cm
-5
 903 ± 545 963 ± 473 0.61 
   Acute 
vasoreactivity 
#
 
 
3/23 (13%) 
 
7/66 (11%) 
0.71 
CMR    
   RVEDV, ml 177 ± 68 137 ± 41 0.001 
   RVEDVI, ml/m
2 
89 ± 36 76 ± 21 0.03 
   RVESV, ml 124 ± 54 93 ± 35 0.001 
   RVESVI, ml/m
2
 62 ± 28 52 ± 19 0.04 
   RVEF, % 31 ± 13 33 ± 11 0.44 
   RVSV, ml 53 ± 30 44 ± 19 0.38 
   RVSVI, ml/m
2
 27 ± 17 25 ± 10 0.38 
   RV mass, g 104 ± 41 81 ± 28 0.009 
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RVEDV, g/ml 
 
0.64 ± 0.31 
 
0.62 ± 0.23 
 
0.75 
Data are presented as mean ± SD. 6MWD = six-minute walk distance, BMI = body mass 
index, CMR = cardiac magnetic resonance imaging, CO = cardiac output, GFR = glomerular 
filtration rate, mPAP = mean pulmonary artery pressure, NT-proBNP = N-terminal pro-brain 
natriuretic peptide, PCWP = pulmonary capillary wedge pressure, PVR = pulmonary 
vascular resistance, RAP = right atrial pressure, RHC = right heart catheterization, RVEDV = 
right ventricular end-diastolic volume, RVEF = right ventricular ejection fraction, RVESV = 
right ventricular end-systolic volume, RVSV = right ventricular stroke volume, WHO FC = 
world health organization functional class. CMR volumes are also provided indexed (I) for 
body surface area. 
*
NT-proBNP was measured in a subgroup of n = 20 males and n = 52 
females. 
#
Acute vasoreactivity was measured in a subgroup of n = 66 females and n = 23 
males. RV mass / RVEDV is a measure of relative RV wall thickness. 
 
Survival and secondary treatment outcomes 
In the 101 patients included median (IQR) follow-up time was 5.7 years (2.5 
to 8.1 years), and there were 26 deaths and 5 lung transplantations. In 
males, cumulative transplant-free survival was 84% at 1 year and 57% at 5 
years. In females, survival was 100% at 1 year and 85% at 5 years (log-
rank, p = 0.002, HR: 3.04, 95% CI: 1.45-6.41, Figure 1). The association 
between sex and survival after adjustment for confounders in multivariate 
analysis remained (HR: 7.21, 95% CI: 4.18-12.43, p<0.001). The 
confounders retained in the final model were height, GFR and WHO FC.  
Male patients had higher NT-proBNP, lower 6-minute walking distance and 
more severe WHO FC at follow-up in basic (Table 2) and covariate-
adjusted models (Table 3). 
 
 
Figure 1. Kaplan-Meier survival analyses of female (black) and male (grey) 
patients with pulmonary arterial hypertension (PAH) starting first-line PAH-
specific therapies. 
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Table 2. Results of linear regression of sex differences in hemodynamics, 
CMR measurements and other secondary treatment outcome parameters 
corrected for the baseline value. 
 
 
 
 
Variable 
Difference for men 
vs. women in 
follow-up measure 
after adjustment 
for baseline
 
 
 
 
 
95% CI 
 
 
 
 
P-value 
WHO FC +1.4 +0.4 to +2.3 <0.01 
6MWD, m -71 -123 to -19 <0.01 
Creatinine, mmol/L +17 +6 to +29 <0.01 
GFR, ml/min -5 -11 to +1 0.12 
NT-proBNP, ng/L +1385 +482 to +2288 <0.01 
RHC    
   Heart rate, bpm +3 -7 to +13 0.56 
   RAP, mmHg +2 -1 to +6 0.17 
   mPAP, mmHg +1 -7 to +9 0.81 
   CO, L/min +0.2 -1 to +1 0.78 
   SV, ml -4 -19 to +11 0.59 
   PVR, dyn·s·cm
-5
 -60 -301 to +182 0.63 
CMR    
   RVEF, % -8.1 -14 to -2 <0.01 
   RVEDV, ml +11.9 -5 to +29 0.18 
   RVESV, ml +13.8 -2 to +30 0.09 
   RVSV, ml -5.5 -14 to +3 0.19 
   RV mass, g +2.9 -12 to +18 0.70 
   RV mass / 
RVEDV, g/ml 
 
+0.04 
 
-0.09 to +0.16 
 
0.57 
b = coefficient for sex (male = 1, female = 0).  
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Table 3. Results of multivariate analysis* of sex specific RHC, CMR 
measurements and other treatment outcome parameter changes compared 
to baseline.  
 
 
 
 
 
Variable 
Difference for men 
vs. women in 
follow-up measure 
after adjustment 
for baseline and 
confounders
 
 
 
 
 
 
95% CI 
 
 
 
 
 
P-value 
WHO FC +1.9 +0.9 to +3.0 <0.001 
6MWD, m -70 -127 to -12 0.02 
Creatinine, mmol/L +14 +3 to +25 0.01 
GFR, ml/min -6 -13 to 0 0.05 
NT-proBNP, ng/L +1385 +482 to +2288 <0.01 
RHC    
   Heart rate, bpm +5 -7 to +17 0.42 
   RAP, mmHg +2 -1 to +6 0.25 
   mPAP, mmHg +2 -8 to +11 0.73 
   CO, L/min +0.0 -1 to +1 0.99 
   SV, ml -7 -24 to +11 0.45 
   PVR, dyn·s·cm
-5
 -35 -337 to +267 0.82 
CMR    
   RVEF, % -7.2 -13 to -1 0.02 
   RVEDV, ml -0.4 -19  to +18 0.97 
   RVESV, ml +5.2 -13 to +23 0.58 
   RVSV, ml -9.5 -19 to 0 0.04 
   RV mass, g +3.8 -13 to +21 0.67 
   RV mass / 
RVEDV,  g/ml 
 
+0.09 
 
-0.05 to +0.24 
 
0.22 
*
Multivariate analysis results showing the coefficient b for sex (male = 1; female = 0) 
corrected for potential confounding by age, weight, height, number of comorbidities, baseline 
RVEF, GFR, PVR, WHO FC and type of PAH specific medical therapy initiated. 
 
RHC and CMR 
RHC showed no significant differences in treatment response associated 
with sex (Tables 2 and 3). Median PVR changes (IQR) were -78 dyn·s·cm-5 
(-523 to +10 dyn·s·cm-5) in males and -165 dyn·s·cm-5 (-436 to +92 
dyn·s·cm-5) in females. 
Eighty patients had baseline and follow-up CMR performed. Reasons for 
not performing follow-up measurements in males were: patient deceased (n 
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= 3), patient follow-up <1 year (n = 3), patient too disabled to undergo CMR 
(n = 3), unknown (n = 1). In females these were patient refusal (n = 4), 
patient follow-up <1 year (n = 3), patient too disabled (n = 2), psychiatric 
disorder (n = 1) and technical CMR problems (n = 1). Corrections for 
missing follow-up measurements were made by multiple imputation. 
After the baseline assessment, RVEF decreased in males (median, IQR) -
1.0 % (-11.9 to +6.9 %) and increased in females +3.6 % (-3.0 to +13.0 %). 
Tables 2 and 3 depict results of univariate and multivariate analysis of sex 
difference in CMR changes. Calculated RVEF change corrected for 
confounders was -1.8 ± 6.5 % in males and +5.3 ± 5.4 % in females (p 
<0.001). 
 
Mediator analysis 
Step 1 and step 2 of the mediator analysis were reported above. In step 1 
sex was confirmed as an independent predictor of survival. In step 2 sex 
was confirmed as an independent predictor of RVEF change. Results of 
step 3 are reported in Table 4, which shows the results of cox regression 
for transplant-free survival with sex and the baseline value of the potential 
mediator. The B coefficient of sex changed substantially after RVEF follow-
up measurements were added to the equation and significance of sex as 
predictor of transplant-free survival was lost, thus showing evidence that 
the impact of sex on survival was mediated through RVEF at follow-up. 
There is no evidence for mediation through PVR changes as the B 
coefficient for sex remains similar in the cox regression formula with sex 
and baseline PVR compared to the formula with sex, baseline PVR and 
follow-up PVR. The amount of change in B for sex after adding follow-up 
values of RVEF or PVR to the Cox regression equation gives a sense of 
how much of the variance in outcome associated with sex is explained by 
changes of each hemodynamic parameter. In the basic model, 42.8 % of 
the effect of sex on survival was mediated through RVEF. After adjustment 
for confounders this was 39.0 %. 
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Table 4. Results from cox-regression for transplant-free survival with 
respectively sex and the baseline measurement and subsequently sex, the 
baseline measurement and the follow-up measurement for respectively 
RVEF and PVR. Crude analysis (A) and analysis including corrections for 
confounders (B) is reported. 
  
B
 
 
Exp (B) 
95% CI of 
Exp (B) 
 
P-value 
A     
Gender (male vs. 
female) 
1.029 2.80 1.33 - 5.91 0.007 
Baseline RVEF -0.05 0.95 0.92 - 0.99 0.007 
     
Gender 0.589 1.80 0.81 - 4.01 0.15 
Baseline RVEF -0.01 0.99 0.95 - 1.04 0.81 
Follow-up RVEF -0.07 0.94 0.89 - 0.98 0.006 
B     
Gender 1.397 4.04 2.50 - 6.54 0.004 
Baseline RVEF -0.05 0.95 0.93 - 0.97 0.009 
     
Gender 0.852 2.34 0.93 - 5.92 0.07 
Baseline RVEF -0.01 0.99 0.95 - 1.04 0.76 
Follow-up RVEF -0.07 0.94 0.89 - 0.98 0.006 
A     
Gender 1.11 3.04 2.08 - 4.45 0.003 
Baseline PVR 0.00 1.00 1.00 - 1.00 0.95 
     
Gender 1.20 3.31 1.53 - 7.16 0.002 
Baseline PVR 0.00 1.00 1.00 - 1.00 0.53 
Follow-up PVR 0.00 1.00 1.00 - 1.00 0.12 
B     
Gender 1.51 4.52 1.83 - 11.18 0.001 
Baseline PVR 0.00 1.00 1.00 - 1.00 0.84 
     
Gender 1.476 4.38 1.77 - 10.84 0.001 
Baseline PVR 0.00 1.00 1.00 - 1.00 0.48 
Follow-up PVR 0.00 1.00 1.00 - 1.00 0.19 
 
 
Discussion 
 
Our data confirmed previous findings of worse outcome in males6. This 
survival difference was not associated with either baseline characteristics 
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or differences in responsiveness of the pulmonary vascular bed to therapy, 
but rather differences in RVEF after starting medical therapies. NT-proBNP 
changes are correlated with RV strain and RVEF measured by CMR and 
the NT-proBNP differences found in our study further support our CMR 
findings17-19. In an earlier study RVEF change difference between survivors 
and non-survivors in PAH was 8%, further illustrating that the difference 
found in our study is clinically meaningful20. 
 
Sex differences have been well documented in diseases of the left 
ventricle. In the Framingham study, worse survival was observed in male 
heart failure patients21. Systolic heart failure is predominantly found in men 
whereas women rather present with heart failure with preserved ejection 
fraction22. In analogy female pressure loaded hearts showed more 
preserved ejection fractions in aortic stenosis23. In a recent study of 
hypertensive patients left ventricular mass variance explained by arterial 
blood pressure was much higher in females. This could be interpreted as 
further evidence of better cardiac adaptation in females24.  
Little is known about sex differences in disease of the right ventricle. 
Healthy women have lower RV mass, smaller RV volumes, and higher 
RVEF than men25. Ventetuolo et al. showed an association between higher 
estradiol levels and improved RVEF in women and an association between 
increased androgen levels and increased RV mass and RV volumes26. In a 
rodent model testosterone and estradiol both caused pulmonary 
vasodilation27. In male mice testosterone affected RV hypertrophic stress 
response after pulmonary artery banding through increased myocyte size 
and increased fibrosis. Testosterone deprivation through castration 
improved survival in these mice28. In addition estrogen and estrogen 
receptor agonist therapy restored RV structure and function in a rodent 
model of monocrotaline induced PH29. 
 
Our study found no differences in pulmonary vascular responses to PAH 
specific medications. Hitherto no other studies in humans reported on sex 
differences in pulmonary vascular response. We found no sex differences 
in cardiac output, and this further points out the problems with only looking 
at resting CO, rather than at RV structure and RV systolic function (RVEF). 
During disease progression resting CO can be maintained through an 
increased heart rate. In addition stroke volume can be relatively preserved 
through the Starling mechanism. However, in progressive RV dilation RVEF 
will decrease and RVEF may be a more sensitive parameter for disease 
progression2. It cannot be ruled out that CO differences do occur upon 
exercise.  
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Study limitations 
Our study has some limitations. Not all patients evaluated at our center 
were included. While those included appeared similar to those excluded, 
selection bias could still be possible. We attempted to account for a variety 
of confounders, however we cannot exclude residual or unmeasured 
confounding. There were some missing data; we used multiple imputation 
to allow inclusion of all subjects in the study sample in all analyses. Finally, 
this is an observational study, preventing us from confirming causality, 
however the use of sex as our exposure and prospective reassessments of 
RV function support causal inferences. We only studied the idiopathic, 
heritable and anorexigen associated form of PAH, so these findings may 
not be generalizable to other forms of PAH. However sex differences in 
survival are also reported in connective tissue disease associated PAH30, 
although in associated PAH the survival difference was limited to elderly 
patients9. Since RVEF could explain 40% of the observed survival 
difference, other factors must contribute. However, these factors cannot be 
identified through our study, as the small patient number prohibits further 
exploratory analysis. 
 
 
Conclusions 
 
Our study suggests a sex difference in cardiac adaptation to treatment with 
long-term improvements in RVEF in women, but not in men. Mediator 
analysis suggests this different cardiac adaptation may cause decreased 
survival in males. To further improve treatments, the pathophysiology of 
sex differences in cardiac response to medical therapies should further be 
elucidated. Evidence for differences in cardiac responses in associated 
forms of PAH should be studied. Furthermore, the role of sex hormones, 
and the potential of substances targeting sex-specific pathways, such as 
estrogen receptor agonists should be further evaluated29. 
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Data supplement 
 
Table A1. Patient characteristics and hemodynamics in patients with 
pulmonary arterial hypertension (PAH) included in study compared to those 
excluded. 
 
Variable 
Included 
(n = 101) 
Excluded 
(n = 85) 
Age, years 48 ± 16 57 ± 18 
Gender, m/f 26/75 28/57 
BMI, kg/m
2
 26 ± 5 28 ± 6 
WHO FC, n   
   Class I 3 1 
   Class II 14 19 
   Class III 41 53 
   Class IV 27 28 
Comorbidities, n   
   0 34 30 
   1 32 22 
   2 20 19 
   ≥ 3 15 14 
6MWD, m 362 ± 162 307 ± 126 
6MWD, % predicted 61 ± 24 58 ± 21 
Creatinine, mmol/L 98 ± 21 100 ± 23 
GFR, ml/min 78 ± 24 76 ± 31 
NT-proBNP, ng/L
* 
1765 ± 1865 1824 ± 2486 
RHC   
   RAP, mmHg 9 ± 5 9 ± 6 
   mPAP, mmHg 56 ± 14 49 ± 12 
   PCWP, mmHg 8 ± 5 10 ± 7 
   CO, L/min 4.60 ± 1.63 4.65 ± 1.75 
   CI, L/min/m
2
 2.50 ± 0.93 2.51 ± 0.96 
   PVR, dyn·s·cm
-5
 957 ± 493 802 ± 462 
   PVRI, dyn·s·cm
-5
·m
2 
1760 ± 919 1505 ± 835 
6MWD = six-minute walk distance, BMI = body mass index, BSA = body surface area, CI = 
cardiac index, CO = cardiac output, GFR = glomerular filtration rate (Cochroft), mPAP = 
mean pulmonary artery pressure, NT-proBNP = N-terminal pro-brain natriuretic peptide, 
PCWP = pulmonary capillary wedge pressure, PVR = pulmonary vascular resistance, PVRI 
= pulmonary vascular resistance index, RAP = right atrial pressure, RHC = right heart 
catheterization, WHO FC = world health organization functional class. 
*
NT-proBNP was 
measured in a subgroup of respectively n = 72 and n = 40.  
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Table A2. PAH medical treatment regimens in respectively men and 
women. 
 
Variable 
Male 
(n = 26) 
Female 
(n = 75) 
 
P-value 
First-line therapy, n (%)    
   Prostacyclins 4 (15%) 23 (31%) 0.20 
   ERA 13 (50%) 30 (40%) 0.74 
   PDIE5 4 (15%) 9 (12%) 0.74 
   ERA + PDIE5 2 (8%) 3 (4%) 0.60 
   ERA + Prostacyclins 0 (0%) 3 (4%) 0.57 
   Ca
2+
 blockers 3 (12%) 7 (9%) 0.71 
Add-on therapy, n (%)    
   ERA + PDIE5 4 (15%) 17 (23%) 0.58 
   ERA + Prostacyclins  1 (4%) 1 (1%) 0.45 
   Prostacyclins + 
PDIE5  
0 (0%) 2 (3%) 1.00 
   PDIE5 + 
Prostacyclins  
1 (4%) 0 (0%) 0.26 
   Ca
2+
 blockers + 
PDIE5  
0 (0%) 1 (1%) 1.00 
   Ca
2+
 blockers + 
Prostacyclins 
 
0 (0%) 
 
2 (3%) 
 
1.00 
Switch, n (%)    
   From ERA to PDIE5 1 (4%) 3 (4%) 1.00 
   From Ca
2+
 blockers 
to Prostacyclins 
 
0 (0%) 
 
2 (3%) 
 
1.00 
Data are presented as number of patients n (% within sex). CA
2+
 blockers = calcium channel 
blockers, ERA = endothelin receptor antagonists, PDIE5 = phosphodiesterase type 5 
inhibitors.  
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Abstract 
 
Introduction. In patients with pulmonary arterial hypertension (PAH), the 
mean reduction in pulmonary vascular resistance (PVR) after medical 
treatment is modest but heterogeneous responses with respect to changes 
in load and right ventricular (RV) function exist. The aim of this study was to 
compare the effects of varying degrees of PVR reduction after medical 
treatment on hemodynamics, RV function and survival in patients with PAH.  
Methods. 123 patients underwent right heart catheterization and a subset 
of 81 patients underwent cardiac magnetic resonance imaging at baseline 
and after 1 year of treatment. The study population was divided into three 
equal groups based on tertiles of relative changes in PVR: (1) 
unchanged/small decrease <-12%, (2) modest decrease -12 to -42%, (3) 
large decrease >-42%. In these groups, hemodynamics, RV function and 
survival were compared.  
Results. Compared to groups 1 and 2, group 3 showed the strongest 
improvements in pulmonary pressures and normalisation of cardiac output 
(CO). RV fraction remained unchanged in groups 1 and 2 but improved in 
group 3. During a follow-up of 47 months, 38 patients died/underwent lung 
transplantation. Survival was similar in groups 1 and 2 (54% and 64% 
resp.) but significantly better in group 3 (survival: 90%, sensitivity: 90%, 
specificity: 42%, p = 0.01).  
Conclusions. Compared to a small and modest PVR reduction, only a 
large PVR decrease >-42% after medical treatment is associated with 
normalisation of CO, improvement of RV function and is a sensitive 
predictor of long-term survival in patients with PAH.  
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Introduction 
 
In patients with pulmonary arterial hypertension (PAH) a progressive 
increase in pulmonary vascular resistance (PVR) and pulmonary artery 
pressure result in right ventricular (RV) dysfunction and ultimately RV 
failure and death1,2. It has been shown that normalisation of PVR as 
achieved after lung transplantation, result in restoration of RV function3. 
Furthermore in patients with chronic thromboembolic pulmonary 
hypertension (CTEPH), a strong decrease in PVR after pulmonary 
endarterectomy lead to significant RV improvements4,5. Multiple PAH-
targeted medical therapies have been developed in the past 20 years and 
are proven to lower the PVR6,7. Although the mean PVR decrease is 
modest and has relatively small effects on RV function and survival, 
previous studies have reported a broad range of PVR changes after 
medical therapy7-12. Furthermore, it has been observed that some patients 
responded favourably with improved RV function while others showed 
progressive RV deterioration despite a PVR reduction after therapy and 
was associated with poor survival8. Improved insights in the heterogeneous 
medical therapeutic responses are essential. Therefore the aim of the 
present study was to compare the effects of varying degrees of PVR 
reduction after medical treatment on hemodynamics, RV function and 
survival in patients with PAH.  
 
 
Methods 
 
Study design and study population 
We performed a retrospective cohort study. Cardiac magnetic resonance 
imaging (CMR) data of this study were partly obtained from an on-going 
prospective research program. The other part of our CMR data and all right 
heart catheterization (RHC) data were obtained for clinical purposes. The 
study was approved by the Medical Ethics Review Committee of the VU 
University Medical Center. Due to the fact that the study does not fall within 
the scope of the Medical Research Involving Human Subjects (WMO), the 
study was approved without requirement of informed consent.  
Between January 2000 and January 2012, 1565 patients were referred to 
the VU University Medical Center, Amsterdam, the Netherlands because of 
a suspected diagnosis of pulmonary hypertension (PH). According to the 
World Health Organisation guidelines13, PAH group 1 was diagnosed in 453 
patients. Inclusion criteria for the study were: (1) idiopathic, hereditary, 
anorexigen-related PAH patients or patients with pulmonary veno-occlusive 
disease; (2) incident PAH patients with optimal PAH-targeted medical 
therapies directly initiated after diagnostic baseline measurements; (3) RHC 
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at baseline and after 1 year of follow-up. Exclusion criteria were: PAH 
patients with associated conditions (i.e. congenital systemic to pulmonary 
shunts, connective tissue disease, portal hypertension or HIV infection). 
133 patients met the inclusion criteria but ten patients were excluded due to 
incomplete/insufficient PVR measures. In the present study, a total of 123 
PAH patients were included. 81 out of the 133 patients underwent CMR 
both at baseline and after 1 year of follow-up. CMR and RHC were 
performed within a median time interval of 1 day. Some patients did not 
undergo complete CMR assessment due to logistical reasons (n = 22) or 
contraindications for CMR (n = 12). In addition, eight patients had 
incomplete/insufficient CMR data.  
All patients were followed clinically on a regular basis by outpatient visits 
and telephone contacts until January 1, 2013. Patients with a positive 
response to the acute vasodilator challenge13 were treated with calcium 
channel antagonists. Before 2002, all unresponsive NYHA functional class 
III and IV patients were initiated on prostacyclins. After 2002, NYHA II and 
III patients received oral medical therapy consisting of endothelin receptor 
antagonsists (ERA) and/or phophodiesterase 5 inhibitors (PDE 5I) and 
NYHA IV patients received intravenous prostacyclin with/without additional 
oral medical treatment. All patients received oral anticoagulation. During 
follow-up, many patients went through one or multiple treatment regimens.  
 
Right heart catheterization 
Hemodynamic assessment was performed with a 7F balloon tipped, flow 
directed Swan-Ganz catheter (131HF7, Baxter, Healthcare Corp Irvine, 
California) as previously described14.  
 
Six-minute walking testing 
The six-minute walking test (6MWT) was performed according to American 
Thoracic Society guidelines15. 
 
Blood sampling 
Since November 2002, N-terminal pro-brain natriuretic peptide (NT-
proBNP) measurements have become part of our clinical assessment. NT-
proBNP plasma levels were analysed using the Elecsys 1010 
electrochemiluminescense immunoassay (Roche Diagnostics, the 
Netherlands) as outlined before16. 
 
Cardiac magnetic resonance imaging 
Before April 2008 CMR was performed on a Siemens 1.5T Sonata scanner 
thereafter CMR was performed on a Siemens 1.5T Avanto scanner 
(Siemens, Medical Solutions, Erlangen, Germany). CMR data acquisition 
was obtained according to our routine protocol14.  
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During post-processing, a blinded observer assessed the ventricular 
volumes, mass and function using the MASS-software package (MEDIS, 
Medical Imaging Systems, Leiden, The Netherlands) as described 
previously14. Briefly, stroke volume (SV) was calculated as end-diastolic 
volume (EDV) – end-systolic volume (ESV). RV ejection fraction (RVEF) 
was calculated as SV divided by EDV and multiplied by 100%. Volume 
measurements were indexed to body surface area (BSA). RV systolic wall 
stress was calculated according to the Law of Laplace as explained 
before17. 
 
Statistical analysis 
Data are expressed as mean ± SD for continuous variables and absolute 
for categorical variables. P <0.05 was considered significant. Comparisons 
between and within groups were calculated by unpaired and paired Student 
t-tests respectively. The study population was divided into three equal 
groups, each consisting of 41 patients based on tertiles of the relative 
changes in PVR: (1) unchanged/increased PVR: PVR decline smaller than 
-12% (mean: 20 ± 34%), (2) modest PVR decrease: PVR decrease of -12 
to -42% (mean: -28 ± 9%), (3) large PVR decrease: PVR decrease of more 
than -42% (mean: -59 ± 9%). In each group, 27 patients had underwent 
CMR measurements. Within these three groups, baseline characteristics 
were compared to follow-up measurements by means of a two-way 
repeated measures ANOVA with Bonferroni post-hoc test. In addition, 
survival rates were compared using a Kaplan-Meier landmark analysis 
(landmark at 1 year of follow-up). Cardiopulmonary death and lung 
transplantation were used as endpoint, other causes of death were 
censored. Receiver-operating characteristic (ROC) curve analysis was 
applied to determine the sensitivity and specificity of different threshold 
changes in PVR as indicators of survival. All statistical analyses were 
carried out using SPSS (version 19.0, SPSS inc. Chicago, Illinois).  
 
 
Results 
 
Patient demographics 
Table 1 summarizes the demographics of the study population with and 
without CMR measurements. The mean age of the total study population 
was 48 ± 17 years, 78% was female. Most patients received upfront 
monotherapy consisting of ERA or combination treatment. The median time 
between baseline and follow-up measurements was 12 months (IQR: 10-16 
months). During a subsequent long term median follow-up period of 37 
months (IQR: 13-84 months), 38 patients died due to cardiopulmonary 
causes or underwent lung transplantation.  
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Table 1. Patient demographics. 
 
 
 
Variable 
Total study 
population 
 
(n = 123) 
Patients 
with CMR 
 
(n = 81) 
Patients 
without 
CMR 
(n = 42) 
 
 
 
P-value 
Age, yrs 48 ± 17 46 ± 16 52 ± 17 0.083 
Female, n (%) 96 (78) 69 (85) 27 (64) 0.036 
Diagnosis, n (%) 
   Idiopathic 
   Heriditary 
   Anorexigen 
   PVOD 
 
103 (84) 
10 (8) 
3 (2) 
7 (6) 
 
68 (83) 
7 (9) 
3 (4) 
3 (4) 
 
35 (83) 
3 (7) 
0 (0) 
4 (10) 
0.368 
NYHA, n (%) 
   I/II 
   III 
   IV 
 
41 (33) 
72 (59) 
10 (8) 
 
26 (32) 
47 (58) 
8 (10) 
 
15 (36) 
25 (59) 
2 (5) 
0.536 
BSA, m
2
 1.9 ± 0.2 1.9 ± 0.2 1.9 ± 0.2 0.172 
Medical therapy, n 
(%) 
   Calcium antagonists 
   ERA 
   PDE 5I 
   Prostacyclins 
   Combination 
 
 
6 (5) 
50 (40) 
13 (11) 
25 (20) 
29 (24) 
 
 
5 (6) 
31 (29) 
7 (9) 
20 (24) 
18 (22) 
 
 
1 (2) 
19 (46) 
6 (14) 
5 (12) 
11 (26) 
0.319 
BSA = body surface area, NYHA = New York Heart Association, ERA = endothelin receptor 
antagonists, PDE 5I = phosphodiesterase 5 inhibitors. 
 
Patient characteristics at baseline and follow-up 
Table 2 shows the characteristics of the study population at baseline and 
after 1 year of follow-up. Patients with and without CMR measurements 
showed similar hemodynamics, NT-proBNP and exercise capacity 
(Supplement, Table A1). In the total study population, the mean reduction 
in PVR was -220 ± 409 dyne·s·cm-5 (mean relative change in PVR: -20 ± 
42%), mean pulmonary artery pressure (mPAP) showed a decrease of -6 ± 
12 mmHg and cardiac output (CO) was improved by 1.2 ± 1.6 L/min (all p 
<0.001 for change). RVEDV and RV mass remained unchanged but RVEF 
and SV showed on average small improvements (delta RVEF: 5 ± 11%, 
delta SV: 4 ± 8 mL/m2, both p <0.001).  
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Table 2. Changes in hemodynamics, NT-proBNP, exercise capacity and 
CMR measurements.  
 
Variable 
Baseline 
(n = 123) 
Follow-up 
(n = 123) 
 
P-value 
RHC 
   mPAP, mmHg 
   RAP, mmHg 
   PVR, dyne·s·cm
-5
 
   PCWP, mmHg 
   CO, L/min 
   CI, L/min/m
2
 
   Heart rate, bpm 
   SvO2, % 
 
54 ± 15 
9 ± 5 
900 ± 439 
8 ± 4 
4.5 ± 1.4 
2.4 ± 0.7 
82 ± 20 
64 ± 9 
 
48 ± 14 
7 ± 6 
662 ± 390 
7 ± 3 
5.7 ± 1.9 
3.1 ± 1.0 
81 ± 15 
66 ± 9 
 
<0.001 
<0.001 
<0.001 
0.030 
<0.001 
<0.001 
0.647 
0.013 
NT-proBNP, ng/L* 1684 ± 1626 926 ± 1558 <0.001 
6MWT 
   Distance, m 
 
437 ± 232 
 
461 ± 121 
 
0.393 
CMR† 
   RVEDV, ml/m
2
 
   RVESV, ml/m
2
 
   RV mass, g/m
2
 
   RVEF, % 
   SV, ml/m
2
 
   LVEDV, ml/m
2
 
   LVEF, % 
 
77 ± 20 
52 ± 19 
52 ± 13 
33 ± 10 
25 ± 8 
41 ± 13 
63 ± 11 
 
75 ± 21 
47 ± 20 
52 ± 16 
38 ± 14 
28 ± 9 
46 ± 15 
67 ± 12 
 
0.218 
0.009 
0.820 
<0.001 
0.003 
0.01 
0.001 
6MWT = six-minute walk testing, CI = cardiac index, CMR = cardiac magnetic resonance 
imaging, CO = cardiac output, LVEDV = left ventricular end-diastolic volume, LVEF = left 
ventricular ejection fraction, mPAP = mean pulmonary artery pressure, NT-proBNP = N-
terminal pro-brain natriuretic peptide, PCWP = pulmonary capillary wedge pressure, PVR = 
pulmonary vascular resistance, RAP = right atrial pressure, RHC = right heart 
catheterization, RVEDV = right ventricular end-diastolic volume, RVEF = right ventricular 
ejection fraction, RVESV = right ventricular end-systolic volume, SV = stroke volume, SvO2 
= mixed venous oxygen saturation. *NT-proBNP was measured in a subgroup of 74 
patients, †CMR was performed in 81 patients.  
 
Patient characteristics according to the three groups of changes in 
PVR 
The three PVR groups had similar age, gender, type of diagnosis and 
NYHA functional class.  
The relative change in PVR was not related to the type of single-agent 
therapy (comparisons between ERA, PDE5I and prostacyclins, all p >0.05). 
Of interest, 10% and 14% of the patients in groups 1 (unchanged/small 
PVR decrease) and 2 (modest PVR decrease) respectively received 
upfront combination therapies in contrast to 46% of the patients in group 3 
(large PVR decrease) (group 3 vs. 1 and 2, both p<0.001) (Table 3).  
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Table 3. Demographics according to the three groups of PVR change. 
 
 
 
Variable 
1. Unchanged / 
small PVR 
decrease 
(n = 41) 
2. Modest PVR 
decrease 
 
(n = 41) 
3. Large PVR 
decrease 
 
(n = 41) 
Age, yrs 50 ± 16 46 ± 18 48 ± 16 
Female, n (%) 32 (78) 32 (78) 32 (78) 
Diagnosis, n (%) 
   Idiopathic 
   Other 
 
34 (83) 
7 (17) 
 
36 (87) 
5 (13) 
 
33 (81) 
8 (19) 
NYHA, III/IV, n (%) 30 (73) 24 (59) 28 (68) 
Medical therapy, n (%) 
   Single agent 
   Combination 
 
37 (90) 
4 (10) 
 
35 (85) 
6 (15) 
 
22 (54) 
19 (46)*, † 
*Group 3 compared to group 1: p <0.001, †group 3 compared to group 2: p <0.001. 
 
 
Figure 1. Hemodynamics according to the three groups of PVR.  
(A) Pulmonary vascular resistance (PVR), (B) mean pulmonary artery pressure, (C) Cardiac 
output, (D) Right atrial pressure according to the three groups of PVR (licht grey: 
unchanged/small decrease PVR; black: modest PVR decrease; dark grey: large PVR 
decrease) at baseline (open bars) and after 1 year of follow-up (filled bars). Data are 
presented as mean ± SEM. In bars: *p <0.05, **p <0.01, ***p <0.001 for within group 
difference between baseline and follow-up. Above bars: *p <0.05, **p <0.01, ***p <0.001 for 
difference in change between groups. B = baseline, FU = follow-up.  
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Figure 1 shows the hemodynamics at baseline and at follow-up according 
to the three PVR groups. Group 1 showed a small, significant increase in 
PVR (delta PVR: 129 ± 233 dyne·s·cm-5, p = 0.001) (Figure 1A) and no 
changes in other hemodynamics during follow-up. In comparison to group 
2, group 3 showed stronger improvements in CO (delta CO: 2.7 ± 1.2 and 
1.3 ± 1.2 L/min resp, p <0.001) and reduction in mPAP (delta mPAP: -15 ± 
11 and -4 ± 9 mmHg resp., p <0.001) (Figure 1B, C). RAP was decreased 
in groups 2 and 3 (Figure 1D). In addition, heart rate was decreased in 
group 3 (delta heart rate: -8 ± 15 bpm; p = 0.017) but was unchanged in 
groups 1 and 2 (both: p >0.05). The distance at 6MWT was unchanged in 
all groups during follow-up (all p >0.05 for change) (data no shown). NT-
proBNP was unchanged in groups 1 and 2 (both p >0.05) and was 
significantly decreased in group 3 (delta NT-proBNP: -1293 ± 1160 ng/L; p 
<0.001). In addition, RV volumes and mass showed a decrease in group 3 
and were maintained in groups 1 and 2 (Figure 2A-C). There was no 
change of RV wall stress in group 1 but a trend towards a stronger 
decrease was observed in group 3 compared to group 2 (Figure 2D). SV 
and RVEF remained unchanged in groups 1 and 2 but the patients in group 
3 showed a significant improvement (delta SV: -8 ± 8 ml/m2, delta RVEF:14 
± 2%, both p <0.001) (Figure 2E, F).  
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Figure 2. CMR measurements according to the three PVR groups. 
(A) RV end-diastolic volume, (B) RV end-systolic volume, (C) RV mass, (D) RV wall stress, 
(E) RV Stroke Volume and (F) RV ejection fraction according to the three groups of PVR 
(light grey: unchanged/small PVR decrease, black: modest PVR decrease, dark grey: large 
PVR decrease) at baseline (open bars) and after 1 year of follow-up (filled bars). Data are 
presented as mean ± SEM. In bars: *p <0.05, ***p <0.001 for within group difference 
between baseline and follow-up. Above bars: *p <0.05, **p <0.01, ***p <0.001 for difference 
in change between groups. 
 
Association between changes in PVR and survival 
The mean change in PVR of -20% was not associated with survival (p = 
0.140). ROC-analysis showed that a threshold decrease in PVR of -33% 
predicted survival with the combination of highest sensitivity (78%) and 
specificity (55%) (subsequent five-year survival = 75%, log-rank: p = 
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0.018). Figure 3 shows a landmark survival analysis of the three PVR 
groups. Mean survival rates were similar in patients with a small and 
modest PVR decrease (p = 0.861) but was significantly better in patients 
with a large PVR decrease (group 3: subsequent five-year survival = 85%, 
log-rank: p = 0.01 compared to groups 1 and 2). The large PVR decrease 
of group 3 predicted survival with 90% sensitivity and 42% specificity.  
 
 
Figure 3. Landmark survival analysis according to the three groups of PVR. 
Group 1: unchanged/small PVR decrease (light grey), group 2: modest PVR decrease 
(black), group 3: large PVR decrease (dark grey).  
 
 
Discussion 
 
Our study shows in a large group of PAH patients that compared to a small 
or modest PVR reduction, a large PVR decrease of more than 42% after 
PAH targeted medical therapies is associated with normalisation of CO, 
improved RV volumes and function and is a sensitive predictor of long term 
survival. Of interest, more patients with a large PVR decrease received 
upfront medical combination therapy. 
 
In correspondence with previous studies, we found that a modest PVR 
reduction after current medical therapies does hardly alter RV volumes and 
function8-10. Moreover, relatively modest PVR changes do not prevent RV 
deterioration in a subset of patients8. Current medical therapies have 
primarily vasodilator properties18 but we hypothesize that only a large PVR 
reduction will cause a sufficient decrease in pulmonary pressures that could 
improve RV work and attain favourable direct cardiac effects19,20. We found 
that after a large PVR decrease, a stabilized RV function was guaranteed 
and more than 75% of the patients showed clinically significant 
improvements in RVEF and SV21,22. Furthermore only a large PVR 
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decrease was associated with lowered RV volumes and mass. Similar to 
the results in CTPEH patients who underwent pulmonary endarterectomy17, 
we found that RV wall stress was reduced in the group of patients with a 
large PVR decrease and occurred coincidently with improvements in NT-
proBNP and RVEF; known indicators of wall stress in PAH23.  
RV function was improved but not normalized after the strong PVR 
decrease. However the RV might cope better with the elevated load due to 
the fact that circumstances have been augmented. The tissue balance 
between oxygen supply and demand might have been improved in the 
group of patients with a strong PVR decrease as illustrated by the 
normalization of CO. Although future studies are required to quantify the 
changes in cardiac oxygen handling, we found that after a large PVR 
decrease the two main determinants of RV oxygen consumption in PAH i.e. 
pulmonary pressure and heart rate were reduced24. As a consequence RV 
mechanical efficiency, which is proportional to the ratio of RV power output 
and myocardial oxygen consumption may have been enhanced. This is 
supported by the finding that RVEF which is tightly related to mechanical 
efficiency, was only improved in the group of patients with a large PVR 
decrease25.  
 
In correspondence to the study of Sitbon et al., we found that in order to 
achieve a survival benefit, a large PVR decrease after medical treatment is 
required12. Small-modest PVR reductions were not independently related to 
survival7,26. Similar to Sitbon et al., we found that a PVR decrease of ~30% 
is associated with survival but larger PVR decreases were more sensitive 
indicators to accurately predict long-term survival12.  
In addition, our group has found similar results with respect to the change 
in NT-proBNP. Mauritz et al. showed that a threshold change in NT-proBNP 
rather than a change on a continuous scale was associated with survival27. 
Recently, it has been demonstrated that the mean change in distance at 
6MWT did not provide sufficient clinical information but a threshold change 
of at least 42m might reduce the risk of clinical events28. These studies 
emphasize that clinical outcome can only be improved in case of significant 
treatment effects.  
 
Although we did not observe significantly different effects between the 
various types of single agent therapies, our results demonstrated that a 
large PVR reduction was more frequently obtained after upfront application 
of combination therapies. These findings are in line with the study of 
Humbert et al. who showed that upfront combination of epoprostenol and 
bosentan resulted in a trend towards a stronger reduction in PVR compared 
to epoprostenol alone29. Recently these results were confirmed by Kemp et 
al. who observed a mean decrease in PVR of ~48% after upfront 
combination treatment and showed that these effects were sustained 
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during long term follow-up30. Furthermore, it has been shown that addition 
of sildenafil to background epoprostenol resulted in a stronger PVR 
decrease and longer time to clinical worsening31. Similarly, it was found that 
adding selexipag to patients stable on bosentan or sildenafil resulted in an 
additional 30% PVR reduction32. The study of van Wolferen et al. showed 
favourable effects on RV remodelling after combination treatment but did 
not assess hemodynamics33. 
 
We performed similar analyses in order to find the relevant change in 
mPAP (data not shown) but did not find a significant relationship between a 
threshold change in mPAP and survival. Comparable results were 
previously described by Sitbon et al.12. The explanation for this finding can 
be twofold. First, only few patients in the present study showed such a 
strong improvement in mPAP and therefore the analysis did not reach 
enough statistical power. Second, during end stage disease mPAP 
decreases and therefore does not reflect a treatment benefit. Another 
component of RV load i.e. compliance was not assessed in this study. 
However Lankhaar et al. showed that compliance and resistance are 
inversely related and that this relationship remains unchanged during 
medical treatment34,35. Therefore, at increased values of PVR, compliance 
is low and does not provide additional information. 
 
Clinical implications 
The results of the present study imply that in order to improve RV function 
and achieve long term survival, the PVR has to be substantially reduced 
after medical treatment. Our results show that a large PVR reduction is 
feasible after medical treatment and might be related to upfront 
combination therapy.  
 
Study limitations 
Treatment regimens were not controlled and therefore potential direct 
cardiac effects independent of the changes in PVR were not studied. 
However in correspondence with the EURO-MR study, we did not find 
different effects on RV volumes, mass and function between current types 
of therapy36. Similarly, most patients in the present study received either 
ERA or prostacyclin but we did not find different survival rates between 
these treatment regimens which is in line with previous studies37. In 
general, we did not find an association between type of medical treatment 
and prognosis.  
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Conclusions 
 
In comparison to a small or modest PVR reduction, only a large PVR 
decrease of more than 42% after current PAH targeted medical therapies 
was related to normalized CO, improved RV function and was a sensitive 
predictor of long-term survival in patients with PAH. Of high interest, a large 
PVR decrease was associated with upfront medical combination therapies. 
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Data supplement 
 
Table 1. Comparison of hemodynamics of patients with and without CMR 
measurements. 
 
 
 
Variable 
Total study 
population 
 
(n = 123) 
Patients 
with CMR 
 
(n = 81) 
Patients 
without 
CMR 
(n = 42) 
 
 
 
P-value 
RHC 
   mPAP, mmHg 
   RAP, mmHg 
   PVR, dyne·s·cm
-5
 
   PCWP, mmHg 
   CO, L/min 
   CI, L/min/m
2
 
   Heart rate 
   SvO2, % 
 
54 ± 15 
9 ± 5 
900 ± 439 
8 ± 4 
4.5 ± 1.4 
2.4 ± 0.7 
82 ± 20 
64 ± 9 
 
55 ± 15 
9 ± 5 
938 ± 447 
8 ± 4 
4.5 ± 1.3 
2.4 ± 0.7 
85 ± 19 
65 ± 9 
 
51 ± 13 
10 ± 7 
829 ± 438 
8 ± 4 
4.6 ± 1.4 
2.4 ± 0.7 
76 ± 19 
63 ± 10 
 
0.079 
0.371 
0.185 
0.862 
0.583 
0.926 
0.052 
0.315 
NT-proBNP, ng/L* 1684 ± 1626 1384 ± 1706 1918 ± 1684 0.216 
6MWT 
   Distance, m 
 
428 ± 219 
 
441 ± 238 
 
377 ± 117 
 
0.288 
6MWT = six-minute walk testing, CI = cardiac index, CO = cardiac output, mPAP = mean 
pulmonary artery pressure, NT-proBNP = N-terminal pro-brain natriuretic peptide, PCWP = 
pulmonary capillary wedge pressure, PVR = pulmonary vascular resistance, RAP = right 
atrial pressure, SvO2 = mixed venous oxygen saturation. *NT-proBNP was measured in a 
subgroup of n = 74 patients.  
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Abstract 
 
Introduction. Even after years of a stable response to therapy, patients 
with idiopathic pulmonary arterial hypertension (IPAH) may show an 
unexpected clinical deterioration due to progressive right ventricular (RV) 
failure. If the RV would already show progression during a stable condition, 
RV assessment might predict an ultimate deterioration. The aim of the 
study was to assess in five-year clinically stable IPAH patients whether 
initial differences or subsequent changes in RV volumes precede late 
clinical progression. 
Methods. Included were 22 clinically stable patients, reflected by stable or 
improving NYHA-class II-III and exercise capacity during five years of 
follow-up. Twelve patients remained subsequently stable during a total 
follow-up of 10 years, while ten other patients showed late progression 
leading to death or lung-transplantation after a follow-up of 8 years. All 
patients underwent right heart catheterization and cardiac MRI at baseline, 
1.5, 3.5, 6.5 and, when still alive, 10 years of follow-up.  
Results. Baseline hemodynamics were comparable in both groups and 
remained on average unchanged during the entire follow-up period. 
Baseline RV end-systolic volume (RVESV) was higher and RV ejection 
fraction (RVEF) was lower in late-progressive patients. Late-progressive 
patients demonstrated a gradually increased RV end-diastolic volume 
(RVEDV) and RVESV and, a declined RVEF whereas long-term stable 
patients did not show any RV changes. 
Conclusions. In five-year stable IPAH patients, subsequent disease 
progression is preceded by changes in RV volumes. Our results implicate 
that monitoring of RV volumes allows the anticipation to clinical worsening, 
even at the time of apparent clinical stability. 
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Introduction 
 
In patients with pulmonary arterial hypertension (PAH), increased 
pulmonary vascular resistance (PVR) and pulmonary artery pressure 
ultimately result in right ventricular (RV) failure and death1,2. Various 
effective medical therapies have become available allowing prolonged 
clinical stability and survival3-7. Although a small group of patients may 
survive more than five years after diagnosis, overall long-term mortality 
rates are high8. Much is known about predictors of short-term survival5,6 but 
predictors of ultimate clinical deterioration in patients with an initially 
favorable treatment response have not been identified. A clinically stable 
condition, defined as a stable or improving New York Heart Association 
(NYHA) functional class II-III and six-minute walking test (6MWT)9, was not 
associated with better long-term survival3,10-12. Even patients who are in a 
seemingly sustained stable clinical condition may unexpectedly show rapid 
clinical deterioration due to progressive RV failure, which is associated with 
high mortality rates13-15. Current medical therapies may successfully 
improve 6MWT and cardiac output (CO), but do not necessarily slow RV 
failure progression16-18. If the RV would already show progressive adverse 
remodeling during a stable condition, assessment of RV remodeling 
parameters might predict an ultimate disease progression. Therefore, the 
aim of the present study was to assess whether initial differences or 
subsequent changes in RV volumes precede an ultimate clinical 
deterioration in idiopathic PAH (IPAH) and heritable PAH (HPAH) patients 
with a proven five-year stable clinical condition.  
 
 
Methods 
 
Patients 
At the VU University Medical Center, patients were diagnosed as having 
PAH according to the guidelines, including a right heart catheterization 
(RHC)19. The present study was a retrospective analysis of an ongoing 
prospective study to assess the clinical value of cardiac magnetic 
resonance imaging (CMR) in PAH. The process of selection for the present 
study was made unaware of RHC and CMR results. Inclusion criteria were: 
(1) diagnosis of IPAH or HPAH, (2) age ≥18 years, (3) a proven clinical 
stable condition during the first five years of follow-up, defined as a stable 
NYHA class II-III and no reduction in the 6MWT ≥15%9, (4) CMR, RHC, 
6MWT, NYHA class at baseline and at regular follow-up intervals, (5) a total 
follow-up period of ten years. IPAH/HPAH patients diagnosed between 
February 1999 and February 2004 were selected for the study. In this 
period, 48 out of 58 patients were selected and followed until February 
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2013. Exclusion reasons: no regular CMR due to logistic reasons (n = 4) or 
claustrophobia (n = 1), follow-up in another hospital (n = 2), development of 
LV failure (n =1 ), a positive vasodilator challenge (n = 2)19. Twenty-four out 
of the 48 patients died and two patients showed early clinical disease 
progression within five years of follow-up (i.e. deterioration into NYHA IV 
and >15% reduction in the 6MWT). The other twenty-two patients fulfilled 
the inclusion criteria and were enrolled (Figure 1). The local Medical Ethics 
Committee approved the study without requirement of a consent statement 
because the study does not fall within the scope of the Medical Research 
Involving Human Subjects Act (WMO) (approval number 2012288).  
 
 
Figure 1. Study profile. 
*Excluded due to: no regular CMR because of logistical reasons (n = 4) or claustrophobia (n 
= 1), follow-up in another hospital (n = 2), development of left ventricular failure (n = 1), a 
positive vasodilator challenge (n = 2). 
 
Twelve out of the 22 patients remained in a clinically stable condition during 
ten years (IQR: 10-11 years) of follow-up and were considered to be “long-
term stable” patients. The other ten patients showed late clinical disease 
progression, defined as progression into NYHA IV and a reduction in the 
6MWT >15%9 after five years of initial clinical stability. All ten patients 
subsequently died due to cardiopulmonary causes (n = 6) or underwent 
lung-transplantation (n = 4) by a median of eight years (IQR: 7-10 years) 
after the diagnosis and were considered “late-progressive” patients. All 
patients underwent a complete assessment consisting of RHC, CMR, 
6MWT, and NYHA class at baseline and after 1.5 ± 0.4, 3.5 ± 0.9, 6.5 ± 1.0 
years and, if still alive, after 10.0 ± 1.2 years of follow-up. Additional 6MWT 
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and NYHA class assessments were performed after 5.0 ± 0.4 years of 
follow-up. Furthermore, the number and reasons for acute hospitalizations 
during follow-up were recorded.  
Application of PAH targeted medical therapies was performed in line with 
the guidelines19 and according to the availability in the Netherlands. Before 
2002, all NYHA class III-IV patients were initiated on prostacyclins. After 
2002, NYHA II-III patients were treated with oral medical therapy consisting 
of endothelin receptor antagonists and/or phosphodiesterase-5 inhibitors, 
either as single agent therapy or as combination, while NYHA IV patients 
received prostacyclins with or without additional oral medical therapies. All 
patients received anticoagulation and diuretics. 
 
Right heart catheterization 
Hemodynamic assessment was performed with a 7F balloon tipped, flow 
directed Swan-Ganz catheter as described previously20.  
 
Cardiac magnetic resonance imaging 
CMR was performed on a Siemens 1.5T Sonata or Avanto scanner. Data 
acquisition and post-processing were performed according to our routine 
protocol20. Briefly, during post-processing using dedicated software, a 
blinded observer assessed the left ventricular (LV) and RV volumes, mass 
and function by manual delineation of the endocardial and epicardial 
contours on short-axis images. Disc summation was performed according 
to Simpsons rule. Stroke volume (SV) was calculated as end-diastolic 
volume (EDV) – end-systolic volume (ESV). Ejection fraction was 
calculated as (SV/EDV)*100%. Ventricular relative wall thickness was 
calculated as ventricular mass divided by EDV21. Ventricular volumes and 
masses were indexed to body surface area (BSA).  
 
Six-minute walking test 
The 6MWT was performed according to American Thoracic Society 
guidelines22.  
 
Statistical analysis 
Data are presented as mean ± SD, unless stated otherwise. Unpaired 
Student t-tests or Mann-Whitney tests were used to compare continuous 
variables and loglinear analysis was performed to compare categorical 
variables between the two groups at baseline. Linear Mixed Model analysis 
was applied to assess the differences between the groups over time. 
Residuals were normally distributed for every tested parameter. Model fit 
was evaluated and when necessary, random effects of time variables were 
corrected for intercepts and/or slopes. A sensitivity analysis was performed 
to test whether missing values influenced the results. Data were analyzed 
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using SAS (version 9.2 Inc, Cary, North-Carolina) and SPSS (version 20.0 
Inc, Chicago, Illinois). P-values <0.05 were considered significant.  
 
 
Results 
 
Patient demographics 
Table 1 shows similar demographics in the long-term stable and late-
progressive patients. Baseline 6MWT was comparable in both groups (p = 
0.321) and most patients were in NYHA class III. The 6MWT remained 
unchanged in both groups during follow-up, and both groups developed a 
stable NYHA class II-III during the application of medical treatment that 
persisted during five years of follow-up. After 6.5 years of follow-up, five 
late-progressive patients showed deterioration in NYHA class from II-III to 
IV (Figure 2). 
 
Table 1. Baseline characteristics. 
 
Variable 
Long-term stable 
(n = 12) 
Late-progressive 
(n = 10) 
 
P-value 
Diagnosis, n 
     IPAH 
     HPAH 
 
9 
3 
 
8 
2 
0.781 
 
Age, years  44 ± 14 37 ± 11 0.226 
Gender, female, n 11 8 0.427 
NYHA, II / III / IV, n 2 / 7 / 3 2 / 6 / 2 0.991 
6MWT, distance, m 370 ± 151 439 ± 124 0.321 
6MWT = six-minute walking test, HPAH = hereditary pulmonary arterial hypertension, IPAH 
= idiopathic pulmonary arterial hypertension, NYHA = New York Heart Association. 
 
 
Figure 2. 
(A) Six-minute walking test was comparable between the long-term stable (black) and late-
progressive patients (grey). (B) NYHA functional class improved in both groups after the 
initiation of medical therapies and persisted during five years of follow-up. After 6.5 years of 
follow-up, NYHA class deteriorated in late-progressive patients. Data are presented as 
mean ± SEM. 
*
p <0.05 between groups. 
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During the initial five years of clinical stability, no acute hospitalizations 
were necessary for RV failure progression and no intravenous diuretics 
were administered. During this time of follow-up, five long-term stable and 
three late-progressive patients received mono-therapy, five stable and six 
progressive patients switched from mono to dual-therapy and one stable 
patient switched from mono to dual to triple-therapy because of lack of 
clinical improvement. Furthermore, one long-term stable patient received 
dual-therapy and one late-progressive patient switched from dual to triple-
therapy. Overall, treatment regimens were balanced between groups (p = 
0.992).  
 
Baseline characteristics 
Baseline hemodynamics were similar in the two groups (Table 2). RV end-
diastolic volume (RVEDV), RV mass and RV wall thickness were 
comparable between groups. Late-progressive patients showed higher RV 
end-systolic volume (RVESV) and lower RV ejection fraction (RVEF) 
compared to long-term stable patients (Table 2). No differences in LV 
parameters were observed between both groups.  
The 22 patients included in this study showed similar baseline 
demographics, NYHA class, 6MWT and hemodynamics compared to the 
10 patients who survived five years of follow-up but were excluded from the 
study selection (all p >0.07) (not shown).  
 
Table 2. Baseline hemodynamics and cardiac measures. 
 
Variable 
Long-term 
stable 
Late-
progressive 
 
P-value 
RHC 
     mPAP, mmHg 
     PVR, dyne·s·cm
-5
 
     RAP, mmHg 
     PAWP, mmHg 
     CO, L·min
-1
 
     HR, bpm 
     SvO2, % 
 
53 ± 15 
920 ± 470 
8 ± 3 
6 ± 3 
4.6 ± 1.4 
79 ± 14 
65 ± 7 
 
59 ± 14 
1140 ± 372 
8 ± 4 
8 ± 6 
3.8 ± 0.9 
75 ± 15 
62 ± 5 
 
0.327 
0.244 
0.891 
0.411 
0.090 
0.657 
0.281 
CMR 
  RV remodeling 
     RVEDV, ml·m
-2
 
     RVESV, ml·m
-2 
     RV mass, g·m
-2
 
     RV relative wall thickness
 
  RV function 
     RVEF, % 
     SV, ml·m
-2
 
  LV remodeling 
     LVEDV, ml·m
-2
 
     LVESV, ml·m
-2
 
 
 
73 ± 19 
45 ± 11 
57 ± 13 
0.81 ± 0.23 
 
37 ± 9 
28 ± 11 
 
42 ± 17 
14 ± 7 
 
 
83 ± 10 
59 ± 12 
58 ± 16 
0.70 ± 0.14 
 
29 ± 8 
24 ± 5 
 
44 ± 10 
19 ± 8 
 
 
0.166 
0.015 
0.782 
0.216 
 
0.038 
0.352 
 
0.824 
0.138 
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     LV mass, g·m
-2
 
     LV relative wall thickness 
  LV function 
     LVEF, % 
55 ± 14 
1.42 ± 0.48 
 
66 ± 7 
58 ± 10 
1.39 ± 0.44 
 
58 ± 13 
0.627 
0.861 
 
0.079 
CMR = cardiac magnetic resonance imaging, CO = cardiac output, HR = heart rate, LV = left 
ventricular, LVEDV = left ventricular end-diastolic volume, LVEF = left ventricular ejection 
fraction, LVESV = left ventricular end-systolic volume, mPAP = mean pulmonary artery 
pressure, PAWP = pulmonary arterial wedge pressure, PVR = pulmonary vascular 
resistance, RAP = right atrial pressure, RHC = right heart catheterization, RV = right 
ventricular, RVEDV = right ventricular end-diastolic volume, RVEF = right ventricular ejection 
fraction, RVESV = right ventricular end-systolic volume, SV = stroke volume, SvO2 = mixed 
venous oxygen saturation.  
 
Changes in hemodynamics during follow-up 
Mean pulmonary artery pressure (mPAP) remained unchanged in both 
groups during follow-up (Figure 3). Although absolute values of pulmonary 
vascular resistance (PVR) and cardiac output (CO) were different between 
groups at 1.5 years follow-up (both p <0.05), the changes in both 
parameters during 1.5 years of follow-up were comparable (PVR: p-
interaction = 0.547, CO: p-interaction = 0.821). Furthermore, absolute 
values of PVR and CO were similar in both groups at 3.5 and 6.5 years 
follow-up. Long-term stable patients showed a stronger decrease in right 
atrial pressure (RAP) compared to late-progressive patients during the first 
3.5 years of follow-up (p-interaction = 0.003) but the change in RAP was 
not different between both groups during the overall follow-up period of 6.5 
years (p-interaction = 0.274). In both groups, pulmonary arterial wedge 
pressure, heart rate and mixed venous oxygen saturation remained on 
average comparable and unchanged during the total follow-up period (not 
shown). 
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Figure 3. 
(A) mean pulmonary artery pressure was comparable between the long-term stable (black) 
and late-progressive patients (grey) during follow-up. (B) Pulmonary vascular resistance, (C) 
cardiac output and (D) right atrial pressure showed a temporary difference between the two 
groups during the first years of follow-up but became equal during the subsequent follow-up 
intervals. Data are presented as mean ± SEM. 
*
p <0.05, 
**
p <0.01 between groups. 
 
Changes in cardiac wall thickness, volumes and function during 
follow-up 
Figure 4 demonstrates that during 6.5 years of follow-up, RVEDV and 
RVESV were continuously increased in the progressive patients (within 
group both, p <0.001) but remained unchanged in the stable patients 
(within group both, p >0.597) (both, p-interaction <0.006). No differences 
were observed between groups in the relative RV wall thickness over time.  
 
 
Figure 4. 
(A) Right ventricular (RV) end-diastolic volume and (B) RV end-systolic volume increased 
progressively in the late-progressive patients (grey) but remained unchanged in the long-
term stable patients (black) (both, p-interaction <0.01). (C) RV relative wall thickness was 
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comparable in both groups during follow-up. Data are presented as mean ± SEM. 
*
p <0.05, 
**
p <0.01, 
***
p <0.001 between groups. 
 
SV remained initially unchanged in both groups but became lower in late-
progressive than in long-term stable patients after 6.5 years of follow-up 
(Figure 5). Late-progressive patients showed a decline in RVEF during 6.5 
years of follow-up (p = 0.008), which was different compared to the long-
term stable patients who showed an initial increase during the first 3.5 
years of follow-up and a subsequently stable RVEF during ten years of 
follow-up (p-interaction = 0.006).  
 
 
Figure 5.  
(A) Stroke Volume was comparable in the long-term stable (black) and late-progressive 
groups (grey) during the first 3.5 years of follow-up and became lower in the late-progressive 
patients after 6.5 years of follow-up. (B) RV ejection fraction (RVEF) was lower at baseline 
and showed a gradual decline in the late-progressive patients during 6.5 years of follow-up 
whereas RVEF increased in long-term stable patients during the first 3.5 years of follow-up 
that persisted throughout ten years of follow-up (p-interaction = 0.006). Data are presented 
as mean ± SEM. 
*
p <0.05, 
**
p <0.01, 
***
p <0.001 between groups. 
 
LV end-diastolic volume (LVEDV) and the relative LV wall thickness 
remained comparable in both groups during follow-up (Figure 6). LV end-
systolic volume (LVESV) increased in the late-progressive patients during 
6.5 years of follow-up (p = 0.016) and remained unchanged in the long-term 
stable patients (p = 0.298). However, the changes in LVESV were not 
different in both groups during the overall follow-up period (p-interaction = 
0.253). LVEF remained stable over time in the long-term stable patients 
and decreased in the late-progressive patients during 6.5 years of follow-up 
(within group, p = 0.042). Although the absolute values of LVEF were lower 
in the late-progressive patients than in the long-term stable patients at all 
time points, the changes in LVEF were not significantly different between 
groups (p-interaction = 0.196).  
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Figure 6.  
(A) Left ventricular (LV) end-diastolic volume remained low and unchanged in the long-term 
stable (black) and late-progressive patients (grey). (B) LV end-systolic volume increased in 
the late-progressive patients during the last years of follow-up and remained unchanged in 
the long-term stable patients. (C) LV relative wall thickness was similar in the two groups 
during follow-up. (D) LV ejection fraction was higher in the long-term stable patients 
compared to the late-progressive patients at every follow-up interval. Data are presented as 
mean ± SEM. 
*
p <0.05, 
**
p <0.01 between groups. 
 
 
Discussion 
 
In a unique cohort of long-term surviving PAH patients, we show that RV 
remodeling can be progressive even in patients who are seemingly clinical 
stable during 5-10 years of follow-up. Moreover, we show that an ultimate 
disease progression is preceded by changes in RV volumes and RVEF but 
not by changes in NYHA class, exercise capacity or hemodynamics.  
 
This study provides the first phenotypic descriptions of PAH patients who 
showed an initially favorable treatment response and survived for at least 
five years after diagnosis. Corresponding to previous results, we showed 
that improvements in CO and RAP during the first years of follow-up were 
associated with survival23. However in line with former studies, we show 
that patients with an initially favorable treatment response show no further 
hemodynamic changes during long-term follow-up, regardless of the final 
outcome24,25. These findings might suggest that long-term treatment with 
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PAH specific vasodilator therapies might halt some of the progressive 
pulmonary vascular remodeling and may account for the improved 
outcomes in the current treatment era7,25.  
 
Corresponding to former studies16,20,26, we show that increased RV volumes 
during follow-up provide strong prognostic information. The most important 
finding of the present study was that increasing RV volumes during a 
clinically stable period preceded ultimate clinical deterioration. The absolute 
differences in RV volumes between long-term stable and late-progressive 
PAH patients gradually increased during follow-up which demonstrates 
their incremental prognostic relevance.  
The importance of progressive cardiac remodeling during clinically stable 
disease is supported by previous findings. In studies focusing on LV failure, 
increased LV volumes in asymptomatic patients were independent 
predictors of the development of symptomatic heart failure and mortality27-
29. Other LV studies have found that LV remodeling might progress despite 
the application of medical therapies aiming to preserve CO and clinical 
stability18,30. Similarly, it has been demonstrated that current PAH 
vasodilator medical therapies significantly improve CO but might have 
limited effects on RV adaptation and remodeling17.  
We observed a lower baseline RVEF and a gradual RVEF decline in the 
late-progressive patients during follow-up but not in the long-term stable 
patients. These findings correspond to previous studies showing that a low 
and decreasing RVEF were strong prognostic predictors16,31,32. During long-
term follow-up, the changes in RVEF did not show incremental prognostic 
relevance and did not provide additional information to measures of RV 
volumetric remodeling.  
 
Assessment of RV remodeling is not only of prognostic importance but is 
also of physiological interest. It has been proposed that an increase in EDV 
might be a compensatory mechanism to normalize SV in the setting of 
contractile dysfunction33,34. However an increase in RVEDV can only be 
beneficial when RVESV remains unchanged but this was not the case in 
the late-progressive PAH patients. An elevated RVESV is a poor 
physiological sign since it is associated with a right shift of the pressure-
volume loop and lower RV contractility. According to the Law of Laplace, 
elevated RV volumes lead to increased RV wall stress. In addition, RV wall 
thickness remained unchanged during follow-up and was probably 
insufficient to lower the wall stress35.  
In the patients with a long-term stable condition, there was no progressive 
RV remodeling despite a similar elevation in pulmonary pressures as 
observed in the late-progressive patients. A possible explanation could be 
that these patients showed better intrinsic RV adaptation mechanism to the 
increased afterload with preserved RV-arterial coupling36 or other factors 
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could play a role such as metabolism, neurohormones, inflammation, 
ischemia and genetics36,37.  
 
Compared to LV reference values38 and in line with previous studies in 
PAH, LV filling dimensions in the two currently studied PAH patient groups 
were low20,39-41. Impaired LV filling might be explained by direct ventricular 
interaction due to interventricular dyssynchrony and leftward septum 
bowing41-43, or by a low RV output resulting in LV underfilling. Strikingly, at 
every measured follow-up time point, LV systolic function was lower in the 
progressive patients compared to the stable patients. This might be a result 
of reduced LV filling but previous studies have also demonstrated by LV 
strain imaging that LV contractility and LV torsion were impaired in PAH 
patients39,41. Furthermore, according to the LV pressure-volume 
relationship, an increased LVESV is associated with impaired LV 
contractility.  
 
Clinical implications 
We show that in long-term PAH survivors, a clinically stable profile and 
preserved CO may mask RV failure progression, and that changes in RV 
volumes may be sensitive parameters to predict an ultimate deterioration, 
even at the time of clinical stability. Our results implicate that evaluation of 
RV volumes and RVEF are important in order to detect early heart failure 
development and to permit timely intervention. Our results raise the 
question whether prognosis can be improved by a goal-oriented strategy 
using RV rather than clinical parameters as treatment goal. The findings of 
an ultimate similarity in PVR in long-term stable and late-progressive 
patients also begs the question whether late disease progression could 
have been prevented by more aggressive vasodilator treatment or rather by 
a treatment specifically improving RV adaptation. 
In contrast to patients who died soon after the diagnosis5,6, the late-
progressive patients did not show a severely disturbed hemodynamic 
profile, not even in the last measurement before death. Because 
hemodynamic progression can be very rapid in end-stage disease, it is 
likely that had RHC been performed in the days-weeks prior to death, 
results would have been much worse. In contrast, the considerable RV 
dilatation observed in the late-progressive patients is infrequently 
encountered in patients with shorter survival periods16,20,26. This suggests 
that extensive RV remodeling takes years to develop. Importantly, these 
observations imply that the long-term follow-up results of the present study 
cannot be extrapolated to patients with a more severe hemodynamic profile 
shortly after the initial diagnosis. 
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Limitations 
Although we included a small patient population, clear differences between 
both study groups were found with high levels of statistical significance. 
Previously, Addetia et al. demonstrated that in order to detect specific 
changes in RV volumes and function by CMR in PAH patients, a small 
sample size is sufficient in order to achieve adequate statistical power44. 
Death and lung transplantation together were used as composite endpoint 
to define late-progression. When only non-survivors were included in the 
analysis, we found similar results with more pronounced absolute 
differences between the long-term stable and late-progressive groups (not 
shown).  
During the first years of follow-up, measurements of N-terminal pro-brain 
natriuretic peptide (NT-proBNP) were unavailable in the Netherlands and 
therefore not included. Former studies have shown that although NT-
proBNP contains prognostic information, a sufficient increase is required in 
order to be of clinical relevance. Further studies are required to test the 
sensitivity of early changes in NT-proBNP to detect ultimate disease 
progression11,45.  
 
 
Conclusions 
 
RV volumes and RVEF can deteriorate in apparently stable IPAH/HPAH 
patients and changes in these parameters precede ultimate disease 
progression and mortality. Our results imply that monitoring of RV 
remodeling is essential in order to detect early development of heart failure 
and to permit timely intervention, even at the time of clinical stability.  
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Introduction 
 
Right ventricular (RV) failure may be defined as a complex clinical 
syndrome that can result from any structural or functional cardiac disorder 
that impairs the ability of the right heart to fill or eject appropriately1. In 
pulmonary arterial hypertension (PAH); a progressive pulmonary vascular 
disease resulting in chronic pressure overload, patients die due to the 
consequences of RV failure2,3. In the past, the RV has been largely 
understudied and the pathophysiology of RV failure has remained 
incompletely understood. It has become clear that increased pulmonary 
pressures are insufficient to explain the development of RV failure3-7. 
Furthermore, it is intriguing that end stage RV failure can be completely 
reversed as is observed after lung transplantation8. Recent advanced, non-
invasive imaging techniques have been developed that can directly study 
RV myocardial tissue processes and may increase the insights into the 
factors contributing to the development of chronic RV failure. Cardiac 
magnetic resonance imaging (MRI) and positron emission tomography 
(PET) allow in vivo assessment of RV morphology, function, tissue 
characterization, perfusion and blood flow, metabolism, neurohormonal 
activation and other molecular processes. These techniques may help to 
identify factors which determine risk and prognosis and may allow 
assessment of therapeutic effects on RV function in PAH patients.  
Cardiac MRI provides high resolution imaging, does not need geometric 
assumptions and lacks ionizing radiation. It has been shown that two-
dimensional and three-dimensional cardiac MRI measures are highly 
accurate9,10 and reproducible11. MRI has become the gold standard to 
noninvasively measure RV mass, volumes and function12 and has the 
ability to image perfusion and cellular and molecular tissue characteristics. 
Although the role of MRI in establishing the diagnosis of PAH is limited, it 
allows complete RV phenotyping and is especially valuable in the 
monitoring of therapeutic effects. However because MRI is relative 
expensive and requires operator expertise, this methodology is not widely 
used. Furthermore, scan times are quite long end ferromagnetic objects 
such as pacemakers and defibrillators are incompatible. Nevertheless, its 
(clinical) relevance has been clearly established12. PET is a rapidly 
developing technique allowing perfusion imaging, assessment of molecular 
and physiologic processes and evaluation of the cardiac nervous system. 
Limitations of PET are it’s costs and labor intensity. Furthermore, due to the 
relatively low spatial resolution, current clinical PET-scanners are combined 
with computed tomography (CT). In PAH, PET has only been recently used 
and broader application can be expected in the near future. In addition, 
rapid developments in hybrid scanners consisting of PET and MRI are 
taking place in order to allow integrated cardiac assessment. 
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Here we provide an overview of current and future applications of cardiac 
MRI and PET for assessment of chronic RV failure and review potential 
contributing factors that could help considerably to understand the 
pathophysiology of RV failure in the setting of chronic pressure overload. 
Furthermore, we demonstrate the potential clinical relevance of these 
imaging techniques in patients with PAH.  
 
 
RV structural and functional imaging 
 
 RV remodeling and wall stress 
Figure 1 demonstrates cardiac MRI cine images obtained over time from a 
35 year old, female patient who was diagnosed as having idiopathic PAH, 
New York Heart Association (NYHA) functional class II. Mean pulmonary 
artery pressure was 45 mmHg and cardiac output (CO) was 4.1 L/min. At 
the time of diagnosis, she showed cardiac compensation with a maintained 
crescent shape of the RV, RV hypertrophy with an increased RV mass, 
relatively preserved cardiac dimensions (but a small increase in RV 
volume), no pericardial effusion and moderate RV and left ventricular (LV) 
function (Figure 1A). Despite unchanged pulmonary pressures after 7 years 
of follow-up, she developed symptoms of progressive RV failure, even 
though the CO remained relatively stable. Figure 1 demonstrates the 
characteristics of the progression to RV failure by showing the development 
of a spherical RV shape, progressively enlarged RV cross sectional area, 
apical ballooning, thinning of the RV wall, bulging of the interventricular 
septum (IVS) into the LV, under filling of the LV, an increased right atrium, 
tricuspid insufficiency, pericardial effusion and severely impaired 
biventricular function.  
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Figure 1. Cardiac magnetic resonance imaging (MRI) four-chamber (A1-
C1) and short axis cine images (A2-C2) obtained in a patient with 
pulmonary arterial hypertension (PAH) over time.  
The course from right ventricular (RV) structural compensation to end-stage RV failure is 
demonstrated. This patient was diagnosed with an elevated mean pulmonary artery 
pressure (PAP) of 45 mmHg and a cardiac output (CO) of 4.1 L/min. At baseline, the RV 
showed a concentric RV remodeling pattern with increased RV mass, a crescent RV shape, 
small amounts of dilatation, modest RV function (right ventricular ejection fraction (RVEF): 
39%) and preserved left ventricular (LV) function (left ventricular ejection fraction (LVEF): 
62%) (A1, A2). During 7 years of follow-up, PAP was unchanged and CO remained 
relatively stable. However, the RV remodeling pattern has changed (B, C). RV end-diastolic 
volume (RVEDV) showed a progressive increase from 140 to 449ml after 7 years of follow-
up. Smaller increases in RV mass were observed. Furthermore, the RV developed a 
spherical shape, apical ballooning, bulging of the interventricular septum into the LV (dark 
arrows), LV underfilling, an enlarged right atrium, tricuspid insufficiency, pericardial effusion 
(white arrows). In addition, RVEF and LVEF showed a progressive decline to 8% and 29%, 
respectively. PAP (m / s/ d) = pulmonary artery pressure (mean / systole / diastole); SV = 
stroke volume.  
 
The combined assessment of multiple RV imaging parameters provides 
insights into RV remodeling. According to a basic physiological principle of 
Guyton and Hall, the heart primarily functions as an on-demand pump to 
maintain CO in order to fulfill the needs of sufficient oxygen delivery to the 
body13. In the setting of chronic RV pressure overload, the RV 
compensates enduringly (i.e. by Frank-Starling mechanism), RV dilatation, 
RV hypertrophy, tachycardia, changes in contractility) in order to sustain 
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the CO. However, in the long run RV compensation mechanisms may get 
exhausted resulting in disturbed intrinsic RV structure and ultimately RV 
dysfunction and failure. Importantly, imaging of the RV might be of clinical 
relevance since it is likely that early changes in the RV structure could 
predict an ultimate RV functional deterioration (Figure 1). 
Based on the combined MRI assessment of RV mass, shape and volumes 
and by measures of RV pressure, ventricular wall stress can be estimated 
using the law of Laplace (i.e. wall stress = intraluminal pressure times 
chamber internal radius, divided by wall thickness)14. According to Laplace, 
RV hypertrophy is considered part of the adaptive remodeling response to 
increase RV pumping effectiveness by unloading of the individual muscle 
fibres and lowering ventricular wall stress. In contrast, an increased RV 
mass measured by cardiac MRI is associated with an increased mortality in 
scleroderma PAH patients15 and might have some prognostic relevance in 
idiopathic PAH16. These still ambiguous findings might be explained by 
several aspects. First, although RV mass in patients with PAH measured by 
MRI can be more than 2.5 times increased when compared to normal 
reference values17, the RV often faces at rest a four-fold increase in 
pulmonary artery pressures indicating that the amount of RV hypertrophy 
may or may not be insufficient to lower the wall stress and protect RV 
function. This is in keeping with several MRI studies showing that, in PAH 
patients, RV mass and pulmonary pressures are only modestly 
related15,18,19. Furthermore, it has been observed that patients with PAH 
associated with the Eisenmenger syndrome showed a higher amount of RV 
hypertrophy despite a similar elevation in pulmonary pressure compared to 
idiopathic PAH patients; in those patients RV hypertrophy was associated 
with better RV function and survival20,21. However, in RV autopsy tissue of 
PAH patients and in rat models with pulmonary hypertension (PH) it has 
been found that an increase in RV mass is not necessarily accompanied by 
a similar increase in the number of contractile elements22. Second, using 
MRI with gadolinium contrast it has been demonstrated that degenerative 
changes occur in the hypertrophic RV of PAH patients. It was found that 
delayed contrast enhancement (DCE) appears as a unique pattern at the 
IVS insertion points and might be a reflection of focal fibrosis23-26. The 
extent of DCE was most strongly correlated with increased RV mass, 
volumes and pulmonary pressures (i.e. RV wall stress)23,24. Third, RV 
hypertrophy is associated with maladaptive changes in RV metabolism and 
blood flow (see below).  
During chronic pressure overload, the RV phenotype changes from a more 
concentric (Figure 1A) towards an eccentric remodeling pattern (Figure 1B, 
C). The RV shape becomes more like the LV. In contrast to the crescent 
shape and bellows-like contraction pattern of the normal RV wall, a 
spherical RV shape in PAH might tolerate high pressure without generating 
high wall stress due to a decreased RV wall curvature radius at end-
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systole27. In addition, the RV dilates and it has been found by MRI that 
increased RV end-diastolic volume at baseline and progressive dilatation 
during follow-up were among the strongest predictors of mortality in PAH16. 
Although RV dilatation might be beneficial at first resulting in increased 
preload to increase contractility and sustain CO, this compensatory 
mechanism eventually fails and results in a maladaptive course of 
remodeling with increased wall stress, disturbed RV function and ultimately 
depressed RV output.  
 
 RV contractility 
Load independent RV contractility can be assessed by right heart 
catheterization according to the single beat method28-32. Non-invasive MRI 
approaches have also been developed to estimate RV contractility33,34. In 
PAH patients, RV contractility is increased compared to controls. However, 
paradoxically global RV systolic function (e.g. determined by RV ejection 
fraction and stroke volume) is significantly decreased in PAH. This paradox 
is explained by the fact that in PAH, RV hypercontractility augmentation is 
insufficient for the degree of pressure overload, a phenomenon which has 
been described as ventriculo-arterial uncoupling28,29,33,34. In addition to a 
systolic impairment, it was recently demonstrated that RV diastolic stiffness 
is increased in PAH patients and this was related to disease severity28.  
 
 RV function 
Imaging parameters describing global systolic RV function are all load 
dependent and therefore reflect RV-arterial coupling rather than intrinsic RV 
contractility35. In fact, global RV systolic function is determined by multiple 
factors: preload, afterload, contractility, ventricular synchrony, valvular 
regurgitation and shunt fraction3,36. Low stroke volume and RV ejection 
fraction (RVEF) at baseline and a further decrease during follow-up were 
associated with poor survival4,16,37. Furthermore, stroke volume determined 
by MRI has been validated as imaging parameter to monitor therapeutic 
effects38. In addition, after current medical therapies, it has been found that 
the changes in RVEF were only modestly related to the changes in RV load 
(measured by pulmonary vascular resistance (PVR)). Moreover, despite the 
fact that PVR is reduced by treatment, RVEF can deteriorate. The decrease 
in RVEF was associated with poor outcome, independent of the reduction 
in PVR (Figure 2)4.  
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Figure 2. Relationship between changes in PVR and changes in RVEF 
after medical treatment. 
(A) After 1 year of current PAH targeted medical treatment, the changes in pulmonary 
vascular resistance (PVR) were modestly related to the changes in RVEF. (B) In the PAH 
patients with a reduced PVR after therapy, a decrease in RVEF was associated with a 
worse survival compared to patients with a stable/improved RVEF. Both groups showed a 
similar decrease in PVR after treatment (mean PVR reduction: 284 ± 248 dyne·s·cm
5
) 
(Printed with permission
4
).  
 
The determination of RV ejection fraction is relatively time consuming 
whereas stroke volume can be more easily obtained by phase contrast 
mapping MRI39. Other more readily applicable measures of RV function 
have also been explored. RV shortening in a longitudinal plane (tricuspid 
annular plane excursion or TAPSE) and transverse plane provided simple 
estimates of RV ejection fraction of which transverse shortening showed 
the strongest correlation40. In addition, Mauritz et al. showed that 
assessment of both parameters are valuable, but that changes in 
transverse wall motion rather than changes in TAPSE reflect RV 
dysfunction during end-stage disease37.  
Regional ventricular wall deformation and ventricular synchrony are 
important aspects of RV function. MRI tagging techniques are considered 
as the reference technique to measure the relative amount of myocardial 
wall deformation (segmental strain), the velocity of deformation (strain rate) 
and synchrony (i.e. timing of mechanical activation and relaxation between 
wall segments); all of these parameters can be determined in a 
circumferential, longitudinal and radial axis. It has been found that in the 
healthy RV, there is a predominant longitudinal rather than circumferential 
wall deformation, resulting in a bellows-like or peristaltic action. Normal wall 
deformation is in general larger at the basal and apical segments than at 
the mid-segment41. Patients with PH showed an altered pattern with a 
globally reduced longitudinal and circumferential wall deformation42. 
Furthermore, it has been found that regional longitudinal wall deformation 
can already be disturbed at the time that global RV function is still intact, 
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implying that changes in regional measures could be sensitive parameters 
to detect early RV dysfunction in PAH43.  
In addition, it has been shown by MRI that RV asynchrony may contribute 
to the development of impaired cardiac function. In PAH patients, RV 
mechanical contraction is prolonged and continues after the pulmonary 
valve closes (resulting in a so-called post systolic contraction period) 
rendering RV contraction inefficient44,45. In addition, at the time that the RV 
still contracts, the LV in PAH is already in its relaxation phase, leading to 
leftward septum bowing, a low LV end-diastolic volume and decreased 
stroke volume45-47. In fact, a low LV end-diastolic volume appears to be a 
strong predictor of poor prognosis16.  
 
 
RV molecular and perfusion imaging 
 
 RV metabolic remodeling 
PET studies have demonstrated that in LV cardiomyopathies a switch takes 
place from primarily fatty acid metabolism to glucose metabolism in order to 
maintain the adenosine triphosphate (ATP) supply48,49. In the failing human 
RV under chronic pressure overload, single photon emission computed 
tomography (SPECT) has demonstrated a decreased RV uptake of fatty 
acids which was associated with impaired RV function and poor 
prognosis50. Fatty acid uptake can also be estimated using PET with 11C-
palmitate tracers48,51 but such studies have yet to be performed in PAH. In 
addition, RV myocardial glucose metabolism can be measured by PET with 
18F-2-deoxy-2-fluoro-D-Glucose (18FDG) tracers52. Some studies have 
demonstrated an increase in the ratio of RV to LV glucose uptake in PAH 
patients. However it remains unclear whether this ratio is explained by an 
increased RV glucose uptake53-55 or a lowered LV uptake56. Furthermore, 
inconsistent results have been reported with respect to the relevance of 
glucose metabolism in relationship with RV load and function52,55-59. The 
differences between study results are perhaps due to differences in patient 
populations, scanning protocols or data analysis. At this moment, it remains 
unclear which changes in metabolism occur in the RV of PAH patients and 
whether these changes can be regarded as adaptive or indicative of 
pathological remodeling. This area of imaging of RV metabolism will likely 
be further developed in the coming years.  
 
 RV blood flow and oxygen balance 
Using PET with a combination of 15O-labeled tracers (15O-H2O, 
15O-CO, and 
15O-O2) or by a more practical method using 
11C-acetate tracers, RV 
myocardial oxygen consumption (MVO2) can be estimated
60,61. It has been 
demonstrated that resting MVO2 is significantly elevated in patients with 
PAH (Figure 3) and this finding is primarily determined by increased 
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pulmonary pressures and an increased heart rate59,62. PAH patients in 
NYHA class III show a higher MVO2 compared to NYHA class II patients, 
despite a similar RV power output, which implies that the RV of these 
patients becomes mechanically inefficient (Figure 4)59.  
 
 
Figure 3. Positron emission tomography (PET) with 11C-acetate tracers of 
the heart in a patient with PAH.  
(A) A four chamber (B) and short-axis images obtained in the same patient with end-stage 
RV failure as in Figure 1. It is demonstrated that part of the RV wall shows an increased 
myocardial oxygen consumption (MVO2) (bright) that can be even higher compared to the 
LV.  
 
 
Figure 4. Impaired RV mechanical efficiency in patients with PAH is 
primarily determined by increased MVO2.  
Light grey bars = New York Heart Association (NYHA) Functional class II patients, dark bars 
= NYHA functional class III patients. (A) Patients in NYHA II showed a higher cardiac output 
(CO) (B) and similar mean pulmonary artery pressure (mPAP) compared to NYHA III 
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patients. (E) RV power output (i.e. product of CO and mean PAP) was similar in both 
groups. (C) RV myocardial blood flow determined by positron emission tomography (PET) 
with H2
15
O tracers and (D) oxygen (O2) extraction fraction estimated by PET using 
15
O2 
tracers were not statistically different in both groups. (F) However. there was a significantly 
higher MVO2 per gram of myocardial tissue in NYHA III compared to NYHA II patients. (G) 
RV mechanical efficiency was reduced by ~50% in NYHA III in comparison with NYHA II as 
a result of a similar RV power output but higher MVO2 (Printed with permission
59
).  
 
The normal RV has two mechanisms which generate an increased MVO2 
during stress: (1) coronary flow reserve and (2) oxygen extraction fraction 
(OEF) reserve63-66. In patients with PAH during resting conditions, the OEF 
is already elevated whereas the mean resting myocardial blood flow is 
similar in PAH compared to controls59,67,68. In addition, PAH patients 
showed an impaired perfusion reserve since myocardial blood flow did 
neither increase during adenosine induced stress MRI67 nor during PET 
imaging with cycling exercise69. Surprisingly, the change in myocardial 
blood flow during exercise was unrelated to resting OEF. Especially in 
patients with a high resting OEF, an attenuated increase in blood flow 
during exercise was observed and was related to a poorer clinical, 
hemodynamic and RV condition67,69. The findings of impaired myocardial 
blood flow reserve might be explained by multiple factors. First, although 
mean resting coronary blood flow was unchanged, coronary flow was 
inversely related to the amount of RV hypertrophy68. Transmural blood flow 
may be impaired, perhaps as a consequence of a reduced capillary density 
of the failing RV tissue22. Indeed, impaired angiogenesis might play a role 
in the mismatch between hypertrophic myocytes and capillaries. Second, 
the resting coronary blood flow and perfusion reserve are both negatively 
associated with increased pulmonary pressures67,68, which could imply that 
these extravascular compressive forces may restrict an increase in blood 
flow. Other explanations could be impaired autoregulatory flow 
mechanisms70 and systemic hypotension resulting in reduced coronary 
driving pressures. However, van Wolferen et al. showed that the latter 
factor is probably not a major determinant of impaired RV flow in PAH68.  
To summarize, the increased RV oxygen demand in patients with PAH is 
not adequately compensated for by an increased oxygen supply. As a 
potential consequence, Gomez et al. observed RV ischemia in PAH 
patients by SPECT imaging71.  
 
 
The near future of RV molecular imaging 
 
 RV angiogenesis 
In PH animal models, impaired angiogenesis in the setting of RV 
hypertrophy has been demonstrated, which might lead to RV ischemia and 
fibrosis36,72. Vascular endothelial growth factor (VEGF) is a major 
Chapter 8 
140 
contributor to angiogenesis and integrins serve as important mediators of 
angiogenis. Novel imaging strategies have been developed that can directly 
measure angiogenesis in vivo using PET with tracers such as 64CU-labeled 
VEGF121 or 
18F arginine-glycine-aspartic acid peptide (RGD) with affinity for 
the αvβ3 integrins. Angiogenic imaging has successfully been performed in 
rat models with myocardial infarction73-75 and in a patient 2 weeks after 
myocardial infarction76. These imaging techniques may become important 
in the assessment of pathophysiological mechanisms of RV disease 
processes in vivo in PAH.  
 
 RV apoptosis 
Apoptosis is defined as programmed cell death may play a causal role in 
the development of cardiac hibernation and heart failure77. Radiolabeled 
annexin can be used as an imaging protein that binds to phosphatidylserine 
(PS); a phospholipid expressed on the outer cell membrane during 
apoptosis which serves as a marker for macrophages to remove apoptotic 
cells78. It has been demonstrated by SPECT that increased 99Tc-Labeled 
annexin V uptake was associated with the deterioration of LV function in 
patients with LV failure79 and related to allograft rejection in cardiac 
transplant recipients80. Such studies have not yet been performed in PAH 
patients but in PH animal models increased levels of SPECT cardiac 
annexin V uptake have been detected81.  
In addition, activated caspases are involved in the signal transduction of 
apoptosis and when radiolabeled, they can be used for PET measurements 
of apoptosis in vivo. In mouse models of dilated cardiomyopathies, it has 
been shown that although the overall rate of myocyte apoptosis was low, 
persistent levels can overwhelm the limited regenerative capacity of the 
myocardium contributing to heart failure82. 
 
 RV neurohormonal system 
Preclinical studies have demonstrated that dysfunctional neuronal signaling 
might be an important hallmark in the development of RV failure in PAH83. 
PET imaging with radiolabeled norepinephrine (NE) analogs such as 11C- 
meta-hydroxyephedrine (HED) can be applied to estimate presynaptic 
sympathetic function and 11C-CGP-12177 or 11C-CGP-12388 tracers are 
used to estimate levels of postsynaptic sympathetic β-adrenoceptors. HED 
reuptake and β-adrenoceptor density were reduced in patients with LV 
cardiomyopathies and associated with impaired LV function and worse 
survival84-86.  
The renin-angiotensin-aldosterone system (RAAS) activity in PAH is 
increased and associated with disease severity87. By use of PET imaging 
with 11C-KR31173 tracers, levels of cardiac angiotensin receptors have 
been detected in healthy volunteers88. Such data might be of 
pathophysiological interest also in patients with PAH.  
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 Magnetic resonance spectroscopy 
Magnetic resonance spectroscopy (MRS) is a technically difficult technique 
but can provide insight into cardiac metabolism in vivo without requirements 
of an external tracer. There is limited expertise in the field of PAH89 but 
multiple studies have been performed in patients with LV failure. Multiple 
31Phophorus MRS studies have demonstrated that LV levels of creatine 
and ATP were decreased in advanced heart failure and related to 
survival90.  
 
 Hybrid PET-MRI 
Currently, hybrid PET-CT has become commonplace in clinical practice 
and research settings and has significantly contributed to our insights into 
pathophysiological processes in cardiovascular diseases91. Although CT 
allows detailed structural imaging it is less useful in RV functional 
assessment. Hybrid PET-MRI is an innovative, rapidly accepted technique 
which does not only allow (simultaneous) combination of PET with 
anatomic imaging but also provides functional imaging, perfusion imaging, 
tissue characterization and flow imaging that might provide improved 
insights into the pathophysiology of RV failure. However one limitation of 
hybrid systems with MRI is that information required for attenuation 
correction of nuclear images is not provided. Recently, the first hybrid PET-
MRI results of patients with myocardial infarction have been published and 
have demonstrated high image qualities (Figure 5)92-94.  
 
 
Figure 5. Short-axis images obtained by hybrid PET-MRI in a patient with 
myocardial infarction of the septal and anteroseptal wall.  
(A) MRI with late gadolinium enhancement (LGE) demonstrates the infarct zone with a no-
reflow phenomenon (arrows). (B) Fusion of 
18
F-2-deoxy-2-fluoro-D-Glucose (
18
FDG) PET 
and MRI LGE images demonstrates absent 
18
FDG uptake in the infarcted area (Printed with 
permission
92
). 
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Summary and conclusions 
 
We predict that in vivo cardiac MRI and PET will significantly contribute to a 
better understanding of the pathophysiological processes which lead to the 
development of chronic RV failure. Imaging studies have demonstrated that 
in the setting of chronic pressure overload, the RV compensates enduringly 
to sustain CO by an increase in wall mass, dilatation and contractility and 
marked changes in the RV shape. With passage of time, these 
compensation mechanisms fail, resulting in increased wall stress and 
impaired global RV function. Other factors that might contribute to disturbed 
RV function are a reduced wall deformation and an inefficient RV 
contraction pattern. The resulting interventricular asynchrony is associated 
with leftward septum bowing, impaired LV filling and decreased stroke 
volume. Furthermore, the RV becomes mechanically insufficient: more 
oxygen is required for a comparable power output. At the same time, RV 
oxygen delivery is impaired and tissue oxygenation is reduced. Alterations 
in myocardial metabolism have been observed in PAH, but their overall 
relevance and cause of consequence of RV failure remain unclear. In the 
near future it can be expected that the importance of changes in cellular 
functions and signaling pathways will become clear and ‘imageable’. This 
might allow a regional and quantifiable analysis of processes such as 
angiogenesis, apoptosis and neurohormonal factors. Table 1 provides an 
overview of currently available clinical imaging tracers that could be 
relevant for the assessment of molecular processes of RV diseases in 
patients. In addition, recent developments in (hybrid) PET and MRI might 
allow an integrated RV assessment in vivo. They will likely provide an 
important basis for simultaneous measurements of multiple myocardial 
disease processes.  
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Table 1. Overview of applicable tracers for molecular imaging in patients 
with heart failure. 
Function Tracer MRI Tracer PET 
Angiogenesis  
18
F-arginine-glycine-
aspartic acid peptide 
(RGD) αvβ3 integrins
76*
 
Apoptosis 
 
Iron labeled Annexin 
V
95*
 
Synaptotagmin C2A
96*
 
18
F-Annexin V
97*
 
Metabolism Adenosine triphosphate 
(ATP), 
phosphocreatinine
89,98*, #
 
11
C-palmitate
51*
 
18
F-fluoro-2-deoxy-D-
glucose
59
 
Oxygen consumption  
11
C-acetate
60
 
15
O-H2O, 
15
O-CO, 
15
O-
O2
59,61
 
Neuroreceptors 
   Sympathic signaling 
 
 
   Parasympathic 
signaling 
  
11
C- hydroxyephedrine 
(HED)
85,86*
 
11
C-CGP-12177
86,99*
 
11
C-CGP-12388
100*
 
11
C-MQNB
101*
 
Renin-Angiotensin-
Aldosterone-System 
(RAAS) 
 
11
C-KR31173
88*
 
 
*Previously performed in patients with left ventricular failure but yet has not been applied in 
patients with right ventricular failure. 
#
Using 
31
Phosphorus-magnetic resonance 
spectroscopy. 
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Conclusions 
 
Based on the findings presented in this thesis, we may conclude that in 
patients with pulmonary arterial hypertension (PAH):  
 Right heart remodeling is a spatial heterogeneous process. Right 
ventricular (RV) trabeculae show more hypertrophy than the RV free 
wall. The interventricular septum (IVS) shows a different remodeling 
pattern compared to the RV free wall.  
 RV dysfunction can progress despite a reduction in pulmonary 
vascular resistance (PVR) after current medical therapies. A 
decrease in RV function is associated with poor survival, regardless 
of the changes in PVR.  
 Only if PVR is reduced more than 42% after medical treatment, 
stabilization of RV function and better survival are guaranteed.  
 Male patients show a worse RV function compared to female 
patients despite a similar elevated afterload. This might explain the 
worse survival rates of males compared to females.  
 In longstanding seemingly clinical stable patients under medical 
treatment, changes in RV volumes precede an ultimate clinical 
deterioration.  
 
 
Future perspectives 
 
RV parameters as endpoint in clinical trials 
In order to accurately study RV structural remodeling in PAH patients, RV 
trabeculae cannot be neglected from the RV mass assessment (Chapter 2) 
but the IVS should be not be included (Chapter 3). Although RV mass is of 
physiological importance, the clinical relevance remains uncertain because 
RV mass might be an insensitive measure to assess disease severity due 
to the modest observer-reproducibility and relative small changes in RV 
mass during follow-up.  
Changes in RV volumetric and functional parameters reflect disease 
severity and might be sensitive measures to predict clinical worsening and 
survival (Chapters 4-7)1. These results raise the question whether RV 
volumes and function could be valuable endpoints in clinical trials. As a first 
step, future studies are required to find the extent of change in RV 
measures that will be of clinical importance for monitoring therapeutic 
effects during follow-up. The clinical important difference in stroke volume 
has been determined and was found to be 10ml2. In addition, a change in 
RV ejection fraction (RVEF) >3% could be of clinical relevance (Chapters 4 
and 5). Although the repeatability of RV end-diastolic volume was found to 
be 10ml3, the clinical important difference has to be determined. To date 
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RV structural and functional parameters have not served as endpoints in 
clinical trials studying new therapies, but it is time to use RV imaging 
parameters as an endpoint in the near future.  
 
Raising the bars in the treatment of PAH 
Despite the application of current medical therapies, survival remains 
unsatisfactory4,5. This might be explained by the fact that in a substantial 
number of PAH patients, the RV shows progressive dysfunction despite a 
decrease in PVR and is associated with poor survival (Chapter 4). 
Preservation of RV function is the yardstick for long-term survival. 
Therefore, we have prospectively initiated the “Goal Oriented Strategy to 
Preserve Ejection fraction triaL” (GOSPEL) (to assess whether a goal 
oriented strategy to preserve RV function will result in improved clinical 
outcome of PAH patients. A stable/improved RVEF is considered as the 
primary outcome parameter. 
Although the mean PVR reduction after current therapies might be 
insufficient to improve RV function, a strong decrease in PVR guaranteed a 
stabilized/increased RVEF and was related to long-term survival. In 
correspondence with previous studies5-8, a strong PVR decrease was 
associated with the application of (upfront) combination therapies (Chapter 
6). In line with these findings, we hypothesize in our prospective study that 
RV function can only be preserved when early and aggressive combination 
therapies result in a significant PVR reduction. When this strategy not only 
result in a preserved CO but also leads to a decreased PAP, RV work will 
be decreased relieving stress on the RV and contributing to RV 
preservation9.  
 
Improve insights and treatment of the RV 
The development of RV dysfunction is perhaps not fully explained by the 
elevated load. It remains insufficiently understood why some patients show 
progressive RV dysfunction despite a decrease in PVR after therapy 
(Chapter 4). Alternatively, it remains unclear why some patients with a 
long-term stable clinical condition do not show progressive RV remodeling 
during ten years of follow-up despite a significantly elevated afterload 
(Chapter 7). RV function is profoundly influenced by the sex of the 
individual (Chapter 5) and other factors might play an additional role10-12. 
Future studies are required to improve our knowledge in the underlying 
processes of the development of RV failure. Load-independent RV 
measures might contribute to improved insights in intrinsic RV properties13. 
Advanced imaging of the RV by (hybrid) MRI and PET might lead to better 
pathophysiological understanding in the near future (Chapter 8).  
At the same time it is pertinent to think about direct RV targeted therapies. 
Several experimental studies have suggested a potential benefit of 
betablocker therapies in PAH14-17. In a recent retrospective clinical study, it 
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was demonstrated that betablocker therapies did not adversely affect 
survival18. At the VU Medical Center, a phase-II prospective clinical study 
has been initiated to assess the safety and effects of bisoprolol on RV 
function in PAH patients.  
 
In short, the results of this thesis clearly showed that the RV is not only a 
mere bystander in PAH but an important determinant of the symptoms and 
outcome of the patient. Therefore rigorous monitoring of the RV and the 
search for RV targeted therapy are important tools to improve outcome in 
PAH in the near future.  
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Summary 
 
Pulmonary arterial hypertension (PAH) is a progressive disease of the 
small pulmonary arteries that results in increased pulmonary vascular 
resistance (PVR) and pulmonary artery pressure (PAP). As a consequence, 
the right ventricle (RV) has to cope with the increased afterload in order to 
provide sufficient cardiac output (CO). The RV develops hypertrophy, 
dilates and shows changes in metabolism. However, the RV is not suitable 
to cope with longstanding pressure overload, resulting in RV maladaptation, 
decreased RV function and ultimately RV failure and death. The current 
medical treatment strategy is aimed to improve RV function by reducing the 
afterload. During the last decade, multiple medical therapies have been 
developed that have mainly pulmonary vasodilator effects resulting in 
reduced PVR and improved CO. Despite these therapeutic effects, survival 
remains unsatisfactory. Therefore more insights are warranted in how RV 
dysfunction evolves structurally and functionally during the course of 
disease and under medical treatment.  
The aims of this thesis are twofold. The first aim was to provide improved 
insights in RV structural remodeling to pressure overload. Secondly, we 
aimed to assess the changes in RV adaptation and function over time in 
relationship to the changes in afterload under current PAH targeted medical 
therapies. In this thesis, we performed RV assessment by magnetic 
resonance imaging (MRI), which is considered the gold standard to 
measure RV mass, volumes and function.  
 
In Chapter 2, we studied the hypertrophic response of the RV in PAH 
patients in comparison to control subjects. The RV muscle mass does not 
only consist of the RV free wall but also includes many trabeculae: small 
muscle bundles that support the RV free wall. However, RV trabeculae 
have been generally ignored in previous literature. Therefore, by use of 
MRI and right heart catheterization (RHC), we studied in 50 PAH patients 
and 20 control subjects the hypertrophic response of both the RV free wall 
and trabeculae to pressure overload and assessed the changes in these 
RV mass compartments during one year of medical treatment. We found 
that the RV trabeculae showed a larger contribution to total RV mass in 
PAH patients (~35%) compared to controls (~25%) (p <0.001). Moreover, in 
PAH patients the changes in mass of the RV trabeculae were stronger 
related to the changes in PVR and PAP after one year of medical treatment 
than the mass of the RV free wall. These results implicate that trabeculae 
are important contributors to RV adaptation to chronic pressure overload in 
PAH.  
 
During chronic RV pressure overload, interventricular dyssynchrony is 
associated with leftward bowing of the interventricular septum (IVS) and 
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disturbed IVS function. However, it is unknown what tissue alterations 
occur in the IVS and if they are comparable to the changes in the RV free 
wall. In Chapter 3, we studied in 17 PAH patients by MRI and PET the 
mass and glucose metabolism of the RV, IVS and left ventricle (LV). In 
addition, we studied in more detail whether cellular alterations of the IVS 
were comparable to the RV free wall in a monocrotoline pulmonary 
hypertension (PH) rat model. In PAH patients, we found that the changes in 
IVS mass and glucose metabolism were not comparable to the changes in 
the RV free wall (both p for difference <0.001). In addition, the 
cardiomyocyte cross-sectional area and capillary density remained 
preserved in the IVS but were impaired in the RV free wall of PH rats (both 
p interaction <0.001). Furthermore, we found that although fibrosis and 
inflammation were increased in both the IVS and the RV in PH rats, the 
magnitude of increase was significantly lower for the IVS (both p interaction 
<0.001). These results demonstrate that despite a similar pressure 
overload in PAH, IVS morphology and metabolism remain better preserved 
and do not resemble the remodeling of the RV free wall.  
 
Despite a reduction in PVR accomplished by current medical therapies, 
survival of PAH patients remains grim. This might be explained by the fact 
that this PVR reduction does not automatically result in improved RV 
function. Therefore, in Chapter 4 we studied the relationship between the 
changes in PVR and changes in RV function and survival after medical 
treatment. A large group of PAH patients underwent MRI to measure RV 
ejection fraction (RVEF) as a measure of systolic RV function and RHC to 
measure PVR at baseline and after one year of treatment. We found that 
the changes in PVR were moderately related to the changes in RVEF (R = 
0.33; p = 0.001). 68% of the patients showed a reduced PVR after medical 
treatment. In 75% of these therapeutic responders, this was associated 
with a stable or improved RV function and favorable survival. However, 
25% of these patients showed despite a similar decrease in PVR, 
progressive RV dysfunction which was associated with poor survival.  
 
Since male gender is associated with a poor survival, we assessed in 
Chapter 5 whether this could be explained by a distinct vascular or RV 
response to medical treatment. At baseline, we observed that RVEF and 
PVR were comparable between males and females. Both genders showed 
a similar reduction in PVR after medical treatment (p for difference = 0.63). 
However, females showed an improved RVEF while males showed a 
deterioration in RVEF after medical treatment (p <0.001 after correction for 
confounders) which was associated with a poor survival. One third of the 
effects of gender on survival was mediated by the differences in RVEF, 
which indicates that also other factors could play an important role in the 
gender disparity in PAH. 
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In Chapter 6, we hypothesized that a strong reduction in PVR after medical 
treatment will result in an guaranteed improvement of RV function and 
survival. In this chapter, we investigated the relationships between baseline 
PVR, PVR-response, changes in RV adaptation and function and survival 
after current PAH therapies. we demonstrated that a threshold decrease in 
the relative PVR change of more than 42% was feasible in a substantial 
number of PAH patients and was associated with an improvement in RV 
function, reduction of RV dilatation and long-term survival. A strong PVR 
decrease was related to the application of upfront combination therapies. 
 
Even after years of a stable response to medical treatment (defined by a 
stable New York Heart Association (NYHA) functional class II-III and six-
minute walking test), PAH patients may show an unexpected rapid clinical 
deterioration due to progressive RV failure, which is associated with a high 
mortality rate. If the RV would already demonstrate signs of progressive 
adverse remodeling during the initial stable clinical condition, assessment 
of RV remodeling parameters might predict an ultimate disease 
progression. In Chapter 7, we assessed in 22 five-year clinically stable 
patients with PAH whether differences in RV volumes, precede an ultimate 
disease progression. We compared regularly obtained RHC and MRI 
measures between twelve patients who remained stable during 10 year of 
follow-up and ten other patients who showed late disease progression 
leading to death or lung transplantation after a median duration of eight 
years. We found that RV remodeling can be progressive, even in PAH 
patients who are seemingly clinically stable during 5-10 years of follow-up. 
Moreover, we showed that an ultimate disease progression is preceded by 
changes in RV volumes and RVEF and not by differences in NYHA 
functional class, exercise capacity or hemodynamic parameters.  
 
In Chapter 8, we provided an overview of advanced in vivo imaging of the 
RV by cardiac MRI and PET. We show that imaging of RV hypertrophy, 
shape, dilatation, wall stress, global function, contractility, dyssynchrony 
and IVS bowing, perfusion and metabolism have significantly contributed to 
a better understanding of the pathophysiological processes that contribute 
to the development of chronic RV failure in PAH. Furthermore, we 
explained that in the near future it can be expected that the importance of 
changes in tissue processes such as angiogenesis, apoptosis and 
neurohormonal factors will become more clear and ‘imageable’. In addition, 
recent advances in hybrid PET and MRI might allow integrated assessment 
of the RV in vivo and will be one of the most important future 
developments.  
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Het aanpassingsvermogen en functioneren van 
de rechter hartkamer in pulmonale arteriële 
hypertensie 
 
Pulmonale arteriële hypertensie (PAH) is een chronisch, progressieve 
aandoening waarbij de bloedvaten in de longen zijn veranderd en 
vernauwd. Hierdoor ontstaat een verhoogde weerstand en bloeddruk in de 
longvaten. De diagnose kan worden gesteld wanneer de bloeddruk in de 
longvaten hoger is dan 25 mmHg, invasief gemeten tijdens een rechter 
hartkatheterisatie. De aandoening is zeldzaam en de oorzaak is vaak 
onbekend (idiopathisch) maar kan ook erfelijk zijn of geassocieerd met 
andere aandoeningen zoals aangeboren hartafwijkingen, bindweefsel 
ziekten, drugs of medicijnen. PAH komt twee keer zo vaak bij vrouwen 
voor. De leeftijd waarop de diagnose wordt gesteld, is gemiddeld 40 jaar.  
Het gevolg van de verhoogde longvaatweerstand en bloeddruk, is dat het 
de rechter hartkamer hindert in het pompen van bloed richting de longen. 
De rechter hartkamer probeert zich aan te passen door meer spiermassa te 
ontwikkelen en door uit te zetten. Ook treden er bijvoorbeeld veranderingen 
in metabolisme op. De rechter hartkamer die normaal niet berekend is op 
deze hoge longvaatweerstand en bloeddruk, is onvoldoende in staat om 
zich langdurig aan te passen waardoor het in conditie achteruit zal gaan. 
Dit uit zich bij patiënten in klachten van kortademigheid bij inspanning en 
vermoeidheid. Uiteindelijk overlijden PAH patiënten ten gevolge van het 
falen van de rechter hartkamer.  
In de afgelopen 15 jaar zijn er meerdere medicijnen ontwikkeld die zich 
richten op het verlagen van de longvaatweerstand en daarmee de rechter 
hartkamer proberen te verbeteren. Met behulp van deze medicijnen zijn de 
klachten van patiënten verminderd en is de overlevingsduur verlengd, 
niettemin blijft PAH een ongeneeslijke ziekte. Daarom is meer begrip nodig 
in het structurele en- functionele aanpassingsvermogen van de rechter 
hartkamer aan de chronische overbelasting ten gevolge van de verhoogde 
longvaatweerstand. Tevens is meer inzicht noodzakelijk in de effecten van 
huidige medicatie op de rechter hartkamer.  
 
Dit proefschrift heeft twee doelen: enerzijds meer inzicht verkrijgen in de 
aanpassing van de rechter hartkamer aan de verhoogde 
longvaatweerstand van patiënten met PAH. Anderzijds was het doel om de 
veranderingen in de aanpassing en het functioneren van de rechter 
hartkamer over tijd te bestuderen in relatie met de veranderingen in de 
longvaatweerstand die teweeg worden gebracht met behulp van de huidige 
medicijnen.  
Voor dit proefschrift maakten we gebruik van magnetische resonantie 
imaging (MRI). Dit is beeldvormend onderzoek waarmee de spiermassa, 
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mate van uitzetting en functie van de rechter hartkamer het meest precies 
en betrouwbaar kunnen worden gemeten.  
 
De spiermassa van de rechter hartkamer bestaat niet alleen uit de wand 
maar ook uit vele trabecula (kleine bundeltjes spierweefsel die extra steun 
geven aan de wand). Dit laatste aspect wordt echter vaak buiten 
beschouwing gelaten. In Hoofdstuk 2 hebben we daarom niet alleen naar 
de veranderingen in spiermassa van de wand maar ook van trabecula 
gekeken in relatie tot de chronische overbelasting op de rechter hartkamer 
voor en na medicamenteuze behandeling. In dit onderzoek bestudeerden 
we 50 patiënten met PAH en 20 gezonde controles. We vonden dat de 
trabecula een grotere bijdrage leverden aan de totale spiermassa van de 
rechter hartkamer in PAH patiënten (~35%) dan in de controlegroep 
(~25%). Verder zagen we dat in behandelde PAH patiënten, de 
veranderingen in bloeddruk en weerstand van de longvaten sterker waren 
gerelateerd aan veranderingen van de massa van trabecula dan aan de 
veranderingen in massa van de wand van de rechter hartkamer. Deze 
resultaten impliceren dat de trabecula mogelijk een belangrijke bijdrage 
leveren aan het aanpassingsvermogen van de rechter hartkamer in PAH. 
Trabecula moeten daarom niet genegeerd worden in onderzoek naar de 
rechter hartkamer.  
 
Het doorbuigen richting de linker hartkamer van het septum, het 
tussenschot dat de rechter en de linker hartkamer van elkaar scheidt, is 
kenmerkend voor patiënten met PAH. Het septum heeft in het gezonde hart 
een substantiële bijdrage aan de normale functie van de rechter hartkamer. 
Het is bekend dat het septum in PAH niet optimaal kan functioneren en dat 
de septum doorbuiging zorgt voor belemmering van de functie van de linker 
hartkamer. Er is echter nog nooit onderzoek gedaan naar onderliggende, 
structurele veranderingen in het septum in PAH. In Hoofdstuk 3 
onderzochten we of er onderliggende structurele veranderingen optreden in 
het septum en of deze lijken op de veranderingen zoals deze ook worden 
gezien in de wand van de rechter hartkamer in patiënten met PAH. Ook 
keken we naar de veranderingen in metabolisme met behulp van positron 
emissie tomografie beeldvorming (PET). We deden niet alleen onderzoek 
in patiënten met PAH, maar verrichten ook onderzoek in een ratten-model 
met pulmonale hypertensie om te kijken welke veranderingen er op 
celniveau optreden. We vonden in PAH patiënten dat het septum geen 
toename liet zien in spiermassa, in tegenstelling tot de wand van de rechter 
hartkamer. Ook zagen we dat het septum qua metabolisme niet leek op de 
rechter hartkamer. Op celniveau vonden we in ratten met pulmonale 
hypertensie dat de grootte van de hartspiercellen en het aantal 
bloedvaatjes in het septum niet veranderden ten opzichte van gezonde 
ratten. In de rechter hartkamer van ratten met pulmonale hypertensie 
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waren de hartspiercellen echter sterk vergroot en het aantal bloedvaatjes 
afgenomen. Ondanks het feit dat ratten met pulmonale hypertensie wel een 
toename in bindweefsel en ontsteking lieten zien in het septum, was deze 
toename significant kleiner dan in de wand van de rechter hartkamer. Op 
basis van dit onderzoek kunnen we concluderen dat het septum in PAH 
beter bestand is tegen de verhoogde vaatweerstand en bloeddruk in de 
longen en dat het niet dezelfde veranderingen laat zien als de wand van de 
rechter hartkamer.  
 
De discrepantie tussen het gunstige effect van de medicijnen op de 
longvaatweerstand en de blijvend slechte overleving van patiënten met 
PAH, doet de vraag oproepen of deze longvaatweerstand verlaging wel 
automatisch leidt tot een verbetering van de rechter hartkamer functie. Dit 
hebben we in Hoofdstuk 4 onderzocht. Met behulp van MRI hebben we de 
functie van de rechter hartkamer gemeten en door middel van een rechter 
hartkatheterisatie hebben we de longvaatweerstand gemeten voor en na 1 
jaar medicamenteuze behandeling. Deze studie toonde aan dat de 
verandering in de rechter hartkamerfunctie na behandeling matig was 
gerelateerd aan de veranderingen in longvaatweerstand. We vonden dat in 
de meeste patiënten inderdaad een verlaging van de vaatweerstand 
teweeg werd gebracht met behulp van medicijnen. In 75% van deze 
patiënten was dit geassocieerd met een verbetering van de rechter 
hartkamerfunctie. In 25% van de PAH patiënten was dit echter niet het 
geval en was er sprake van een korte overlevingsduur.  
 
Ondanks het feit dat PAH vaker voorkomt onder vrouwen, hebben mannen 
een kortere overlevingsduur. In Hoofdstuk 5 onderzochten we of dit 
verschil in overleving verklaard kan worden door een verschillende respons 
op behandeling. We lieten zien dat voor de start van behandeling mannen 
en vrouwen een vergelijkbare longvaatweerstand en rechter 
hartkamerfunctie hadden. Na 1 jaar behandeling lieten beide groepen een 
vergelijkbare daling in longvaatweerstand zien. Vrouwen lieten daarop een 
verbetering van de functie van de rechter hartkamer zien, terwijl deze 
functie bij mannen verslechterde. Deze verslechtering in hartfunctie was 
gerelateerd aan de kortere overlevingsduur in mannen met PAH.  
 
In Hoofdstuk 6 vroegen we ons af of de achteruitgang van de rechter 
hartkamerfunctie ondanks een verlaging in longvaatweerstand verklaard 
zou kunnen worden door het feit dat de huidige behandelingen gemiddeld 
een te kleine verandering in longvaatweerstand teweeg brengen om de 
rechter hartkamer de kans te geven om te verbeteren. In deze studie 
vergeleken we verschillende maten van dalingen in de longvaatweerstand 
en onderzochten de effecten daarvan op de functie van de rechter 
hartkamer en overleving. In dit hoofdstuk lieten we zien dat alleen wanneer 
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de longvaatweerstand met meer dan 42% werd verlaagd met behulp van 
medicatie, dit gegarandeerd leidde tot een stabilisatie/verbetering van de 
rechter hartkamerfunctie en geassocieerd was met een langdurige 
overleving.  
 
Een belangrijk probleem in de kliniek is dat na een lange stabiele situatie 
onder medicamenteuze behandeling, een patiënt met PAH soms heel 
onverwachts kan verslechteren ten gevolge van achteruitgang van de 
rechter hartkamer. In Hoofdstuk 7 hebben we onderzocht aan welke 
parameters we zouden kunnen herkennen welke patiënt uiteindelijk zal 
gaan verslechtering en bij welke patiënt dit niet zal gebeuren. In dit 
hoofdstuk toonden we aan dat ondanks een stabiele klinische situatie, de 
rechter hartkamer al veranderingen kan laten zien in het 
aanpassingsvermogen en dan vooral in de mate van uitzetting (dilatatie). 
De mate van uitzetting was een voorspeller voor een toekomstige klinische 
achteruitgang. Deze uiteindelijke achteruitgang kon niet voorspeld door de 
initiële klinische conditie, inspanningsvermogen en hoogte van de 
longvaatweerstand en bloeddruk. De resultaten van deze studie impliceren 
dat het in de gaten houden van het aanpassingsvermogen van de rechter 
hartkamer belangrijk is om de eerste tekenen van hartfalen te kunnen 
ontdekken om daarmee een uiteindelijke verslechtering te kunnen 
voorkomen.  
 
In Hoofdstuk 8 geven we een overzicht van de mogelijke manieren om de 
rechter hartkamer te onderzoeken met behulp van MRI en PET. Ook 
beschrijven we methoden die nog in ontwikkeling zijn maar uiteindelijk een 
belangrijke rol kunnen gaan spelen in het verkrijgen van nieuwe inzichten in 
de ontwikkeling en preventie van hartfalen in patiënten met PAH.  
 
 
Conclusies 
 
Samenvattend heeft dit proefschrift inzicht gegeven in het structurele en 
functionele aanpassingsvermogen van de rechter hartkamer op de 
verhoogde druk en weerstand in de longvaten van patiënten met PAH. Op 
basis van dit proefschrift kunnen we in patiënten met PAH de volgende 
conclusies trekken: 
 Tijdens chronische drukbelasting tonen de trabecula een sterkere 
toename in spiermassa dan de wand van de rechter hartkamer. Het 
septum laat niet dezelfde veranderingen als de wand van de rechter 
hartkamer zien, ondanks dezelfde drukbelasting.  
 De functie van de rechter hartkamer kan afnemen ondanks een 
verlaging van de weerstand in de longen na medicamenteuze 
behandeling. Een verslechtering in de functie van de rechter 
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hartkamer, ongeacht de veranderingen in longvaatweerstand, is 
geassocieerd met een korte overlevingsduur.  
 Mannen hebben een slechtere functie van de rechter hartkamer dan 
vrouwen ondanks een vergelijkbare longvaatweerstand en 
bloeddruk. Dit verschil kan de kortere overlevingsduur van mannen 
ten opzichte van vrouwen verklaren.  
 Alleen een sterke verlaging van de longvaatweerstand garandeert 
een stabilisatie/verbetering van de rechter hartkamerfunctie en is 
geassocieerd met een langdurige overleving. 
 In patiënten met een langdurig stabiele respons op 
medicamenteuze behandeling kan een uiteindelijke verslechtering 
in een vroeg stadium worden voorspeld op basis van veranderingen 
in de mate van uitzetting van de rechter hartkamer. 
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List of abbreviations 
 
6MWT  = six-minute walking test 
APAH   = associated pulmonary arterial hypertension 
ATP   = adenosine triphosphate 
BMI   = body mass index 
BSA   = body surface area 
CMR   = cardiac magnetic resonance imaging 
CO   = cardiac output 
CI   = cardiac index 
CSA   = cross sectional area 
CT   = computed tomography 
DCE   = delayed contrast enhancement 
ERA   = endothelin receptor antagonist 
18FDG   = 18F-2-deoxy-2-fluoro-D-Glucose 
GFR   = glomerular filtration rate 
HPAH   = heritable pulmonary arterial hypertension 
HR   = heart rate 
IPAH   = idiopathic pulmonary arterial hypertension 
IVS   = interventricular septum 
LV   = left ventricle or left ventricular 
LVEDV  = left ventricular end-diastolic volume 
LVEF   = left ventricular ejection fraction 
LVESV  = left ventricular end-systolic volume 
mPAP   = mean pulmonary artery pressure 
MRglu  = myocardial glucose uptake 
MRI   = magnetic resonance imaging 
MRS   = magnetic resonance spectroscopy 
MVO2   = myocardial oxygen consumption 
NT-proBNP  = N-terminal pro-brain natriuretic peptide 
NYHA   = New York Heart Association 
OEF   = oxygen extraction fraction 
PAH   = pulmonary arterial hypertension 
PAP   = pulmonary artery pressure 
PAWP  = pulmonary arterial wedge pressure 
PCWP  = pulmonary capillary wedge pressure 
PDE-5I  = phosphodiesterase five inhibitor 
PET   = positron emission tomography 
PH   = pulmonary hypertension 
PAH   = pulmonary arterial hypertension 
PVOD   = pulmonary veno-occlusive disease 
PVR   = pulmonary vascular resistance 
RAP   = right atrial pressure 
RHC   = right heart catheterization 
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ROC   = receiver operating characteristic curve analysis 
RV   = right ventricle or right ventricular 
RVEDV  = right ventricular end-diastolic volume 
RVEF   = right ventricular ejection fraction 
RVESV  = right ventricular end-systolic volume 
RVFW  = right ventricular free wall 
SPECT  = single photon emission computed tomography 
SV   = stroke volume 
SvO2   = mixed venous oxygen saturation 
TAPSE  = tricuspid annular plane systolic excursion 
TPM   = trabeculae and papillary muscles 
WHO FC  = world health organization functional class 
 
 172 
 
 
 
 
 
 
 
 
  
  
  
 
  
 173 
 
 
 
 
 
 
List of publications 
 
  
Publications 
174 
Full papers 
 
Contractile dysfunction of left ventricular cardiomyocytes in patients with 
pulmonary arterial hypertension 
E. Manders, H.J. Bogaard, M.L. Handoko, M.C. van de Veerdonk, 
A. Keogh, N. Westerhof, G.J.M. Stienen, C. G. dos Remedios, M. 
Humbert, P. Dorfmüller, E. Fadel, C. Guignabert, J. van der Velden, 
A. Vonk Noordegraaf, F. S. de Man, C.A. C. Ottenheijm. J Am Coll 
Cardiol 2014; in press.  
 
The interventricular septum in pulmonary hypertension does not show 
features of right ventricular failure  
G. Ruiter*, M.C. van de Veerdonk*, H.J. Bogaard, J.T. Marcus, 
A.A. Lammertsma, N. Westerhof, W.J. van der Laarse, F.S. de Man, 
A. Vonk Noordegraaf. Int J Cardiol 2014; epub ahead of print. 
 
Right ventricular dilatation precedes late clinical progression of initially 
stable patients with pulmonary arterial hypertension 
M.C. van de Veerdonk, J.T. Marcus, H.J. Bogaard, F.S. de Man, A. 
Boonstra, M.W. Heijmans, N. Westerhof, A. Vonk Noordegraaf. 
Submitted.  
 
Cardiac MRI and PET scanning in right ventricular failure (Book chapter). 
M.C. van de Veerdonk, J.T. Marcus, H.J. Bogaard, A. Vonk 
Noordegraaf. 2014; in press. 
 
State of the Art: Advanced Imaging of the Right Ventricle and Pulmonary 
Circulation in Humans (Review).  
M.C. van de Veerdonk, J.T. Marcus, H.J. Bogaard, A. Vonk 
Noordegraaf. Pulm Circ 2014; in press.  
 
The importance of trabecular hypertrophy in right ventricular adaptation to 
chronic pressure overload. 
M.C. van de Veerdonk, S.A. Dusoswa, J.T. Marcus, O.A. Spruijt, T. 
Kind, H.J. Bogaard, A. Boonstra, N. Westerhof, A. Vonk 
Noordegraaf. Int J Cardiovasc Im 2014; 30:357-365. 
 
The right ventricle explains sex differences in survival in idiopathic 
pulmonary arterial hypertension patients 
W. Jacobs, M.C. van de Veerdonk, P. Trip, F.S. de Man, M.W. 
Heijmans, J.T. Marucs, S.M. Kawut, H.J. Bogaard, A. Boonstra, A. 
Vonk Noordegraaf. Chest 2013; epub ahead of print. 
 
Publications 
175 
 
Changes in Right Ventricular Function Measured by Cardiac Magnetic 
Resonance Imaging in Patients Receiving Pulmonary Arterial 
Hypertension-targeted Therapy; The EURO-MR Study.  
A.J. Peacock, S. Crawley, L. McLure, K. Blyth, C.D. Vizza, R. 
Poscia, M. Francone, I. Iacucci, H. Olschewski, G. Kovacs, A. Vonk 
Noordegraaf, J.T. Marcus, M.C. van de Veerdonk, F.P. Oosterveer. 
Circ Cardiovasc Im 2014; 7:107-114. 
 
Prognostic relevance of exercise parameters in pulmonary arterial 
hypertension.  
H. Groepenhoff, A. Vonk Noordegraaf, M.C. van de Veerdonk, A. 
Boonstra, N. Westerhof, H.J. Bogaard. PLoS One 2013; 8:e72013. 
 
Effects of Diaphragm Plication on Pulmonary Function and 
Cardiopulmonary Exercise Parameters.  
W.N. Welvaart, P.M.C. Jak, M.C. van de Veerdonk, J.T. Marcus, 
C.A.C. Ottenheijm, M.A. Paul, A. Vonk Noordegraaf. Eur J 
Cardiothorac Surg 2013; 44:643-647. 
 
Accurate assessment of right ventricular systolic function in patients with 
pulmonary hypertension.  
P. Trip, T. Kind, M.C. van de Veerdonk, J.T. Marcus, F.S. de Man, 
N. Westerhof, A. Vonk Noordegraaf. J Thor Heart Lung 2012; 32:50-
55. 
 
Progressive Right Ventricular Dysfunction in Patients with Pulmonary 
Arterial Hypertension Responding to Therapy. 
M.C. van de Veerdonk, T. Kind, J.T. Marcus, G.J. Mauritz, M.W. 
Heijmans, H.J. Bogaard, A. Boonstra, K.M.J. Marques, N. 
Westerhof, A. Vonk-Noordegraaf. J Am Coll Cardiol 2011; 58:2511-
2519. 
 
Progressive Changes in Right Ventricular Geometric Shortening and Long-
term Survival in Pulmonary Arterial Hypertension.  
G.J. Mauritz, T. Kind, J.T. Marcus, H.J. Bogaard, M. van de 
Veerdonk, P.E. Postmus, N. Westerhof, A. Vonk-Noordegraaf. 
Chest 2011; 141:934-943. 
 
Clinically significant change in stroke volume in pulmonary hypertension. 
S.A. Van Wolferen, M.C. van de Veerdonk, G.J. Mauritz, W. 
Jacobs, J.T. Marcus, K.M. Marques, J.G. Bronzwaer, M.W. 
Heymans, A. Boonstra, P.E. Postmus, N. Westerhof, A. Vonk 
Noordegraaf. Chest 2010; 139:1003-1009. 
 
Publications 
176 
Right ventricular ejection fraction is better reflected by transverse rather 
than longitudinal wall motion in pulmonary hypertension. 
T. Kind, G.J. Mauritz, J.T. Marcus, M. Van de Veerdonk, N. 
Westerhof, A. Vonk Noordegraaf. J Cardiovasc Magn Reson 2010; 
12:35. 
 
Maggot excretions inhibit biofilm formation on biomaterials.  
G. Cazander, M.C. van de Veerdonk, C. M. Vandenbroucke-
Grauls, M.W. Schreurs, G. N. Jukema. Clin Orthop Relat Res 2010; 
468:2789-2796. 
 
 
Oral presentations 
 
MRI and right ventricular function.  
M.C. van de Veerdonk. PAH meeting. Oslo, Norway, 2013. 
 
Improved right ventricular function after substantial afterload reduction in 
patients with pulmonary arterial hypertension. 
M.C. van de Veerdonk, J.T. Marcus, H.J. Bogaard, N. Westerhof, 
A. Vonk Noordegraaf. European Respiratory Society Conference, 
Vienna, Austria 2012. 
 
In pulmonary hypertension changes in right ventricular ejection fraction 
better predict mortality than changes in pulmonary vascular resistance. 
M.C. van de Veerdonk, J.T. Marcus, N. Westerhof, A. Vonk-
Noordegraaf. European Respiratory Society Conference, Barcelona, 
Spain 2010. 
 
MRI one stop shop for severe pulmonary arterial hypertension.  
M.C. van de Veerdonk. Multimodality imaging and decision making 
in cardiology. La Sapienza University, Rome, Italy, 2013. 
 
MRI one stop shop for severe pulmonary arterial hypertension.  
M.C. van de Veerdonk. Multimodality imaging and decision making 
in cardiology. La Sapienza University, Rome, Italy, 2012. 
 
Imaging the right ventricle in pulmonary arterial hypertension. 
M.C. van de Veerdonk. Stanford University, San Francisco, USA, 
2012. 
 
  
Publications 
177 
 
The relationship between right ventricular function and afterload in 
pulmonary arterial hypertension.  
M.C. van de Veerdonk. CPC-INSERM Retreat, Munich, Germany, 
2012. 
 
The cardiorenal syndrome in pulmonary arterial hypertension.  
M.C. van de Veerdonk. Erasme Hospital, Free University, Brussels, 
Belgium, 2011. 
 
 
Poster presentations 
 
Characteristics of a stable and satisfactory condition in long-term survivors 
of pulmonary arterial hypertension.  
M.C. van de Veerdonk, J.T. Marcus, H.J. Bogaard, F.S. de Man, A. 
Boonstra, N. Westerhof, A. Vonk Noordegraaf. European 
Respiratory Society Conference, Barcelona, Spain, 2013.  
 
Heart function and survival improve after a strong reduction in afterload in 
patients with pulmonary arterial hypertension.  
M.C. van de Veerdonk, J.T. Marcus, H.J. Bogaard, F.S. de Man, N. 
Westerhof, A. Vonk Noordegraaf. American Thoracic Society 
Conference, Philadelphia, USA, 2013. 
 
Changes in right ventricular mass are related to changes in pulmonary 
pressures in pulmonary arterial hypertension. 
M.C. van de Veerdonk, S.A. Dusoswa, T. Kind, J.T. Marcus, N. 
Westerhof, A. Vonk Noordegraaf. European Respiratory Society 
Conference, Amsterdam, The Netherlands, 2011 
 
Association of renal dysfunction with cardiac output and right atrial pressure 
in pulmonary arterial hypertension. 
M.C. van de Veerdonk, A. Boonstra, A. Vonk Noordegraaf. 
European Respiratory Society Conference, Amsterdam, The 
Netherlands, 2011. 
 
Changes in Right Ventricular Ejection Fraction rather than Pulmonary 
Vascular Resistance Predict Outcome in Pulmonary Arterial Hypertension. 
M.C. van de Veerdonk, J.T. Marcus, N. Westerhof, A. Vonk-
Noordegraaf. American Thoracic Society Conference, New Orleans, 
USA, 2010. 
Right Ventricular Function is a Strong Prognostic Predictor of Mortality in 
Pulmonary Arterial Hypertension. 
Publications 
178 
M.C. van de Veerdonk, T. Kind, G.J. Mauritz, N. Westerhof, J.T. 
Marcus, A. Vonk-Noordegraaf. European Respiratory Society 
Conference, Vienna, Austria, 2009. 
 
De interactie van madenexcreten en bacteriële biofilms op traumatologisch-
orthopedische materialen.  
G. Cazander, M.C. van de Veerdonk, C.M.J.E. Vandenbroucke-
Grouls, G.N. Jukema. Chirurgendagen, Veldhoven, the Netherlands, 
2009. 
 
 
Grants 
 
2013 ATS Scholarship. M.C. van de Veerdonk. American Thoracic Society 
Conference, Philadelphia, USA, 2013.  
 
2010 ERS Young Scientist Sponsorship. M.C. van de Veerdonk. European 
Respiratory Society Conference, Barcelona, 2010.  
  
Publications 
179 
 
 
 
Curriculum vitae 
180 
Curriculum vitae 
 
181 
 
Curriculum vitae 
 
Mariëlle Carolijn van de Veerdonk was born in Hilversum, the Netherlands 
on February 19, 1986. In 2004 she completed secondary school (vwo) at 
the Erfgooiers College in Huizen. After first being eliminated by numerous 
clausus from medical school she started the study Psychology and finished 
her propaedeutic in 2005. Subsequently she started studying Medicine at 
the VU University of Amsterdam. In 2008 she obtained the Bachelor of 
Science degree. In the fourth year of medical school, she started with 
scientific research on pulmonary arterial hypertension at the department of 
pulmonary diseases of the VU University Medical Center, under supervision 
of prof. dr. A. Vonk Noordegraaf. After 6 months of a research internship, 
she continued her research as a student assistant during the internship 
years of medicine. She performed her final internship at the department of 
cardiology at the Flevoziekenhuis, Almere under supervision of dr. H. 
Verheul. She graduated from medical school in July 2011. Subsequently, 
she commenced full-time PhD research on her topic of pulmonary arterial 
hypertension. In January 2014, she started to work as a specialist not in 
training at the department of cardiology at the Sint Lucas Andreas Hospital 
under supervision of dr. J. Schroeder-Tanka.  
 
Mariëlle Carolijn van de Veerdonk werd geboren te Hilversum, Nederland 
op 19 februari 1986. In 2004 slaagde zij voor haar eindexamen VWO op 
het Erfgooiers College in Huizen. Nadat zij werd uitgeloot tijdens de 
numerus fixus voor de geneeskunde-opleiding, begon zij aan de studie 
psychologie waarvan zij de propedeuse behaalde in 2005. Daarna kon zij 
alsnog starten met de studie geneeskunde aan de Vrije University van 
Amsterdam. In 2008 verkreeg zij de graad Bachelor of Science. Tijdens het 
vierde jaar van de studie geneeskunde begon zij aan haar 
wetenschappelijke stage naar pulmonale arteriële hypertensie op de 
afdeling longziekten van het VU medisch centrum onder begeleiding van 
prof. Dr. A. Vonk Noordegraaf. Na afloop van deze stage continueerde zij 
haar onderzoek tijdens haar co-schappen. Haar oudste co-schap deed ze 
op de afdeling cardiologie van het Flevoziekenhuis in Almere, onder 
begeleiding van dr. H. Verheul. In juli 2011 behaalde zij haar artsexamen. 
Aansluitend continueerde zij haar wetenschappelijk onderzoek naar 
pulmonale arteriële hypertensie maar nu op fulltime basis in het kader van 
een promotietraject. Sinds januari 2014 werkt zij als arts-assistent niet in 
opleiding op de afdeling cardiologie van het Sint Lucas Andreas ziekenhuis 
onder leiding van dr. J. Schroeder-Tanka.  
Curriculum vitae 
182 
 
 
 
 
 
 
 
 
  
 
  
 
 183 
 
 
 
 
 
 
Dankwoord 
 
  
Dankwoord 
184 
 
 
  
Dankwoord 
185 
 
Het maken van dit proefschrift was niet mogelijk geweest zonder de grote 
bijdrage en betrokkenheid, plezierige samenwerking en enthousiasme van 
vele collega’s en patiënten. De volgende personen wil ik in het bijzonder 
bedanken: 
 
Promotor: geachte prof. dr. Vonk Noordegraaf, beste Anton, wat heb ik veel 
van jou geleerd. Ik vond (en vind) het geweldig om met jou te mogen 
samenwerken. Jouw kritische blik spoorde mij aan scherp te zijn; de vele 
discussies, altijd in hoog tempo, vond ik leerzaam en fascinerend en jouw 
onuitputtelijke energie en enthousiasme werkten aanstekelijk. Jij bent het 
voorbeeld voor goede patiëntenzorg. Jij weet jouw klinische expertise te 
vertalen naar wetenschappelijk onderzoek. Vanaf het begin heb jij mij 
gestimuleerd en gemotiveerd en jij bleef, ondanks grote belasting met 
andere werkzaamheden, altijd betrokken.  
 
Co-promotor: geachte dr. Marcus, beste Tim, met grote precisie, geduld en 
inzet heb jij voor een enorme MRI-database gezorgd. Zonder deze bijdrage 
zou een MRI-promotietraject onmogelijk zijn geweest. Ik wil je graag 
bedanken voor de goede samenwerking, betrokkenheid en 
wetenschappelijke bijdrage aan dit proefschrift.  
 
Co-promotor: geachte dr. Bogaard, beste Harm-Jan, jouw eeuwige 
positieve instelling en enthousiasme werkten aanstekelijk en leverden een 
onmiskenbare bijdrage aan dit proefschrift. Zonder jouw vakinhoudelijke 
kennis, laagdrempelige toegankelijkheid en bereidheid tot meeschrijven en 
meedenken, had dit proefschrift niet tot stand kunnen komen. Graag zou ik 
onze plezierige samenwerking in de toekomst willen voortzetten.  
 
Geachte opponenten en leden van de leescommissie, dr. A. Boonstra, dr. 
B.J. Bouma, dr. L.J. Meijboom, prof. dr. N. van Royen, prof. dr. P.J. Sterk 
en dr. P. Symersky, hartelijk dank voor het kritisch lezen en beoordelen van 
dit proefschrift. Prof. dr. A.J. Peacock, thank you for the assessment of my 
thesis.  
 
Geachte emeritus prof. dr. Westerhof, beste Nico, veel plezier heb ik 
beleefd aan onze overlegmomenten, discussies en ‘privé-colleges’ 
fysiologie. Ik wil u bedanken voor uw grote betrokkenheid, openheid en 
bijzondere toegankelijkheid. U bent van onschatbare waarde voor de 
promovendi. 
 
Geachte dr. Boonstra, beste Anco, ontzettend bedankt voor de leuke 
samenwerking, jouw klinische bijdrage aan het wetenschappelijke 
onderzoek en bovenal jouw onuitputtelijke enthousiasme. Ik heb genoten 
van onze gesprekken en vond het bijzonder en leerzaam dat jij mij in de 
Dankwoord 
186 
avonduren naar de afdeling meenam om patiënten te bezoeken. Jouw zeer 
goede patiëntenzorg werkt inspirerend en motiverend.  
 
Geachte dr. Handoko-de Man, beste Frances, dank voor jouw steun, 
betrokkenheid en begeleiding. Gefeliciteerd met de vele beurzen die jij 
recent hebt mogen ontvangen en veel succes met de vele, grootse 
onderzoeksprojecten.  
 
Beste Frank Oosterveer, jouw betrokkenheid bij het wetenschappelijk 
onderzoek, goede patiëntenzorg en jouw onvermoeibare inzet waarbij niets 
jou te veel lijkt, hebben enorm bijgedragen aan het tot stand komen van dit 
proefschrift. Ik wil je graag bedanken voor de prettige samenwerking van 
de afgelopen jaren. 
Beste Martha Wagenaar en Iris van der Mark, bedankt voor de fijne 
samenwerking. Bedankt voor de vele zaken die jullie voor mij hebben 
geregeld in het kader van de wetenschappelijke studies.  
 
Beste dr. Taco Kind en dr. Gert-Jan Mauritz, in 2008 ben ik onder jullie 
begeleiding begonnen aan mijn wetenschappelijke stage. Met veel plezier 
kijk ik terug op deze periode waarbij ik mij nog goed de grote hoeveelheden 
koffie en besprekingen kan herinneren. Taco en Gert-Jan, dank voor de 
leuke samenwerking en de vele momenten dat jullie de tijd en geduld voor 
mij konden opbrengen om al mijn vragen te beantwoorden, te discussiëren 
en samenvattend een zeer uitgebreide begeleiding hebben gegeven.  
 
Beste kamergenoten, Wouter Mellema, Romane Saouti-Schook en Onno 
Spruijt, dank voor alle gezelligheid en grote steun de afgelopen jaren. 
Beste Wouter, ik weet zeker dat jij nog vele jaren in het wetenschappelijk 
onderzoek betrokken zult blijven en daar veel successen mee zult boeken. 
Beste Romane, veel plezier en succes in de opleiding tot huisarts en alle 
geluk gewenst voor jouw gezin. Beste Onno, bedankt voor de leuke 
samenwerking en het continueren van onze MRI-onderzoeksprojecten. 
Veel succes met het vervolg van jouw promotie onderzoek.  
Beste Pia Trip en Gerrina Ruiter, bedankt voor de gezelligheid, 
samenwerking en de geweldige reis door San Francisco.  
Beste Justine Kuiper, Paul Johannesma, Cathelijne van der Bruggen, 
Joanne Groeneveldt, Bart Boerrigter, Nabil Saouti, Jasmijn van Campen, 
Esther Nossent, Yeun Ying Wong, Erik Phernambucq, Herman 
Groepenhoff, Marieke Overbeek, Wouter Jacobs en Serge van Wolferen, 
bedankt voor de goede samenwerking en de gezellige tijd tijdens en buiten 
het werk. 
 
Beste Sophie Dusoswa en Amal Abdi, bedankt voor jullie bijdrage aan dit 
proefschrift.  
Dankwoord 
187 
 
Beste Pim Welvaart en Patrick Jak, bedankt voor de leuke samenwerking 
en de mogelijkheid om mijn horizon te kunnen verbreden waarbij ik veel 
heb kunnen leren van het onderzoek naar diafragma stoornissen. 
 
Anny Kijk in de Vegte en Ella Wetser, bedankt voor jullie hulp. 
 
Graag wil ik alle patiënten bedanken voor hun medewerking, motivatie, tijd 
en bereidheid om een bijdrage te leveren aan het wetenschappelijk 
onderzoek naar pulmonale hypertensie.  
 
Mijn familie en vrienden wil ik bedanken voor hun interesse en support voor 
mijn promotietraject en voor de gezellige avonden van ontspanning en 
afleiding in de afgelopen jaren.  
 
Anneloes van den Heuvel, bedankt voor het opmaken van de cover voor 
mijn proefschrift. Lieve Anneloes, vanaf de eerste dag van de groentijd 
hadden wij een klik met elkaar en in de afgelopen 8 jaar hebben wij een 
hele mooie vriendschap opgebouwd. Ik waardeer onze gesprekken, 
gezellige etentjes, jouw eerlijkheid en directe opmerkingen en dankjewel 
dat jij er altijd voor mij bent.  
 
Mijn paranimfen Maurijn van de Veerdonk en Gina Spierenburg, bedankt 
dat jullie mij wilden bijstaan op deze belangrijke dag.  
 
Lieve Maurijn, lieve broer, dank voor alle support. Ik denk dat wij samen 
een bijzondere band hebben en ben blij dat jij zo dicht bij mij staat. Bedankt 
dat jij er altijd voor mij bent. Ik geniet van onze gezellige avonden en de 
chique feestjes waar jij mij mee naar toe neemt.  
 
Lieve Gina, dank voor jouw betrokkenheid en het feit dat jij in de afgelopen 
10 jaar altijd voor mij hebt klaargestaan. Door jou voel ik me begrepen en 
gesteund. Jouw lieve kaartjes en onze vele gesprekken betekenen heel 
veel voor mij.  
 
Lieve pap en mam, bedank voor jullie onvoorwaardelijke steun, jullie 
vertrouwen in mij en dat jullie er altijd voor mij zijn. Fijn dat jullie zoveel 
interesse in dit onderzoek hebben getoond en het op de voet hebben 
gevolgd. Ik hou van jullie.  
 
Lieve Jordi, heel veel dank voor al jouw liefde, steun, betrokkenheid en 
geduld rondom het uitvoeren van mijn promotie onderzoek. Een betere 
partner dan jij is niet mogelijk. Jij maakt mij compleet en gelukkig. Ik hou 
zielsveel van je en kijk enorm uit naar onze toekomst samen. Wat een 
leven! 
 188 
 
  
 
 189 
 
 
 
